Finding the Signal Within the Noise: Investigating the Interaction Between Histamine, Exercise, and Inflammation by Mangum, Joshua
FINDING THE SIGNAL WITHIN THE NOISE: 
INVESTIGATING THE INTERACTION BETWEEN HISTAMINE, EXERCISE, AND 
INFLAMMATION 
 
 
 
 
 
 
 
 
 
 
 
 
by 
 
JOSHUA EARL MANGUM 
 
 
 
 
 
 
 
 
 
 
 
 
 
A DISSERTATION 
 
Presented to the Department of Human Physiology 
and the Graduate School of the University of Oregon 
in partial fulfillment of the requirements 
for the degree of 
Doctor of Philosophy 
 
June 2020 
ii  
DISSERTATION APPROVAL PAGE 
 
 
Student: Joshua Earl Mangum 
 
Title: Finding the Signal Within the Noise: Investigating the Interaction Between 
Histamine, Exercise, and Inflammation 
 
This dissertation has been accepted and approved in partial fulfillment of the 
requirements for the Doctor of Philosophy degree in the Department of Human 
Physiology by: 
 
John Halliwill, PhD Chairperson 
John Halliwill, PhD Advisor 
Christopher Minson, PhD Core Member 
Damien Callahan, PhD Core Member 
Annie Zemper, PhD Institutional Representative 
 
and 
 
Kate Mondloch Interim Vice Provost and Dean of the Graduate School 
 
Original approval signatures are on file with the University of Oregon Graduate School. 
Degree awarded June 2020 
iii  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2020 Joshua Earl Mangum 
iv  
 
DISSERTATION ABSTRACT 
 
Joshua Earl Mangum 
Doctor of Philosophy 
Department of Human Physiology 
June 2020 
Title: Finding the Signal Within the Noise: Investigating the Interaction Between 
Histamine, Exercise, and Inflammation 
 
Histamine is commonly associated with immune responses, typically involved in allergic 
reactions. It can be released in multiple tissues, including skeletal muscle during exercise; 
however, it is unknown what it is specifically about exercise that causes the release of 
histamine. In addition, the role of histamine in inflammatory responses implies that it 
may be involved in the acute post-exercise inflammatory response. Histamine’s role and 
context outside of exercise, such as its role in mediating sustained post-exercise 
vasodilation, has guided the creation and interpretation of the studies within this 
dissertation. This dissertation has two major aims, with multiple experiments addressing 
the first aim and one larger study addressing the second aim. The first aim was to 
determine what is the exercise “trigger” that causes the release of histamine during 
exercise in skeletal muscle. The data gathered from the studies within this aim suggest 
that increased skeletal muscle temperature, which occurs during exercise, may be the 
exercise trigger that is resulting in the observed increase in skeletal muscle histamine 
during exercise. Furthermore, data from Chapter V demonstrates there is a local factor or 
factors released from skeletal muscle during exercise that causes mast cells to degranulate 
more so than in resting conditions. Finally, the second aim sought to determine the role of 
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histaminergic signaling in the acute post-exercise inflammatory response to aerobic 
exercise in untrained individuals. Our data suggests that histamine H1/H2 receptor 
antagonism using over-the-counter medications does not augment the systemic 
inflammatory response, out to 48 hours, following a novel bout of exercise in untrained 
individuals. While there was no effect of histamine receptor antagonism on systemic 
circulating inflammatory factors, future work should investigate how histamine receptor 
antagonism may affect inflammatory responses in skeletal muscle where histamine is 
formed and released. The findings of the studies within this dissertation highlight the 
interaction between exercise and histamine release in skeletal muscle. Further research 
expanding upon these findings will help to elucidate all the factors of exercise that may 
influence the release of histamine in skeletal muscle and the role of histaminergic 
signaling in the inflammatory milieu of skeletal muscle following exercise. 
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CHAPTER I 
INTRODUCTION 
 
 
 
Background and Statement of the Problem 
Our laboratory has investigated cardiovascular regulation during the recovery 
from aerobic exercise for nearly two decades. Within the vasculature of previously 
exercised skeletal muscle, there is a physiological response termed sustained post- 
exercise vasodilation, in which blood flow leading to exercise skeletal muscle is elevated 
above resting levels for up to 2 hours following the cessation of exercise (65). This 
elevated blood flow in previously exercised skeletal muscle can also lead to systemic 
changes, such as a lowered mean arterial blood pressure which also can last for hours 
following exercise (90, 91). This lowered mean arterial blood pressure can be particularly 
beneficial in populations with elevated blood pressure (hypertension). With whole body 
aerobic exercise, this physiological response is mediated by both neural and local 
mechanisms. The neural mechanisms involve central resetting of the arterial baroreflex 
and reduced sympathetic vascular transduction (48). Whereas, our lab and others have 
demonstrated that the local vascular component is vastly dependent upon histamine H1 
and H2 receptor activation. Our lab has shown the importance of histamine and 
histaminergic signaling, as post-exercise vasodilation is reduced by 80% following 60 
mins of cycling exercise using histamine H1/H2 receptor antagonist over-the-counter 
medications (94). Furthermore, we have shown that this pharmacological intervention 
abolishes the post-exercise vasodilatory response following smaller muscle mass isolated 
exercise, such as unilateral dynamic knee extension exercise (7). Our lab has established 
an important role for histamine and histaminergic signaling in mediating the local 
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mechanisms regulating the typically observed post-exercise vasodilatory/hypotensive 
response following aerobic exercise. However, there still remains much to be learned 
about the formation of histamine in response to exercise and its role in the exercise 
responsome. 
Histamine is a biogenic amine that is typically associated with immune and 
inflammatory reactions (37). While histamine concentrations in plasma are moderately 
elevated or not changed at all during or following exercise (37, 163); our lab has 
observed that histamine concentrations increase locally in active skeletal muscle during 
and following unilateral dynamic knee-extension exercise measured via intramuscular 
microdialysis (127). The source of this histamine may be from one of two sources: mast 
cell degranulation which releases histamine from its granules and/or de novo formation 
(104). The synthesis and release of histamine from mast cell degranulation typically 
occurs by antigen-immunogloblin interaction during allergic reactions, however mast cell 
degranulation can be initiated from non-immunologic stimuli such as hypoxia, vibration, 
chemokines, and other factors that are often associated with exercise (9, 55). De novo 
formation is reliant upon activation of the enzyme histidine decarboxylase (HDC), which 
converts the amino acid L-histidine to histamine (132, 133). This occurs secondary to 
increased translation, transcription, and activation of the HDC enzyme. Similar to 
stimulation of mast cell degranulation, histamine formation via HDC typically occurs in 
response to similar exercise-related stimuli such as hypoxia, changes in cytokine 
concentrations, and alterations in temperature among others (102, 129). In both methods 
of histamine formation and release, exercise related factors have been proven to be potent 
stimuli. While our lab has been able to demonstrate that histamine concentrations rise in 
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active skeletal muscle in response to exercise, it is still unknown what it is about exercise 
that is causing this increase in skeletal muscle histamine. There are many physiological 
factors that change during exercise systemically and locally in skeletal muscle that could 
be responsible for this histamine release. The question remains, what is it about exercise 
that causes the increase of skeletal muscle histamine? Is there an “exercise factor” that 
causes mast cells to degranulate and/or causes an increase the enzymatic activity of 
HDC? 
In addition to histamine playing a significant role in the post-exercise vasodilatory 
and the post-exercise hypotensive response, our lab has also demonstrated that 
histaminergic signaling may impact the exercise transcriptome in skeletal muscle 
following exercise (126).  We had subjects perform 60 minutes of dynamic unilateral 
knee extension exercise and obtained skeletal muscle biopsies before and 3 hours 
following exercise. RNA sequencing was performed on the skeletal muscle biopsy tissue 
to examine changes at the transcriptome level. We observed that in previously exercise 
skeletal muscle, over 3000 protein-coding genes were affected by the bout of exercise 
demonstrating a profound effect of exercise on the transcriptome of skeletal muscle. 
Furthermore, within these protein-coding genes affected by exercise, 795 of those genes 
were differentially expressed in subjects under histamine H1/H2 receptor antagonism. 
These genes included mediators and factors involved in vascular function, metabolism, 
and inflammation. Some of the genes that were differentially expressed are involved in 
the acute post-exercise inflammatory response, with some having important roles in both 
upregulating and mediating the pro- and anti-inflammatory responses to exercise. These 
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data suggest that histamine and histaminergic signaling might play an important role in 
the acute post-exercise inflammatory response. 
Following exercise in healthy humans, there is a tight balance of pro and anti- 
inflammatory responses that serves to clean debris from damaged muscle, repair, and 
adapt for future exercise sessions (118). This inflammatory response can be magnified 
depending on the type of exercise and/or the training status of the individual (59). The 
inflammatory cascade in response to exercise has been studied for decades and continues 
to be investigated, as we are just beginning to understand the regulation and modulation 
of this delicate balance and response. As previously mentioned, our lab has shown that 
ingestion of histamine H1/H2 receptor antagonist medications results in significant 
changes in skeletal muscle mRNA inflammatory marker expression, suggesting a 
possible role for histamine and histaminergic signaling in the post-exercise inflammatory 
response. However, this data was localized to skeletal muscle and only measured out to 3 
hours following exercise. The inflammatory response to a novel bout of exercise typically 
lasts 24-48 hours (164), involves a systemic inflammatory response, and we do not know 
how histamine receptor antagonism may affect inflammatory signaling in this longer but 
still considered acute post-exercise window. Given the data collected, it has provided 
evidence that histamine and histaminergic signaling may play a role in the post-exercise 
inflammatory response and antagonizing its action on receptors may impair or enhance 
the typical response. We observed that histamine receptor antagonism affected expression 
of inflammatory markers in skeletal muscle. However, we only measured out to 3 hours 
following exercise and the post-exercise inflammatory “window” typically lasts 24-48 
hours following cessation of exercise. Therefore, the question remains to be fully 
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answered, does histamine receptor antagonism result in an augmented acute post-exercise 
inflammatory response following aerobic exercise? 
The studies detailed in this dissertation were designed to provide novel insight 
into the overall role of histaminergic signaling in response to exercise and its role in acute 
post-exercise inflammation. As previously mentioned, it is known that histamine is 
released from skeletal muscle during exercise and that it plays a role in sustained post- 
exercise vasodilation, however gaps remain in our understanding the full impact of 
exercise induced histamine release and signaling. The studies detailed were designed to 
address how histamine is involved in exercise in multiple facets: including what about 
exercise is causing histamine to be released in skeletal muscle and how histaminergic 
signaling may impact inflammation following exercise. In chapter IV, we examined if 
increased temperature is the exercise-related factor mediating the release of histamine in 
skeletal muscle during and following exercise. In addition, we aimed to investigate if 
increasing temperatures to physiological values resulted in increased mast cell 
degranulation in vitro. In chapter V, utilizing in vivo and in vitro techniques, we 
examined if there was a/were factor(s) released locally in exercising skeletal muscle that 
caused increased mast cell degranulation above basal levels, in turn causing the release of 
histamine. To investigate the role of histaminergic signaling in post-exercise 
inflammation, in chapter VI we examined if H1/H2 receptor antagonism using over-the- 
counter medications augmented the acute post-exercise inflammatory response to a novel 
bout of exercise in untrained individuals. 
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Purposes and Hypotheses 
 
This dissertation was conducted in order to test the following hypothesis: 
 
1.  In chapter IV, the purpose of these set of studies was to determine if increased 
skeletal muscle temperature during exercise is the “exercise factor” that results in 
elevated skeletal muscle histamine concentrations. We hypothesized that 
passively increasing skeletal muscle temperature to temperatures observed during 
exercise would cause an increase in skeletal muscle histamine concentrations 
measured in skeletal muscle dialysate. In a follow up study, we hypothesized that 
in-vitro, physiological step-wise increases in temperature would increase mast cell 
degranulation in isolated human mast cells. 
 
 
2. In chapter V, the purpose of this study was to determine if there is a/are local 
factor(s) produced in exercising skeletal muscle that cause increased mast cell 
degranulation above basal levels. We collected skeletal muscle dialysate from 
both the exercising and resting leg during dynamic unilateral knee extension 
exercise. We hypothesized that dialysate collected in vivo from exercising and 
previously exercised skeletal muscle would increase mast cell degranulation, 
measured in vitro by β-hexosaminidase release, compared to dialysate from 
resting skeletal muscle. 
 
 
 
3. In chapter VI, the purpose was to determine the impact of histamine receptor 
H1/H2 antagonism on the acute post-exercise inflammatory response following a 
7  
novel bout of moderate intensity aerobic exercise in untrained individuals. We 
obtained venous blood samples from volunteers at multiple timepoints out to 48 
hours following exercise to investigate the acute inflammatory response in 
placebo and histamine receptor antagonism conditions. We hypothesized that 
histamine receptor antagonism on H1 and H2 receptors would decrease the acute 
systemic inflammatory response in a novel bout of aerobic exercise in untrained 
individuals compared to placebo. 
 
 
 
Significance 
 
Our lab has shown that histamine increases in muscle in response to exercise and 
we have shown an important role for histamine in a multitude of exercise responses. We 
have shown that histamine receptor antagonism affects post-exercise vasodilatory 
responses, glucose uptake, endurance performance, pain perception, changes in exercise- 
related transcriptome changes. In light of all we know, there still remain gaps in our 
knowledge in this interaction. While we show that histamine increases in skeletal muscle 
with exercise, we still do not understand the exercise related cellular signaling 
mechanisms in skeletal muscle that cause the release of histamine and how it may affect 
other cellular signaling processes involved with exercise. These studies will help us to 
further understand the impact of histamine receptor antagonism on the exercise 
responsome. 
In addition to their significance in understanding the science of how histaminergic 
signaling impacts exercise and vice versa, these studies are innovative as they can 
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possibly elucidate the link between histamine and post-exercise inflammation, this 
inflammatory response being an important component of exercise-induced adaptations. 
We have data that suggests that histamine receptor antagonism appears to affect 
inflammatory markers in skeletal muscle following exercise, however we have not 
examined the systemic response nor a longer-term window following exercise. Our 
previous work only examined out to 3 hours following exercise, while the inflammatory 
response to exercise can extend to 48 hours following exercise. During this window of 
time, there is a balance between pro- and anti-inflammation that is critical following 
exercise. This has become a popular area of current research examining post-exercise 
interventions which are designed to help individuals recover faster/better. Some of these 
interventions include icing, supplementation with nutrition, active recovery, and other 
approaches. These interventions may help the participant “feel better” however they may 
positively or negatively influence the post-exercise inflammatory cascade of events 
which in turn can affect the typical exercise associated adaptations (44, 143, 48). Using 
state-of-the-art methods, we aim to determine how histamine influences this 
inflammatory milieu in skeletal muscle following exercise and if blocking the actions of 
histamine has deleterious (or positive) ramifications on the acute inflammatory response. 
Regarding post-exercise inflammation, further understanding of how 
antihistamines can affect the exercise response and inflammatory processes may help to 
shape and inform recommendations for their use in conjunction with exercise and 
exercise training. The inflammatory response following exercise is a tightly regulated 
process consisting of both pro- and anti-inflammatory responses that can be impacted by 
multiple factors including diet, age, training status, medications and others (27, 92, 136). 
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The post-exercise inflammatory response involves a host of cytokines and other cells 
types that are mobilized from bone marrow and the spleen, to repair damaged skeletal 
muscle. This mobilization and movement into skeletal muscle is critical for proper repair 
and adaptations to occur, and it is possible given its nature that histamine might play a 
role in this immune response. Given what our lab has found thus far and what questions 
remain, we designed these sets of experiments in order to address the significant gaps in 
our knowledge regarding the interaction of histamine, exercise, and inflammation. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
 
 
Histamine and Histamine Receptors 
 
Allergic reactions are due to complex interactions between different types of 
inflammatory cells: including basophils, neutrophils, eosinophils, and mast cells (157). 
All these cells produce different inflammatory mediators and the biogenic amine 
histamine derived from mast cells plays an important role in allergic and inflammatory 
responses. Amongst these allergic responses include the maturation and activation of 
leukocytes and chemotaxis, the process of movement of cells being mediated by 
histamine (165). Histamine is considered to be a primordial signaling molecule, as it is 
present in single and multiple cell organisms and has a molecular mass of 111 Dalton 
(103, 46). Histamine is intricately involved in both pro-inflammatory and anti- 
inflammatory responses which is highly dependent upon the receptor subtype and the cell 
types that are stimulated (108). Some of the functions of histamine include 
neurotransmission, chemotaxis, phagocytosis, mediation of urticaria, and cell growth (18, 
151). Beyond these allergic and inflammatory reactions, histamine and histaminergic 
signaling is involved in a vast number of cellular processes and other physiological 
responses. In the line of physiological responses beyond inflammation, early work from 
Best and colleagues discovered that histamine is formed endogenously within the lung 
and liver and it has a potent vasodilatory effect (12). 
Histamine has four known receptor subtypes (H1-H4) and can act in paracrine 
and/or autocrine signal manners with all these receptor subtypes belonging to the G 
protein coupled receptor family (144, 157). These histamine receptor subtypes are 
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characterized by their structure, function, and their affinity to histamine. The H1 receptor 
is expressed in a vast array of tissues, including nerves, endothelial cells, dendritic cells, 
and respiratory endothelium. Given the location of these receptors, the H1 receptor has 
roles in nociception, vasodilation, and bronchoconstriction (5, 21). H2 receptors are found 
in various tissues, including dendritic cells, gastric parietal cells, and vascular smooth 
muscle. The H2 receptor subtype mediates gastric acid secretion, regulating cell growth 
and maturity, and airway mucus production (159). The use of histidine decarboxylase 
knockout mice (HDC-/-) has demonstrated a critical role of H2 receptors. In this murine 
line, the enzyme histidine decarboxylase is lacking, which leads to structural 
abnormalities of mast cells and abnormal histamine formation to where the lack of 
histamine leads to a downregulation of H2 receptors, in a tissue-specific manner (106). 
The H3 receptor is primarily located throughout the central nervous system, including 
areas such as the cerebral cortex, hippocampus, and striatum (144). It has been 
demonstrated that histamine signaling via H3 receptors plays an important role in neural 
function and neuro-inflammatory diseases. H4 receptors were recently discovered in the 
past 20 years and are primarily expressed on leukocytes (70, 168). Mast cells can be 
activated by histamine binding to H4 receptors on leukocytes, which can then lead to a 
robust inflammatory cascade which leads to a migration of inflammatory cells to the site 
of inflammation. Thus, histamine and the binding of histamine to H4 receptors has been 
identified as having an important role in the inflammatory response. 
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Sources of Histamine 
 
Histamine has two sources that have been clearly established in the research 
literature. It can be released from mast cells via degranulation, which is a cellular process 
in which molecules (including histamine) are released from secretory vesicles found 
inside the cells (83). The other source of histamine is de novo formation via an enzyme 
termed histidine decarboxylase (HDC) which converts the amino acid L-histidine to 
histamine (65). Mast cells were first described in 1878 in a doctoral thesis by Ehrlich and 
given the name “Mastzellen” which literally translates to well-fed cells (82, 8). This is 
due to their cytoplasm being stuffed with granular material and their unique staining 
characteristic when examined under a microscope in which the granules are easily 
observed. Mast cells play an important role in inflammatory and immediate allergic 
reactions. Typically, mast cells are localized to tissue and not found circulating in the 
blood stream under normal physiological conditions (29). Depending on their tissue 
location, they can possess unique characteristics as the mast cells that are present in the 
skin are slightly unique from mast cells that are located in the gastric mucosa (98). The 
cytoplasm of mast cells contains 50-200 large granules that store a host of inflammatory 
mediators, including histamine (97). Mast cells can migrate to target tissue locations, 
mediated by integrins, chemokines, and cytokines. HDC is expressed in a vast number of 
tissues in which it plays an important role in histamine production. The molecular weight 
of HDC is approximately 53-55 kDa and the active form of HDC is a homo-dimer (102). 
HDC can be expressed in mast cells and basophils and is regulated transcriptionally with 
cell differentiation and maturation. In the case where histamine is synthesized by HDC 
and not released from mast cell degranulation, this histamine is termed ‘nascent 
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histamine’ and the histamine in tissues from this process are typically in the uM range 
(129). Activity of HDC can be induced due to a list of different stimuli, including 
endotoxin-induced inflammation, dermatitis, and allergic inflammation. Given all of this, 
histamine plays an important role in a host of different roles and has multiple functions 
ranging from inflammation to vascular permeability and even functions involved in 
central nervous system responses. 
 
 
The Role of Histaminergic Signaling in Post-Exercise Responses 
 
As previously mentioned, histamine is a primordial signaling molecule that can 
exert its effects via multiple different cell surface receptors (160). Often, since histamine 
is associated with allergic reactions, medications are taken to block the associated 
symptoms with which histaminergic signaling results in. Individuals may suffer from 
seasonal allergies and may take histamine receptor antagonists, commonly referred to as 
antihistamines, to stop the common symptoms (140). Over the counter histamine receptor 
antagonists such as Allegra (histamine H1 receptor) and Zantac (histamine H2 receptor) 
are among the most widely used medications globally (44). While these medications have 
been shown to effectively reduce the binding and signaling of histamine on its cell 
receptors, much is still to be learned about the role of histamine within the exercise 
responsome. 
Of the previously discussed four histamine receptor subtypes, H1 and H2 receptors 
are the most characterized. These two receptor types are found throughout, and 
particularly found within skeletal muscle vasculature including, but not limited to, 
endothelial cells, vascular smooth muscle cells, and pericytes (100, 89). Our lab has data 
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demonstrating that during exercise, histamine is released from skeletal muscle (127). As 
previously discussed, this release can occur via mast cell degranulation and/or de novo 
formation via the enzyme histidine decarboxylase. Once released, this histamine can then 
activate local H1 and H2 receptors. The exercise-induced release and binding of histamine 
causes vasodilation via decreased intracellular calcium levels in smooth muscle (68) and 
increased formation of local vasodilator substances from the endothelium (156). Given 
the locations of these H1 and H2 receptors, the binding of histamine to these receptors in 
response to exercise, and consequently blocking them, can have significant effects on the 
typically observed post-exercise vasodilatory responses. 
While typical physiological responses during exercise have been extensively 
studied, there is an intriguing phenomena post-exercise that occurs known as post- 
exercise hypotension. For many years, the Halliwill Lab has focused on sustained post- 
exercise hypotension, which is typically a result of sustained post-exercise vasodilation 
which is defined as increased conductance and blood flow to previously active skeletal 
muscle. This post-exercise phenomenon can last for several hours. By having subjects use 
histamine receptor antagonists during exercise, our lab has shown that about 80% of the 
observed sustained post-exercise vasodilation can be attributed to the activation of 
histamine (H1 and H2) receptors (86, 94, 60) . This research has culminated in a take- 
home message that histamine and histaminergic signaling is important in exercise- 
induced vascular responses. We and others have demonstrated that histamine plays an 
important role and is released locally in skeletal muscle in response to exercise, but there 
is still a gap in the literature regarding what it is about exercise that causes this increase 
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in skeletal muscle histamine. What is the factor or the factors that are unique to exercise 
that are responsible for this rise in histamine? 
Exercise Factors 
 
During exercise, there are both changes systemically as well as local changes in 
the exercising tissue. These can be termed as exercise “factors” as they are altered by 
exercise and have downstream effects on the active tissue, other tissue, and certain cell 
types. Some of these factors include changes in pH, increase of temperature in both the 
core and working skeletal muscle, increase in reactive oxygen species, and release of 
cytokines from exercising skeletal muscle (1, 51, 153). While there is a plethora of 
research on the changes that occur during exercise, which of these factors is/are the most 
important and how they change in response to exercise is still being investigated. 
The change in pH in response to exercise and its effect on contractile properties in 
skeletal muscle has been extensively studied over the past century, originating in work 
done in skinned fibers from frogs (124). Both resistance based and aerobic based exercise 
have shown to shift the blood pH to more acidic, this shift being dependent both upon 
intensity and duration. At lower and slower running speeds, lactate is removed from the 
muscles as quickly as it produced, with typically no appreciable decreases in pH. Below 
work rates of 50-60% VO2max, muscle lactate and pH does not typically change 
significantly. However, it has been reported that exercise above 60% VO2max for 
durations longer than 30 minutes have shown significant reductions in blood and muscle 
pH. In addition, resistance exercise has been demonstrated to alter pH levels, however 
these protocols are at higher workloads, such as 60-80% of 1 rep-max. 
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During both aerobic and resistance based exercise, the accumulation of CO2 and 
lactate can reduce cellular pH in exercising skeletal muscle, and acidosis has been shown 
to have a direct vasodilatory effect on vascular smooth muscle cells (88). In addition to 
this, alterations in pH can affect vascular K+ channels and can possibly activate sensory 
nerve endings within the muscle interstitium (68, 149). The changes in pH during 
exercise has primarily been measured in venous blood pH, however more recent literature 
has begun to investigate the interstitial pH changes in skeletal muscle during exercise. It 
can be and has been measured with near-infrared spectroscopy (NIRS) and by 
microdialysis combined with the use of the pH-sensitive fluorescent dye BCECF (148, 
93). 
In relation to aerobic based exercise, interstitial pH in exercising skeletal muscle 
has been shown to decrease gradually during exercise and is reduced in proportion to 
power output. In order to mitigate this decrease in pH, plasma bicarbonate can act to 
buffer the changes in pH (49). In addition, aerobic-based sport athletes have utilized 
sodium bicarbonate as exogenous buffering agent to mitigate the changes in pH in order 
to improve performance (24). Indeed, sodium bicarbonate has been used by athletes for 
decades as it has been shown to improve performance in cycling athletes and can be 
considered an ergogenic substance. While it has been shown to improve performance by 
possibly affecting pH concentrations, the dosage of sodium bicarbonate must be carefully 
selected as it can produce a great deal of gastrointestinal stress (75, 73, 87). pH has been 
shown to play an important role in exercise responses and altering pH utilizing buffering 
agents has been shown to improve performance in certain circumstances, however this 
evidence is not incontestable. What is incontestable is that pH is altered by exercise, is 
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dependent upon type, intensity, and duration of exercise, and the change in pH can have a 
multitude of effects on active skeletal muscle. 
Another factor that is impacted or influenced by exercise is the creation of 
reactive oxygen species (ROS). During normal cellular function and particularly during 
exercise, free radicals are generated. These free radicals can be both beneficial and can 
also be toxic if not able to be processed appropriately by the body. When there is an 
accumulation of ROS, this can lead to oxidative damage or also known as oxidative 
stress. This can occur during exercise, and ROS can be involved in the regulation of 
exercise-induced mitochondrial biogenesis via peroxisome proliferator activated receptor 
y coactivator-1-a (PGC-1a)(79, 6). ROS generated during exercise can have been shown 
to have a multitude of effects on different cell types during and following exercise, ROS 
can be damaging to tissues if left unchecked by ROS-scavenging mechanisms (35). 
Our lab has investigated the role of oxidative stress during exercise on histamine 
release. Subjects performed 60 minutes of unilateral dynamic knee extension exercise at 
60% of peak power (125). Subjects performed this exercise under three different 
conditions: control, i.v. ascorbate infusion, and ascorbate infusion plus oral H1/H2 
histamine receptor blockade. Post exercise-vasodilation did not differ between ascorbate 
and ascorbate plus H1/H2 blockade. Since it is possible that ascorbate can catalyze the 
degradation of histamine in vivo, a follow up study was performed with infusions of the 
antioxidant N-acetylcysteine prior and during exercise. Post-exercise vascular 
conductance was similar for control and N-acetylcysteine conditions. These data suggest 
that exercise-induced oxidative stress does not appear to contribute to sustained post- 
exercise vasodilation. Therefore, we can confidently “check off” oxidative stress as an 
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exercise factor that mediates histamine release and histaminergic signaling that regulates 
post-exercise blood flow responses. with no effect on the histaminergic signaling 
pathway suggested that the oxidative stress associated with exercise is not necessary for 
histamine release. While we have been able to rule out this factor, there are still other 
signals/factors that are present during exercise that may lead to this increase in histamine 
release. Elevated temperatures have been shown to induce mast cell degranulation as well 
as having transcriptional and translational effects on other cytokines/soluble factors that 
can be found within skeletal muscle, thus can be a likely candidate as an exercise factor 
causing release of histamine (97). 
Both during aerobic exercise and resistance-based exercise, there are increases in 
both core temperature and the temperature of exercising skeletal muscle. Similar to other 
factors, this heat production will be highly dependent on intensity and duration. Kenny et 
al showed that with treadmill running exercise, intensity affected the change in 
temperature elevation. In subjects that ran for 15 minutes at 70% VO2 max, core 
temperature was elevated 0.97 degrees C and those that ran at 93% VO2max, temperature 
was increases by 2.17 degrees C from baseline. These observations have been 
corroborated from others, similar to changes in pH, highlighting a “threshold” for 
appreciable changes in temperature and intensity/duration dependence on changes in 
temperature. 
In skeletal muscle, metabolic heat production is increased during exercise above 
resting levels and regulating temperature requires a close coordination of heat-loss 
responses. Exercise hyperemia increases convective heat exchange and dissipates some, 
but not all of the heat produced during muscular contraction. Extensive work by Saltin et 
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al. reported that intramuscular temperature was increased in response to aerobic unilateral 
dynamic knee extension exercise and that the gradient between deep and superficial 
skeletal muscle is maintained during submaximal exercise (128). Work from Taylor et al 
has indicated that intramuscular temperature increases in response to exercise and will 
eventually plateau at an equilibrium temperature (77). Thermosensitive elements have 
been suggested to exist within skeletal muscle, and muscle temperature can also modulate 
the discharge frequency of groups I-IV muscle afferents, which are involved in pain and 
pressure perception (71, 154). Increases in skeletal muscle temperature have been shown 
to have direct effects on skeletal muscle properties and processes involved in exercise, 
such as excitation-contraction coupling, enzymatic activity, as well as cross-bridge 
cycling which can affect force production (22, 53). In addition to its effects on properties, 
the increase of temperature on enzyme activity can increase the rate of reaction of most 
enzymes. Changes in temperature in skeletal muscle have been shown to alter activity of 
enzymes that are involved in skeletal muscle metabolism, including lactate 
dehydrogenase, citrate synthase, and hydroxy acyl dehydrogenase (40,30). Alterations in 
the enzymatic activity of these particular enzymes can have profound effects on 
metabolism and fuel utilization which then will directly impact exercise performance. 
Regarding HDC, in isolated cell preparations, temperature has been shown to influence 
the enzymatic velocity of HDC (133). With increasing temperatures, there is a linear 
increase in HDC activity up to a point where it reaches a plateau. Since HDC is involved 
in histamine production, it makes temperature and heat production from exercise in 
skeletal muscle a likely candidate for the observed release of histamine in skeletal muscle 
that has not yet been investigated. Therefore, a gap exists in the literature examining the 
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role of increased skeletal muscle temperature in response to exercise on skeletal muscle 
histamine release. Therefore, in this dissertation we propose a set of studies that will 
investigate if heat and local factors released in muscle cause the release of histamine in 
skeletal muscle during exercise. 
Exercise and Inflammation 
 
During and following exercise (whether it be aerobic or resistance), there is an 
inflammatory response that occurs. Within this response, there are a multitude of 
cytokines, molecules, and cell types that are either up-regulated or down-regulated at 
different time points. The response of these factors are highly dependent on the type of 
exercise, the time course following the exercise, as well as the status of the individual 
who performed the exercise (i.e. trained, untrained, healthy, unhealthy, age etc) (164) 
These inflammatory responses are put into distinct classifications to categorize their 
actions, while of course there has been some debate in regards to some specific targets 
and their generalizable actions. 
Following muscle damaging exercise (typically having to include eccentric or 
lengthening components), there is ultrastructural damage to the skeletal muscle that 
results in many consequences. Typically, there is a reduction in force output for hours to 
days depending upon the severity of damage, pain and tenderness localized to the 
exercise area, and an increase in inflammatory cells both in the area and systemically. 
The strength loss that is observed after eccentric muscle damage happens immediately, 
and can last up to one week as has been shown in some studies (4, 145). Often, these long 
delays in strength loss are due to major structural damage to muscle fibers, including 
hallmark observations such as Z-line streaming and sarcomere disruption (146). The 
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inability to produce similar force from baseline stems from many of the contractile 
proteins being damaged and a lack of stability of the actin/myosin interaction along with 
titin, due to damage to the Z-line. Some studies have even shown myofibrillar necrosis 
with a lack of regeneration even out at 10 days following a severe protocol (158), 
indicating that this structural damage has a major role in force production following an 
eccentric exercise protocol. This ability to produce force may stem from the pain, 
tenderness, and swelling that is often observed during the recovery period from damaging 
exercise. The pain and soreness that are typically associated with recovery from muscle 
damaging exercise have a few potential sources. Some have argued that the mechanical 
strain itself, the damage that has been caused to the tissue may sensitive pain nerve fibers 
(nociceptors) which gives the perception of pain. There are also theories as to how this 
pain is perceived, whether that be truly peripherally or if it is more centrally based with 
“perception and sensitivity” playing a role, however this is beyond the scope of this 
review (69). 
Certain inflammatory mediators released within skeletal muscle may cause the 
release of nerve growth factor, which can alter the threshold at which pain is perceived 
and may result in more pain. Therefore, there may be a direct causal relationship between 
the amount of inflammation and the amount of pain perceived. As well, chemokines 
released in and around the muscle may stimulate more of these mediators, exacerbating 
the response. Therefore, the main causes of this pain observed may be directly from the 
tissue damage or due to the inflammatory, or possibly a combination of both (99, 134). 
Some studies have shown that the pain can be observed without any evidence of 
structural damage, indicating that structural disruptions are not obligatory for pain to be 
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observed. Similar to the strength decreases, pain sensations are typically elevated 
immediately following muscle-damaging exercise. This pain and soreness will typically 
peak around 2-3 days following the eccentric damaging exercise bout; however this may 
slightly shift due to protocol and subjects involved. The pain and soreness usually 
subside by day 5-7, however as previously mentioned this could last up to 10-14 days 
depending on the amount of damage that was done (43). 
Following both muscle damaging and moderate to high-intensity aerobic exercise, 
leukocytes are recruited immediately the damaged muscle tissue. Most of these leukocytes 
are neutrophils, they are recruited to the area from chemotactic factors such as previously 
mentioned pro-inflammatory cytokines which have this ability. Within minutes of 
completion of exercise, possibly even during exercise, both neutrophils and monocytes are 
recruited to the damaged tissue, monocytes can then differentiate into macrophages to work 
with resident macrophages that may already be present. Their primary purpose is 
phagocytosis as well as releasing other proteolytic enzymes and other free radicals to 
upregulate the inflammatory environment present in that tissue (112). Following exercise, 
cytokines/myokines IL-6 is rapidly upregulated, being present immediately in skeletal 
muscle following damaging exercise. Other pro-inflammatory cytokines such as tumor 
necrosis factor alpha (TNF-a) and interleukin-1 beta (IL-1B) are typically upregulated a 
few hours following exercise, with some showing that this can occur within the first hour. 
Monocyte-chemoattractant protein 1 (MCP1) can be upregulated later in the 24-hour period 
following an exercise bout, and may remain elevated for days following. Other cells such 
as mast cells can migrate into the tissue within the first hour, releasing inflammatory 
mediators such as histamine and tryptase (107). While anti-inflammatory cytokines are 
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typically thought to help resolve the inflammation later on, their up-regulation is often seen 
within a few hours of exercise at lower levels, and ramping up as time moves on. Certain 
anti-inflammatory cytokines have been shown to increase within the first hour of exercise, 
and still be present up to a week following the damaging exercise. Near the end of the 
resolution, satellite cell activation and type 2 pericytes aid in the repair of muscle by 
increasing differentiation of myocytes, expressing factors such as myogenin and MyoD 
and ultimately leading to satellite cell quiescence at the complete resolution following the 
bout (166). Depending on the type of exercise and the amount of damage that has occurred, 
this can shift the expression and localization of certain cells, however this observation of 
an immediate response from neutrophils and pro-inflammatory cytokines followed by a 
recruitment of anti-inflammatory cytokines and resolution based cell types is the typical 
pattern. Pournot et al had subjects perform a muscle damaging protocol involving extended 
running that included level, up-hill and down-hill components (63). They examined both 
cytokine levels and mobilized leukocytes out to 96 hours post-exercise to investigate the 
time course changes. In their control group that did exercise with no intervention, they 
observed a rapid increase immediately post exercise in IL-6, IL-10, while c-reactive protein 
(CRP) was not elevated until 2 days later interestingly. IL-6 had decreased back down at 
24 hours as well as IL-10, however IL-1Ra had a delayed increase as discussed before. 
Interestingly, there were no changes in TNF-a in the post-exercise period even out to 96 
hours post. Both leukocytes and neutrophils were up post-exercise in the one hour period, 
however both were not significantly different at 24 hours and deceased from there. This 
initial pro-inflammatory response followed by and upregulation in IL-1Ra and then 
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decrease in leukocyte count follows the typical trends observed following damaging 
exercise. 
With respect to inflammation, pro-inflammatory and anti-inflammatory are 
typical categories that the cell types are placed in to. Pro-inflammatory is referring to a 
cytokine or molecule that: initiates, amplifies, and/or progresses the inflammatory 
response (109). Pro-inflammatory mediators have specific actions on their own, they are 
also able to signal the release or produce other key inflammatory markers via intracellular 
signaling mechanisms. Anti-inflammatory mediators tend to inhibit the inflammatory 
response or inhibit the release of pro-inflammatory mediators. Sometimes this response is 
to serve as a controlling mechanism to the upregulation of pro-inflammatory mediators, 
working as a balance to keep inflammation in check following an insult (25). There is a 
delicate balance between the pro- and anti-inflammatory responses. In certain conditions 
and situations, an imbalance with unregulated pro-inflammatory responses is often linked 
to low-grade inflammation and deleterious consequences if left unchecked. This is 
important in the anti-inflammatory response as well, particularly after exercise. A 
dysregulated anti-inflammatory response could be negative as it may serve as an immune 
system depressant, possibly not allowing proper pro-inflammatory responses to occur or 
not allowing proper resolution of inflammation (138). Therefore, the post-exercise up- 
and down-regulation of inflammation, helps to clean cell debris in damaged tissue, set the 
stage to repair the muscle (as well as vasculature, tendons, etc) following the exercise 
bout, as well as allow appropriate adaptations to occur in preparation for the next bout. 
The type of exercise can affect the inflammatory response to exercise, whether it 
be aerobic or resistance-based exercise. Regarding aerobic exercise, there appears to be a 
25  
“threshold” in intensity that needs to be met for leukocytosis and a response of exercise 
related cytokines. There is debate on what this threshold might be, with different 
percentages stated by different authors. In a meta-analysis, Cerqueira et al found that on 
average this “threshold” needed to be aerobic exercise above 64% VO2max (29). While 
changes were observed in more moderate exercise, exercise above this percentage 
resulted in greater elevations in white blood cells, and pro-inflammatory cytokines such 
as IL-6 and IL-8 (20). Studies that utilized models of eerobic exercise that was below the 
64% VO2 max did not show consistent alterations in white blood cells or pro- 
inflammatory cytokines. A common marker of exercise-induced muscle damage is 
circulating levels of creatine kinase, an enzyme found in skeletal muscle that should not 
be found circulating. It was noted that short low intensity aerobic exercise did not alter 
creatine kinase levels, and only increased after intensive and long exercise bouts (36). 
There is an inflammatory response to resistance-based exercise, this type of 
exercise usually involves extensive damage to muscle cells with disrupted contractile 
structures and other cytoskeletal components. While leukocytosis occurs in response to 
resistance exercise, it cannot be used as a reliable marker to quantify the amount of 
muscle damage that has occurred (95). Typically following intense resistance exercise, 
there is a release of creatine kinase into the blood stream, similar to the higher intensity 
aerobic exercise models. Elevations of muscle specific antigens (CD11b, CD15, CD56, 
CD163) are typically observed over a period of hours to days following resistance 
exercise and this elevation is typically dependent on the intensity of the muscle damage 
and exercise bout (96). Cytokines such as IL-6 and IL-8, which are primarily pro- 
inflammatory in their circulatory nature, are typically observed following strenuous 
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resistance exercise (115). Certain cytokines are expressed differently depending on the 
intensity and type of resistance based exercise. It has been shown that the kinetics of IL-6 
response differ between concentric and eccentric exercise, with greater responses 
observed with eccentric exercise, which is more damaging to skeletal muscle (120). In 
line with this, following resistance based muscle damaging exercise, there is typically 
soreness and tenderness, termed delayed onset muscle soreness. The exact cause and 
mechanism of soreness has been and is still debated, however it appears that this is due 
the swelling of muscle fibers that activate nocioceptors, which may or may not be 
directly caused by inflammatory markers (169). Further work needs to be done to fully 
elucidate the role of inflammatory markers on muscle soreness following strenuous 
resistance-based exercise. 
This time course transition from a primarily pro-inflammatory environment to 
more anti-inflammatory and resolute phase, in specifically referring to macrophages is 
known as the M1 to M2 shift. This has been shown to occur following both aerobic and 
resistance-based type exercise (52). This M title derives from macrophage and focuses on 
the population of macrophages. M1 macrophages are the CD86+ population and M2 are 
the CD163+ population, denoting a specific marker on their cell surface. CD86+ 
macrophages are upregulated early following exercise, typically within a few minutes. 
The CD86+ macrophages phagocytose cells, release free radicals to lyse cells and can 
alter the redox state of the skeletal muscle to aid in initial breakdown and response (51). 
These macrophages are also able to increase chemotactic ability of other cells and will 
help recruit other phagocytotic cells to the damaged tissue. The M1 population is 
upregulated quickly after exercise, will stay elevated for hours and typically decreases by 
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the 24-48 hour mark (161). Anti-inflammatory cytokines such as IL-10 and IL-4 can 
upregulate the differentiation of the M2 macrophages, which shift the inflammatory 
profile. The M2 population express the CD163+ marker and will typically replace the M1 
macrophages, dependent on the amount of tissue damage that has occurred. While 
stimulated by cytokines, CD163+ macrophages can also promote the release of IL-10 and 
stimulate production of IL-1Ra, as well as promote angiogenesis and upregulate 
production of glycoproteins to aid in cytoskeletal matrix remodeling (51). This helps to 
bring resolution to the inflammatory response, inhibiting the initial pro-inflammatory 
response from CD86+ macrophages. The upregulation of these CD163+ macrophages 
typically occurs around 24 hours, reaching peak elevations around 48 hours and staying 
elevated until up to 96 hours in some studies (111). All of these are targets that we intend 
to measure in the proposed study, as they are common exercise-related inflammatory 
markers and our genomic data suggests there could be alterations in the post-exercise 
inflammatory profile under histamine blockade. 
Following exercise, there is an upregulation of both pro- and anti-inflammatory 
responses and both are critical for recovery and adaptation to exercise. Data from our lab 
demonstrates that histamine blockade affects many of the genes that are associated with 
this post-exercise inflammatory response. Therefore, work is warranted to further 
examine the impact of histamine blockade on both the systemic and local inflammatory 
response to exercise. 
Histamine and Post-Exercise Recovery/Inflammation 
 
Work within our lab group has expanded to look at histamine’s actions on a 
broader scale. We have shown that exercise stimulates the release of histamine from mast 
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cells within skeletal muscle (127), turning on a pathway that potentially triggers a broad 
range of beneficial cellular adaptations in response to exercise (126, 60). Blocking the 
actions of histamines has been shown to alter multiple typical physiological responses 
that are associated with exercise. Among these exercise responses are: post-exercise 
hemodynamics (94, 60, 7) , glucose delivery and insulin sensitivity in skeletal muscle 
(41, 114) and broad mRNA and protein abundance effects during the acute recovery from 
exercise (126). 
This broad histamine footprint on the human exercise transcriptome leads to 
many interesting follow up questions. Part of these nearly 800 genes that were 
differentially affected by histamine receptor antagonism following exercise include 
vascular function, metabolism, and inflammation. Within the realm of inflammation, one 
of the top differentially expressed protein-coding gene that was downregulated by 
histamine receptor antagonist was IL-6. As previously discussed, IL-6 can be released by 
skeletal muscle and can have both pro-inflammatory and anti-inflammatory actions. In 
addition to IL-6, many of the other differentially expressed protein-coding genes are 
involved in cytokine and chemokine signaling. Therefore, these data suggest that 
histamine receptor antagonism may affect the post-exercise inflammatory response. 
However, as previously discussed, the acute inflammatory response to exercise lasts from 
24-48 hours and these protein coding gene data were only collected until 3 hours 
following exercise. Therefore, it is unknown if histamine receptor blockade has longer 
term effects on post-exercise vasodilation. As well, systemic markers of inflammation 
measured by venous blood draws have not been measured after exercise under histamine 
receptor antagonism. Our histamine transcriptome data gives promising direction that 
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post-exercise inflammation is impacted by histaminergic signaling and warrants further 
investigation. In addition, the widespread use of histamine receptor antagonists in the 
public suggest the need to further examine the role of histamine in exercise responses. 
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CHAPTER III 
EXPANATION OF THE METHODOLOGY 
 
 
 
General Experimental Approach 
 
All studies from the dissertation were conducted on the University of Oregon 
Eugene Campus in Esslinger Hall. All experimental visits were conducted in the Exercise 
and Environmental Physiology Laboratory utilizing the Evonuk Environmental Chamber 
for VO2peak tests and the Exercise Lab for all other experimental procedures. 
The study detailed in chapter IV was conducted in 3 parts. In part 1, an 
intramuscular thermocouple placed in the vastus lateralis of volunteers was used to 
measure skeletal muscle temperature during 60 minutes of unilateral dynamic knee 
extension exercise at 60% of peak power. In part 2, a skeletal muscle microdialysis probe 
was implanted in the right vastus lateralis to collect microdialysis effluent (dialysate) 
before and during 60 minutes of passive heating of the leg using pulsed short-wave 
diathermy. In addition, utilizing similar sterile insertion technique, an intramuscular 
thermocouple was also placed in the right vastus lateralis to monitor skeletal muscle 
temperature during the passive heating. Central hemodynamics (heart rate and blood 
pressure) were measured before and during exercise. In part 3, isolated human mast cells 
were exposed to varying physiological temperatures to investigate the direct effects of 
increased temperature on mast cell degranulation to further elucidate the role of 
temperature produced in exercising skeletal muscle on histamine release from mast cells. 
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In the study detailed in Chapter V, skeletal muscle microdialysis probes were 
placed in both the right and left vastus lateralis to collect skeletal muscle dialysate from 
subjects before, during, and after 60 minutes of unilateral dynamic knee extension 
exercise at 60% of peak power. In all subjects, the right leg served as the “exercise” leg 
and the left leg was the “rest” leg. Central hemodynamics (heart rate and blood pressure) 
were measured before, during, and after exercise. In vitro, isolated human mast cells were 
utilized to analyze mast cell degranulation when exposed to dialysate from different 
timepoints and exercise conditions (exercise leg vs rest leg, pre vs during vs after 
exercise). 
In the study detailed in chapter VI, venous blood samples were collected from 
subjects before and after 60 minutes of cycling exercise at 60% of their VO2peak once 
under placebo and once under H1 and H2 histamine receptor antagonism (using over-the- 
counter medications) to investigate the effect of histamine receptor antagonism on the 
acute inflammatory response to aerobic exercise. Subjects were given 4 weeks between 
their exercise visits, visits were block-randomized for drug conditions. Venous blood 
samples following exercise were obtained: immediately after,6,12,24, and 48 hours 
following exercise. Subjects also filled out 3-day food diaries to ensure diet was not 
significantly different on their two visits. Central (heart rate and blood pressure) and 
peripheral (femoral artery blood flow) hemodynamics were measured before and after 
each exercise session. 
32  
Subject Overview 
 
 
All studies conducted in this dissertation were approved by the Institutional 
Review Board at the University of Oregon (Protocols #02022017.003 for experiments in 
Chapter VI and V and #02172011.029 for the experiment in Chapter VI). Studies were 
conducted in accordance with guidelines set forth by the Office for Protection of Human 
Subjects at the University of Oregon. Written informed consent from all subjects 
subsequent to a verbal and written briefing of all experimental procedures for a given 
study. 
Twenty-eight (twenty-one men and seven women) healthy subjects participated in 
studies detailed in this dissertation (28 ± 6 years, 160.5 ± 13.5 cm, 72.5 ± 15.8 kg, 24.5 ± 
4.1 BMI) (mean ± SD). Subjects were deemed healthy following a standard health 
screening. All subjects were required to abstain from caffeine, alcohol, and exercise for at 
least 24hr prior to all studies. Subjects reported to the lab after an overnight fast for all 
studies described in chapters IV, V, and VI. No subjects were using any over-the-counter 
or prescription medications at the time of the study, with the exception of oral 
contraceptives. Female participants were studied during the early follicular phase of their 
menstrual cycle or during the placebo phase of their oral contraceptive. All female 
subjects had a negative pregnancy test prior to all studies. 
Specific Methodology 
Subject Characterization 
In the studies detailed in this dissertation, a combination of demographic and 
anthropometric measures including, age, height, weight, and BMI in addition to aerobic 
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capacity were used to portray the subjects and generalize the study findings. Subject 
weight was measured using a digital scale (Sartorius model MAPPIU-150FE-L, Elk 
Grove IL; Chapters IV, V, VI) and height was measured using a standard stadiometer 
(SECA North America, Chino CA; Chapters IV, V, VI). 
Passive Heating Utilizing Pulsed Short-Wave Diathermy 
 
As previously mentioned, study 2 in chapter IV examined collected intramuscular 
dialysate before and during 60 minutes of direct heating. There are multiple modalities 
that can be used for direct, passive heating of limbs. Some of these modalities include 
water immersion, using hot packs, as well as water-perfused suits (102, 103, 104). One of 
the goals of this study was to raise muscle temperature while minimizing the hydrostatic 
effects of water immersion and keeping a sterile field clear for placement of the 
intramuscular thermocouple and microdialysis fiber. For this study, we decided to utilize 
pulsed short-wave diathermy (PSWD) as it is a technique that has been safely and 
effectively used by the athletic training community to increase skeletal muscle 
temperature without adverse increases to skin temperature or surrounding tissues (147, 
117, 64). PSWD uses high-frequency electromagnetic currents emitted from a drumhead 
to heat skeletal muscle tissue, typically for therapeutic reasons. PSWD heats in a much 
larger area than typical ultrasound methods and increases in skeletal muscle temperature 
from 4-6°C have been observed utilizing different settings (81). We used the Megapulse 
II, which is a PSWD unit model designed by Accelerated Care Plus, seen in Figure 3.1. 
Based on previously collected pilot data from study 1 in Chapter VI, our goal was to heat 
skeletal muscle to an “exercising temperature” of 39.7°C. In order to do this, the settings 
for the PSWD unit were set to 800 pulses per second for 400 microseconds (40-48 W 
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average power, 150 W peak power) for 60 minutes applied directly above the vastus 
lateralis. The drumhead of the PSWD was approximately 2 cm from the surface of the 
skin for all subjects and did not make direct contact with the skin. No subjects reported 
any adverse local or systemic effects during or after the PSWD session. This passive 
heating modality also has not been reported to have any direct systemic cardiovascular 
effects and we did not note any significant central hemodynamic changes during the 
passive heating with PSWD session. 
 
 
Figure 3.1. Pulsed Short Wave Diathermy Unit. For study 2 in Chapter VI, pulsed 
short wave diathermy was used as a passive heating modality to directly increase skeletal 
muscle temperature. The model used was Megapulse II (Accelerated Care Plus 
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Skeletal Muscle Microdialysis 
 
Utilizing skeletal muscle microdialysis, it is possible to collect extracellular fluid 
in vivo. The integrity of the microdialysis fibers is maintained during exercise, allowing 
the ability to sample the extracellular fluid from muscle during both moderate and high 
intensity exercise. The modern probe for microdialysis utilizes a hollow semi-permeable 
membrane which can be implanted safely into different tissues including skin, brain, and 
skeletal muscle (31, 137). There are different permeability options based upon their 
molecular weight cutoff that can be selected for the probe, with higher permeabilities 
allowing for larger molecules to pass through and smaller permeability options being 
more conservative and selective. These permeability options typically range from 3 to 
100 kilodaltons (kDa). This semi-permeable membrane is connected to inlet/outlet tubing 
and a saline solution is used with a microdialysis pump to sample the extracellular fluid 
which is then collected in tubes connected to the outlet tubing. For these experiments, we 
chose to use the 63MD model with 100 kDa cutoff utilizing a non-linear probe as it was 
well-tolerated by subjects during exercise and the integrity of the microdialysis fibers 
survived during the repeated contractions from dynamic unilateral knee-extension 
exercise. 
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Figure 3.2. Intramuscular microdialysis fiber. The intramuscular microdialysis fiber 
consists of a semi-permeable membrane that is inserted into the skeletal muscle to collect 
extracellular fluid. Saline is pumped through inlet tubing via a syringe pump, mixes with 
the extracellular fluid, and dialysate (sample) is collected in a tube collected to the outlet 
tubing. (Note: Figure from ALEXYS Neurotransmitter analyzer, 4) 
 
 
For experiments in chapters IV and V, all probes were implanted using sterile 
technique. The skin was anesthetized using Lignospan (Septodont Inc, PA) which is an 
injection mixture consisting of lidocaine hydrochloride 2% and epinephrine 1:100,000. 
The underlying fascia was anesthetized using (Septodont Inc, PA) which is a 4% 
prilocaine hydrochloride injection solution. Care was taken to ensure that prilocaine was 
not injected into the skeletal muscle and probes were inserted in a direction parallel with 
muscle fiber orientation. Muscle fiber orientation was assessed utilizing ultrasound 
technique before placement of fibers. The probes were held in place by covering the entry 
site with Tegaderm (3M), sterile transparent medical dressing. No probes ruptured or 
broke before, during, or after exercise in any of the subjects. The probe was perfused with 
a 0.9% saline at a rate of 5µl min using a microinfusion pump (CMA 400 Microdialysis 
pump, CMA, MA). This perfusion rate was chosen based upon successful experiments 
performed by our lab using this specific perfusion pump and rate. 
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As previously mentioned, dialysate from the skeletal muscle was collected into an 
outlet tube which consisted of a sterile microtube. The microtubes were covered with 
non-porous tape during the sampling period. For the experiment in chapter IV, samples 
were collected every 30 minutes before heating and every 20 minutes during passive 
heating. For the experiment in chapter V, dialysate samples were collected every 30 
minutes before exercise, every 20 minutes during 60 minutes of exercise, and every 20 
minutes following 60 minutes of recovery from exercise. For both experiments, 
microtube weight was documented before and after dialysate collected. Samples were 
stored at -80°C until analysis. 
Intramuscular Thermocouple to Measure Intramuscular Temperature 
 
For study 1 and study 2 in the experiments detailed in chapter IV, an 
intramuscular thermocouple probe was placed into the vastus lateralis to monitor 
intramuscular temperature. In its most basic definition, a thermocouple is a 
thermoelectric device used for measuring temperatures. Typically, a thermocouple is 
composed for two dissimilar metals that are joined together to form two junctions (105, 
32). One junction is placed in the environment that is being measured, in this case the 
skeletal muscle, and the other junction remains at a known constant temperature. The 
change in temperature in the junction in the skeletal muscle is measured in millivolts as it 
flows through the loop, this is then measured utilizing software (Windaq) in which a 
given change in millivolts is equal to a change in temperature. For this experiment, we 
utilized the IT-17 (Physitemp, PA). We selected this particular probe for its accuracy 
(0.1°C in the physiological range according to the manufacturer), certification by the 
National Institute of Standards and Technology, and its common usage in the research 
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literature. This company utilizes copper and constantan as their wire metals. Sterile 
technique was used for the placement of the intramuscular thermocouple in to the vastus 
lateralis. The skin was anesthetized using Lignospan (Septodont Inc, PA) which is an 
injection mixture consisting of lidocaine hydrochloride 2% and epinephrine 1:100,000. 
The underlying fascia was anesthetized using (Septodont Inc, PA) which is a 4% 
prilocaine hydrochloride injection solution. Care was taken to ensure that prilocaine was 
not injected into the skeletal muscle and probes were inserted in a direction parallel with 
muscle fiber orientation. The probe wire is typically connected to a computer running 
Windaq software. For this experiment, we connected the probe wire to a portable 
thermocouple thermometer device to monitor skeletal muscle temperature. Temperature 
was constantly monitored throughout the experiment and recorded every 10 minutes 
during the passive heating protocol. An illustration of the intramuscular thermocouple 
provided by the manufacturer is below. 
 
 
 
 
 
Figure 3.3. Intramuscular Thermocouple 
Temperature is measured at the end of the probe, which is 36 standard length. The plug 
on the end of the extension was plugged in to a portable thermocouple thermometer to 
measure intramuscular temperature during the passive heating protocol. Illustration 
provided by Physitemp™ 
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Exercise Interventions 
 
Unilateral Dynamic Knee-Extension Exercise 
 
Many labs, including ours, have utilized whole-body exercise such as treadmill 
running and cycling to examine exercise responses. There also exist exercise modalities 
that are aerobic in nature that require less muscle mass, such as unilateral dynamic knee- 
extension exercise (19, 3). This exercise model is unique and beneficial in that it isolates 
muscle activation to the quadriceps, allowing for targeted investigation of a single muscle 
group. As well, the other leg remains at rest so that intra-subject characterizations can be 
made. Our lab has shown an abolishment of the post-exercise vasodilatory response 
utilizing H1 and H2 histamine receptor antagonism following 60 minutes of dynamic 
unilateral knee extension exercise (7). This is different from the moderate intensity 
cycling response in which histamine receptor blockade results in an 80% reduction (94). 
With the abolishment observed following unilateral dynamic knee-extension exercise, the 
post-exercise vasodilatory response following this exercise modality is entirely histamine 
H1/H2 receptor dependent and is an optimal exercise modality for histamine related 
exercise research. 
For study 1 described in chapter IV and the study described in chapter V, 
unilateral dynamic knee-extension exercise was performed on a custom-built knee 
extension ergometer based on a computer-controlled step-motor. This provided resistance 
against the subjects’ lower leg on extension and allowed for passive relaxation. Power 
was calculated and maintained at the assigned level based on real-time measures of 
angular velocity and torque. Subjects were seated with their back at 60° upright and knee- 
extension exercise was performed with the right leg over a 45° range of motion, starting 
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with the leg hanging at 90° of flexion. Subjects maintained a cadence of 45 kicks per 
minute with visual feedback provided from custom software. 
For study 1 in chapter VI and the study in chapter V, subjects performed 60 
minutes of unilateral dynamic knee extension exercise at 60% of peak power. Peak power 
was determined during a maximal unilateral dynamic knee extension exercise test. To 
determine peak power, subjects performed a five-minute warm-up at a workload of 5 
watts and then the workload was ramped incrementally at a rate of 3 watts per minute. 
Subjects were required to maintain power within 1 watt of the target workload in addition 
to maintaining a cadence within 5 kicks per minute. Cadence was set on a metronome to 
45 kicks per minute. Subjects were encouraged to continue and performed the exercise 
until volitional fatigue. During the experimental visit of 60 minutes of dynamic knee 
extension exercise, subjects were required to maintain power within 1 watt of the target 
workload (60% of peak power) and also maintain a cadence within 5 kicks per minute. 
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Figure 3.4. Unilateral Dynamic Knee Extension Exercise. For study 1 detailed in 
Chapter IV and the study detailed in Chapter V, we used a custom-built ergometer for 
subjects to complete unilateral dynamic knee extension exercise. We have used this 
ergometer and methodology of exercise extensively in our lab to examine post-exercise 
hemodynamic responses 
 
 
 
Peak Aerobic Power 
 
For the study detailed in chapter VI, subjects were asked to perform an 
incremental cycle exercise test (Lode Excalibur, Groningen, the Netherlands) comprised 
of one-minute workload increments in order to determine their peak oxygen uptake 
(VO2peak). After a two-minute warm-up period of light cycling (20-30 W), workload 
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increased by 25 W every minute. Subjects maintained 60 rpm throughout the test and 
whole-body oxygen uptake was measured with a mixing chamber (Parvomedics, Sandy, 
UT). The peak test was ended when subjects were no longer able to keep at least 60 rpm 
and subjects were given a cool-down period (50 watts) following the test. All subjects 
reached subjective exhaustion (rating of perceived exertion of 19-20) within the 8-12 
minute period and peak aerobic power was determined to be obtained if the respiratory 
exchange ratio was greater than 1.10. True peak tests should be accompanied by high 
ratings of perceived exertion (19-20), heart rate (>95% of predicted), a respiratory 
exchange ratio greater than 1.0, and a plateau of VO2 measures with increasing 
workloads. We utilized an open circuit technique for oxygen consumption measurement, 
this required knowledge of gas concentrations in the room air (inspired) and expired air. 
Open circuit spirometry was chosen for this study due to the ease of obtaining the 
measurement and the accuracy provided to determine the workload for the exercise 
intervention in Chapter VI. 
Moderate-Intensity Dynamic (Cycle Ergometer) Exercise 
 
For the study detailed in chapter VI, subjects returned to the lab to perform 60 
minutes of seated cycling exercise on a stationary cycle ergometer at a workload 
corresponding to a steady state VO2 of 60% of VO2peak. This was estimated from the 
equation: 
Estimated workload (watts) = (Target VO2 (ml/min)/12) – 25 
 
Steady state oxygen consumption was obtained within 3-5 minutes and the 
subjects remained there for the entirety of the exercise session. We chose this intensity 
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specifically since it produces a sustained post-exercise vasodilatory/hypotensive response 
that is blunted by H1 and H2 histamine receptor antagonism. Heart rate, blood pressure, 
and RPE were monitored throughout the exercise session. 
Rating of Perceived Exertion 
 
The concept of “perceived exertion” typically refers to the strain or exerted effort 
that is perceived by a subject regarding the work demanded on the musculoskeletal, 
cardiovascular, and pulmonary systems. Volunteers are typically asked to rate their 
exertion “right now” on a Likert scale. For the study detailed in Chapter VI, a 6-20 scale 
was used. The 6-20 scale was developed by Gunnar Borg in 1982 and is advantageous in 
that the numbers approximate heart rate (60-200 beats per minute)(15). Descriptions of 
perceived exertion are: 6 none; 7-8 very, very light; 9-10 very light; 11-12 fairly light; 
13-14 somewhat hard; 15-16 hard; 17-18 very hard; and 19-20 very, very hard. While 
other exertion scales have been utilized (such as a 1-10 scale utilized in resistance 
training protocols), we chose the Borg 6-20 as it has been extensively used in the research 
literature as a reliable method to ascertain perceived exertion of subjects, particularly 
during aerobic exercise. 
 
 
 
Hemodynamic Measurements 
 
In the studies detailed in chapters IV, V, and VI all hemodynamic measurements 
were made in a thermoneutral room (23°C). Measurements were made with the subject 
supine before and after exercise and upright while performing the knee extension exercise 
or stationary cycling. 
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Heart Rate 
 
Heart rate was monitored using a three-lead electrocardiograph (Tango+, SunTech 
Medical, Raleigh NC) in the experiments listed in chapters IV, V, VI. It is expressed as 
beats per minute (BPM). 
Arterial Blood Pressure 
 
Arterial blood pressure was measured in the right arm using an automated 
sphygmomanometer (Tango+, Suntech Medical, Raleigh NC). It is expressed as 
millimeters of mercury (mmHg). Mean arterial pressure was calculated as: 
MAP = Diastolic BP + [Systolic BP – Diastolic BP/3] 
 
Femoral Blood Flow 
 
Our laboratory has used and has continued to use Doppler ultrasound technology 
for the assessment of femoral blood flow due to its lack of invasiveness and high 
accuracy. Classic techniques to measure blood flow in human physiology research 
include indicator infusion methods. These are based on a known infused indicator mixing 
in blood and blood flow is measured by the dilution of dye within the blood with some of 
these indicators being indocyanine green dye and Evans blue dye (58, 131). While easy to 
perform, these measurement approaches require invasive catheterization and steady-state 
conditions. We use Doppler ultrasound as it is a widely accepted and a reliable technique 
to monitor blood flow velocity. This method consists of using a probe, which produces 
sound waves that bounce off tissues and a 2-dimensional image is created from the 
difference between the outgoing vs incoming wave velocities. This image then allows for 
the measurement of arterial diameter and the shift in sound waves, known as the doppler 
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shift, is used to calculate the velocity of blood flowing past the probe. It provides high 
temporal resolution and continuous sampling (67). Due to its lack of invasiveness, high 
reliability, and consistency in accurate measurements it is used for our studies. 
Specifically, it was used to image skeletal muscle for microdialysis fiber/thermocouple 
placement in Chapter IV, microdialysis fiber placement in Chapter V, and for femoral 
blood flow measurements in Chapter VI. 
For the study detailed in chapter VI, a linear array vascular ultrasound probe was 
used (9 MHz, Phillips iE33, Andover MA). An insonation angle of 600 was used to 
measure blood flow in the common femoral artery, approximately 2-3 cm proximal to the 
bifurcation. The Doppler ultrasound machine was interfaced with a computer running 
custom audio recording software. Velocity measurements were determined using an 
intensity-weighted algorithm (Duc2, custom software), subsequent to demodulation of 
forward and reverse Doppler frequencies. Femoral diameter was measured in triplicate 
during diastole following velocity measurements. The diameter measurement of the 
common femoral artery was made 2-3 cm proximal to the bifurcation of the superficial 
and deep femoral artery branches of the leg. Femoral blood flow was expressed in ml per 
min and calculated using the following equation: 
FBF = π(diameter/2)2  x mean blood velocity x 60 
 
Femoral blood flow is expressed in ml*min-1, mean blood velocity is in cm*s-1, 
femoral diameter is in cm, and 60 was used to convert from ml*s-1 to ml*min-1. Femoral 
vascular conductance was used to account for arterial blood pressures influence on 
femoral blood flow. Vascular conductance was expressed as ml per min per mmHg and 
calculated using the following equation. 
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FVC = Femoral Blood Flow/Mean Arterial Blood Pressure 
 
Venous Blood Sampling 
 
In the study detailed in Chapter VI, blood samples were collected using a 
venipuncture method to collect blood from the antecubital space of the right and left arm. 
Blood was collected before, immediately after, and 6, 12, 24, and 48 hours after exercise 
using a Safety-Lok blood collection set (Becton, Dickinson and Company, Franklin 
Lakes NJ). Blood was collected into 3 mL vacutainers that were coated with K2EDTA 
(BD Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ). At each 
collection point, 2 tubes were centrifuged for 10 min at 1000 RCF and plasma was 
extracted and frozen at -80°C until further analysis. At each time point, one tube was 
processed for quantification of white blood cell populations via flow cytometry (see 
Assays and Analysis for further details). 
Oral Drugs 
 
Oral antihistamine drugs were used in the study detailed in chapter VI. Histamine 
H1 and H2 receptors were blocked using 540 mg fexofenadine and 300 mg ranitidine. 
3 subjects in the study of chapter VI were given 40 mg famotidine in place of 300 mg 
ranitidine. Famotidine was substituted in place of ranitidine due to a voluntary FDA 
recall on ranitidine. Published pharmacokinetic studies performed by others assured us 
that we would have similar results for H2 receptor antagonism using 40 mg famotidine in 
place of 300 mg ranitidine. We have shown that this combination of fexofenadine and 
ranitidine blunts the sustained post-exercise vasodilation following unilateral dynamic 
knee extension exercise. Responses are 90% inhibited within 1 hour and remain inhibited 
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6 hours after administration. Time to peak concentration and half-life for the medications 
used: fexofenadine is 1.15 hours with a half-life of 12 hours, ranitidine is 2.2 hours with a 
half-life of 2.6 hours, famotidine is 1.5 hours with a half-life 3 hours. None of these drugs 
have any known direct cardiovascular effects when they are administered in resting 
situations, do not elicit any major cardiovascular changes, and do not cross the blood- 
brain barrier. Subjects ingested the histamine receptor antagonists with 6-8 oz of water 60 
minutes prior to exercise. 
Assays and Analysis 
 
Histamine Assay. Interstitial histamine concentrations were analyzed in intramuscular 
dialysate collected in the study detailed in chapter IV. Interstitial histamine was measured 
using a standard enzyme-linked immunosorbent assay (Rocky Mountain Diagnostics, 
Colorado Springs, CO) and performed in accordance to the manufacturer’s instructions. 
All samples and standards were acylated by combining them with 25 µl of acylation 
buffer and 25ul acylation reagent and incubating on a plate shaker at 600 rpm for 45 
minutes at room temperature. 200 µl distilled water was added to all wells and the 
microplate was incubated on a plate shaker at 600 rpm for 15 minutes at room 
temperature. 25ul of the samples and standards were transferred to a 96-well microplate 
pre-coated with an antibody raised against human histamine. 100 µl of a histamine goat 
anti-serum was added to all wells. The microplate was then incubated on a plate shaker at 
600 rpm for 3 hours at room temperature. The plate was then washed four times and 100 
µl of an enzyme conjugate containing an anti-goat IgG was added to all wells and 
incubated on a plate shaker at 600 rpm for 30 minutes at room temperature. The plate was 
again washed and 100 µl of a tetramethylbenzidine substrate solution was added to all 
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wells and incubated on a plate shaker at 600 rpm for 25 minutes at room temperature. 
Finally, 100 µl of a stop solution containing sulfuric acid was added to all wells. The 
absorbance was then measured at a wavelength of 450 for each sample and plotted 
against the absorbance of a set of known histamine standards using a 5-parameter logistic 
regression. 
Mast Cell Culturing Protocol. Isolated human mast cells (Kerafast LLC, Boston, MA) 
were cultured for experiments in Chapter IV and Chapter V. Cells arrived frozen from the 
manufacturer and we woke them by warming the vial of cells in a 37°C bath just until 
thawed. The cell suspension was transferred to a 15ml conical tube containing 5ml of 
warm growth medium. Warm growth medium consisted of basal medium (Gibco 
10639011), penicillin-streptomycin 10,000U/ml (Gibco 15140), L-glutamine 200mM 
(Gibco 25030-081) and Primocin 500mg (Fisher). Cells were mixed in warm growth 
medium and centrifuged at 450g for 5 minutes at room temperature. Cells were 
resuspended in 5ml of growth medium and transferred to a T25 flask. Cells were left for 
2-3 days and then transferred to a T75 flask with additional 15ml of fresh growth 
medium. Cells were split approximately every 3-4 days over the course of 2 weeks. After 
approximately two weeks and once cells were at an appropriate viability (greater than 
80%) the cells were prepared for freezing for future use in experiments. Cells were then 
centrifuged at 600rpm for 10 minutes. Supernatant was removed and cells were 
resuspended in pZERVE (Protide Pharmaceuticals) to have a density of 5x106 cells/ml. 
pZERVE is a cryopreservation solution that does not contain any dimethyl sulfoxide 
(DMSO), fetal bovine serum (FBS), nor any other animal protein. This suspension was 
dispensed in to sterile cryotubes in 1-2ml aliquots, sealed and stored at room temperature 
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for 30 minutes with gentle agitation. Following this step, vials were then placed in an 
insulated container at -20°C for 60 minutes. Insulation was removed and vials were 
placed in -80°C for 60 minutes. Vials were then transferred to vapor phase of liquid 
nitrogen for 24 hours. Following this 24-hour incubation period, vials were finally moved 
to liquid phase of liquid nitrogen for storage until use for experiments. The above- 
mentioned waking protocol was used to prepare the frozen cells for experiments. The 
waking protocol typically took 1-2 weeks for cells to reach appropriate cell density and 
viability for experiments. 
In-Vitro Mast Cell Degranulation Assay. Isolated human mast cells (Kerafast LLC, 
Boston MA) were used for study 3 detailed in Chapter IV and for the study detailed in 
Chapter V. This was a degranulation protocol that we developed in our lab based upon 
previously published protocols utilizing isolated mast cell lines. Mast cell degranulation 
was quantified in response to temperature (Chapter IV) or exposure to human skeletal 
muscle dialysate (Chapter V). Degranulation was determined as the release of the granule 
marker β-hexosaminidase. Cultured human mast cells were transferred in to wells on a 
96-well plate in imaging medium buffer. For study 3 in the set of experiments in Chapter 
IV and the study in Chapter V, 48/80 was used as a positive control. 2 mg of compound 
48/80 was dissolved in 1 ml imaging buffer. 50 ul of 2mg/ml of compound 48/80 was 
added to the plated mast cells in the respective positive control wells. 50 ul of imaging 
buffer was used as a negative control, and used to subtract background in respective 
experiments. For study 3 in the set of experiments detailed in Chapter IV, mast cells were 
exposed to three physiological temperatures to measure degranulation: 34, 37, and 39°C 
for 20 minutes. In the study detailed in Chapter V, mast cells were exposed to 50ul of 
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dialysate collected from skeletal muscle for 20 minutes at 37°C. In both set of 
experiments, after 20 minutes, cells were centrifuged and the supernatants removed. 
Supernatants were reacted with 2 mM 4-Nitrophenyl N-acetly-B-D-glucosamide (Sigma) 
at 37°C for 2 hours. Then, 0.5 M Tris(hydroxymethyl)aminomethane was used to stop the 
reaction, and the absorbance was read at 405 nm. Total content was determined by 
addition of Triton X-100 to lyse the cells. Degranulation is expressed as a percentage of 
β-hexosaminidase activity in the supernatant divided by the total (supernatant plus pellet) 
activity. 
Inflammation Panel. In the study detailed in Chapter VI, plasma was analyzed for 
inflammatory cytokines in 5 subjects via a bead-based flow cytometry kit (Biolegend, 
LEGENDplex Human Inflammation Panel 1, multi-analyte flow assay kit). This method 
of cytokine identification uses beads of varying size coated with antigens specific to 
cytokines of interest (MCP-1, IL-8, IL-10, IL-17A). The size and fluorescence of the 
beads allows for separation and quantification of the cytokine by flow cytometry 
(Gallios, Beckman Coulter Life Science, Indianapolis IN). 
Cell Staining Preparation from Whole Blood. For flow cytometry analysis, our 
laboratory technician Karen Needham helped to develop a cell staining protocol in 
conjunction with established, published literature. 2.0 ml of fresh whole blood was added 
to a 10x solution of red blood cell lysis buffer. This was incubated for 10 minutes at room 
temperature. Tubes were centrifuged at 500G for 10 minutes and supernatant was 
removed. The pellet was resuspended in 30mL 1x phosphate-buffered saline (PBS) and 
passed through a 40 micron filter into a fresh tube. The sample was then spun for 10 
minutes at 500G and supernatant was removed. The pellet was then resuspended in 3 ml 
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PBS and cell count was quantified. Cells were diluted to 1x106 cells/ml with cold PBS 
and 1µl violet stain per ml of cell suspension was added and incubated for 30 minutes at 
room temperature. Violet stained cells were diluted up to 30 ml with cold PBS and tubes 
were spun for 10 minutes at 500G. Supernatant was discarded, and the pellet was 
resuspended with 4% paraformaldehyde at 1ml per 1 million cells. After a 10-minute 
incubation in paraformaldehyde at room temperature this suspension was topped off to 
30ml with cold PBS. This cell suspension was spun for 10 minutes at 500G, supernatant 
removed, and the cell pellet was resuspended in 2 mL of PBS. This was stored in the 
dark at 4°C until ready for staining and cytometering. 
Cell Staining Protocol. Cell suspensions were re-suspended and 1.5 x 106 cells were 
transferred to individual 2.0ml microcentrifuge tubes for each staining sample plus the 
unstained cells. Cells were pelleted at 500G for 5 minutes. Cells were re-suspended in 
100ul of staining buffer (PBS + 1% BSA + 10% FBS = Biolegend 420201 + 50 mL FBS 
– Gibco 26140-129, heat deactivated at 560 for 45 minutes) plus 10ul mouse IgG 
(Jackson Immuno – ChromPure 015-000-003). Suspensions were incubated for 30 
minutes at room temperature. Cells were washed with 1mL of staining buffer, centrifuged 
and supernatant was discarded. 100ul of antibody staining cocktail was added to each 
tube and incubated for 30 minutes in the dark at room temperature. 1 mL of staining 
buffer was added to each tube, cells were centrifuged, and supernatant was discarded. 
Cell pellet was re-suspended in 500uL staining buffer and read in a flow cytometer. The 
following antibodies were used for the leukocyte staining protocol: CD62E, CD86, 
CD309, CD34, CD192, CD66B, CD14, CD16, CD3, CD19, CD56, CD45. 
Statistical Analysis 
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Statistical inferences were drawn from a combination of paired t-tests, 1-way, and 
2-way repeated measures of analysis of variance (ANOVAs) using GraphPad Prism 
(GraphPad Software, San Diego, CA, USA). Fisher’s Least Significant Differences was 
used as a post-hoc analysis where main or interaction effects were observed. For all tests, 
significance was set at P < 0.05. Variables describing the distribution of the subject 
population, including anthropometric and demographic measures are presented as means 
± standard deviation (SD). Data describing physiological variables between conditions or 
over time are presented as means ± standard error of the mean (SEM) to display the 
precision of the interventions. 
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CHAPTER IV 
 
THE ROLE OF TEMPERATURE ON EXERCISE-INDUCED SKELETAL 
MUSCLE HISTAMINE RELEASE 
 
 
Introduction 
 
Blood flow to previously exercised muscle remains elevated for several hours 
following the cessation of exercise, termed sustained post-exercise vasodilation. This 
results in systemic responses with mean arterial pressure being reduced below pre- 
exercise levels following moderate-intensity aerobic exercise (76, 60). Our lab has 
demonstrated that this response is highly dependent upon histamine receptor activation, 
as histamine H1 and H2 receptor antagonism using over-the-counter medications reduces 
this post-exercise response ~80% (94). In addition, our lab has also demonstrated that 
histamine concentrations within skeletal muscle increase in response to exercise (127). 
The source of this histamine can either be released from mast cells via degranulation 
and/or de novo formation via increased activity of the enzyme histidine decarboxylase 
(HDC) which converts the amino acid l-histidine to histamine (135). While we have 
shown that histamine is an important mediator in this sustained post-exercise vasodilatory 
response, the exercise “signal” that causes the increase in histamine levels has not been 
identified. Our lab has ruled out exercise-induced oxidative stress as a potential trigger 
(125), however there still remain other exercise factors that have not yet been 
investigated. 
There are multiple exercise factors or conditions both systemically and locally in 
active skeletal muscle that are altered during exercise. Some of these localized responses 
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include a decrease in pH, the physical contraction of skeletal muscle fibers, an increase in 
skeletal muscle temperature, an increase in reactive oxygen species, and others (148, 148, 
45). It has been well established in the research literature that during exercise, there is 
heat production by exercising skeletal muscle resulting in an increase in skeletal muscle 
temperature (54). This increase in skeletal muscle temperature is beneficial as it can 
increase enzymatic activity of key molecules that are necessary for appropriate exercise 
responses. One particular enzyme that is both important for force production in skeletal 
muscle and is temperature sensitive is myofibrillar ATPase (mATPase). During the cross- 
bridge cycle, myosin molecules binds and hydrolyzes ATP during force generation. 
ATPase activity is positively correlated with muscle contraction velocity, with slower 
fiber types containing less ATPase enzyme than fast fiber types. It has been shown that 
the increase in temperature in human skeletal muscle can aid in the increase of mATPase 
enzymatic activity, in turn allowing for greater force production that is needed with 
higher intensity exercise. Increases in skeletal muscle temperature have also been shown 
to have positive allosteric effects on rate-limiting metabolic enzymes such as 
phosphofructokinase (glycolysis) and cytochrome oxidase (aerobic respiration). In 
addition, this increased skeletal muscle temperature can also have beneficial effects on 
excitation-contraction coupling and mechanical contraction of muscle fibers (22). 
Relating back to our focus on histamine, elevated temperatures in skeletal muscle can 
cause the release of cytokines and soluble factors that can be found within skeletal 
muscle (150). This elevation of temperature in skeletal muscle could cause an increase in 
mast cell degranulation, which in turn would cause an increased release of histamine. 
Elevated temperatures have been shown to increase activity of HDC in a linear fashion up 
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to a point, where it then plateaus beyond what is typically physiologically observed in 
human skeletal muscle (132, 133). Due to the nature of the enzyme, it is possible that an 
increase in temperature in skeletal muscle during exercise might increase the activity of 
histidine decarboxylase leading to the observed increase in histamine concentrations in 
skeletal muscle. 
Given that elevated temperatures can possibly induce human mast cell 
degranulation and/or alter enzymatic activity of histidine decarboxylase and it is known 
that increased temperature plays an important role in skeletal muscle during exercise, the 
study was proposed to investigate if heat production may be the “exercise signal” for the 
increases in intramuscular histamine observed with exercise. Therefore, the overall 
purpose of this study was to determine if the increase in skeletal muscle temperature is an 
important mediator in the upstream signaling that leads to histamine release in skeletal 
muscle with exercise. Our goal was to investigate the temperature of skeletal muscle 
during unilateral knee extension exercise and then attempt to isolate the increase in 
temperature apart from other exercise factors. To isolate temperature as a variable, we 
sought a passive heating modality which would not involve muscle contraction, alter pH, 
and other exercise “factors.” Study 1 was operationally-driven and we aimed to 
investigate the rise in skeletal muscle temperature using our exercise model of dynamic 
unilateral knee extension exercise. In study 2, we tested the hypothesis that passively 
heating skeletal muscle up to 39°C using pulsed short-wave diathermy would result in 
increases in intramuscular histamine concentrations that are closely matched to exercising 
values. In study 3, a follow-up study, the purpose was to determine if increases in heat 
would directly cause increased degranulation of mast cells in vitro. We hypothesized that 
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step-wise increases in heat (matched to physiological values) would increase mast cell 
degranulation, measured by β-hexosaminidase release. 
Methods 
 
 
Subjects 
 
 
For study one, five (1 female, 4 males) young healthy non-smoking subjects volunteered. 
For study two, we had seven (2 females, 5 males) young healthy non-smoking subjects 
volunteer. There was no subject that participated in both study one and study two, each 
study had a unique cohort of subjects. All studies were approved by the Institutional 
Review Board at the University of Oregon and was performed in accordance with the 
principles outlined by the Declaration of Helsinki. Written, informed consent was 
obtained from all subjects subsequent to a verbal and written briefing of all experimental 
procedures. Subjects were deemed healthy following a standard health history 
questionnaire. All subjects were required to abstain from caffeine, alcohol, and exercise 
for 24 h before studies. Additionally, subjects reported to the laboratory in the morning 
after an overnight fast. No subjects were using over-the-counter or prescription 
medications at the time of study, with the exception of oral contraceptives. Female 
participants were studied during the early follicular phase of their menstrual cycle or 
during the placebo phase of their oral contraceptive. 
 
Screening Visit 
 
 
During this visit, subject’s physical characteristics were obtained (height, weight, body 
mass index) and they were familiarized with the exercise model and hemodynamic 
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measurements. Arterial pressure was assessed using an automated auscultatory 
sphygmomanometer (Tango+; SunTech Medical, Raleigh, NC, United States) after 5 min 
of supine rest. 
 
Study Visit (Study 1) 
 
 
Experimental approach 
 
 
The goal of this experiment was to measure temperature in skeletal muscle during 
dynamic unilateral knee extension exercise. This was operationally driven research, 
considered pilot work to determine the change of skeletal muscle temperature over the 
course of one hour using this exercise modality. An intramuscular thermocouple was 
placed into the vastus lateralis before exercise under sterile technique to measure 
intramuscular temperature. Subjects then performed unilateral dynamic knee extension 
exercise at 60% of their peak kicking power for 60 minutes. 
 
Study Visit (Study 2) 
 
 
Experimental approach 
 
 
The goal of this experiment was to passively raise skeletal muscle temperature to values 
observed during dynamic unilateral knee extension exercise and measure histamine 
concentrations in collected skeletal muscle dialysate. We had a goal to raise skeletal 
muscle temperature utilizing the data we collected in study 1 to determine the time course 
of skeletal muscle temperature during our typical protocol of unilateral knee extension 
exercise at 60% of peak kicking power for 60 minutes. The data from this pilot 
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experiment is presented in Figure 4.1. Skeletal muscle temperature rose rapidly and then 
begin to plateau at around 30 mins at approximately 39°C. Therefore, this experiment 
aimed to passively raise skeletal muscle temperature to the values observed during 
exercise while collecting skeletal muscle microdialysate, with the end goal to compare 
these skeletal muscle histamine concentrations to those observed from exercise. 
 
 
 
Measurements 
 
 
Pulsed Short Wave Diathermy 
 
 
The diathermy unit used to increase the temperature of skeletal muscle was the 
Megapulse (Accelerated Care Plus-LLC, Topeka, Kansas) with an operating frequency of 
27.12 MHz and a pulsed mode yielding 800 bursts per second. A picture of the 
Megapulse unit can be found in the “Chapter II - Explanation of the Methodology” 
section on Page 32. The diathermy unit consists of an induction drum coil electrode that 
was used to deliver the electromagnetic energy. The diathermy drum was 200 cm2 and 
had a 2.5 cm space plate to protect the tissue from direct contact with the electrode. We 
placed the diathermy drum above the anterior aspect of the muscle belly 1 cm above the 
subject's skin. We positioned the drum so that the tip of the thermistor was in direct line 
with the center of the drum. Diathermy was applied for 60 minutes at the following 
settings: 800 bursts per second; 400-psecond burst duration; 850-psecond interburst 
interval with a peak root mean square amplitude of 150 W per burst and an average root 
mean square output of 48 W. 
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Skeletal muscle microdialysis and histamine ELISA 
 
 
All probes were inserted using sterile technique. The skin was anesthetized using 
a lidocaine (2%) and epinephrine (1:100,000) solution (Septodont, France) and 
underlying fascia was anesthetized using prilocaine hydrochloride (4%) (Septodont, 
France). Care was taken to ensure that the lidocaine and prilocaine was not injected into 
the skeletal muscle. Probes were inserted in the vastus lateralis in a direction parallel with 
muscle fiber orientation (~19°, relative to long-axis of muscle) using a splittable 
introducer. After insertion, probes were held in place by covering the entry site with a 
sterile transparent medical dressing. Probes used to measure interstitial histamine had a 
100-kDa molecular mass cutoff with a 30-mm polyarylethersulphone membrane (63 MD 
Catheter, MDialysis, Stockholm, Sweden). Subsequent to insertion, microdialysis probes 
were perfused continuously at a rate of 5 µl/min (CMA 400 Microdialysis pump, CMA, 
North Chelmsford, MA). Probes used to measure histamine were perfused with a 0.9% 
saline solution. After insertion of the fiber and intramuscular thermocouple, dialysate 
was collected during 60 minutes of supine rest before heating and then every 20 minutes 
during heating. 
 
Interstitial histamine was measured using an enzyme-linked immunosorbent assay 
(Rocky Mountain Diagnostics, Colorado Springs, CO) and performed in accordance with 
the manufacturer’s instructions. Interstitial tryptase was measured using an enzyme- 
linked immunosorbent assay and performed in accordance with the manufacturer’s 
instructions adapted for microdialysis (Kamiya Biomedical, Seattle, WA). 
60  
Intramuscular temperature 
 
In both study 1 and study 2, an intramuscular thermocouple was placed into the 
vastus lateralis under similar sterile technique to measure skeletal muscle temperature 
during the passive heating protocol. The skin and fascia were anesthetized using the same 
lidocaine/epinephrine solution at the skin surface and prilocaine at the skeletal muscle 
fascia. An 18 gauge introducer Tuohy needle (Integra LifeSciences Corporation) was 
inserted into the vastus lateralis. The inner cannula was removed from the Tuohy needle 
and the thermocouple wire was threaded through the inner portion of the introducer 
needle. Once the thermocouple wire was in place within the skeletal muscle, the 
introducer Tuohy needle was removed leaving the thermocouple wire in place and it was 
connected to a desktop computer to monitor real time skeletal muscle temperature during 
the study protocol. Windaq software was utilized to record skeletal muscle temperature 
during the entirety of the study and temperature was also recorded on paper at 10 minute 
intervals. 
In-Vitro Mast Cell Degranulation Assay 
 
For study 3, degranulation of mast cells was determined as the release of the 
granule marker β-hexosaminidase. Human mast cells were cultured and plated on a 96- 
well plate in imaging medium buffer. 2 mg of compound 48/80 was dissolved in 1 ml 
imaging buffer. Then, to serve a as positive control, 50 ul of 2mg/ml compound 48/80 
was added to plated mast cells in those respective wells. In the negative control wells, 50 
ul of imaging buffer was added. Cells were then incubated at 34, 37 and 39°C for 20 
minutes before being centrifuged and the supernatants removed. Supernatants were 
reacted with 2 mM 4-Nitrophenyl N-acetly-B-D-glucosamide (Sigma) at 37°C for 2 
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hours. Then, 0.5 M Tris(hydroxymethyl)aminomethane was used to stop the reaction, and 
the absorbance was read at 405 nm. Total content was determined by addition of Triton 
X-100 to lyse the cells. All test conditions were done in duplicate in a single experiment 
and each experiment consisted of dialysate from 1-2 subjects at all time points, imaging 
buffer, 48/80, and histamine. Degranulation is expressed as a percentage of β- 
hexosaminidase activity in the supernatant divided by the total (supernatant plus pellet) 
activity. Total content was determined by addition of Triton X-100 to lyse the cells 
 
Heart Rate and Blood Pressure 
 
 
For study 1 and study 2, heart rate was monitored using a three-lead 
electrocardiograph and arterial pressure was assessed in the right arm employing an 
automated sphygmomanometer (Tango+; SunTech Medical, Raleigh, NC, United States). 
Mean arterial pressure was calculated as (systolic – diastolic)/3 + diastolic pressure. 
 
Statistical Analysis 
 
 
Our primary outcome variables in study 1 and 2 were analyzed using a One-Way 
ANOVA (GraphPad Prism) to test for differences in skeletal muscle temperature over 
time and for histamine concentrations over time. In study 3, our primary outcome 
variable was analyzed using a One-Way ANOVA (GraphPad Prism) to test for 
differences in mast cell degranulation expressed as a percentage over different 
physiological temperatures. Fishers LSD was used for post-hoc analysis for all tests. 
Significance was set at P < 0.05. Data are reported as mean SEM unless stated otherwise 
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(e.g. SD is used in Table 4.1 and 4.2 to indicate variability in the subject pool and for the 
experiment performed in study 3, data shown in Figure 4.3). 
 
 
 
Restults 
 
 
Subject Characteristics 
 
 
Subject physical characteristics and data obtained during the screening visit for 
study 1 are shown in Table 4.1. Subject physical characteristics and data obtained during 
the screening visit for study 2 are shown in Table 4.2. No subject participated in both 
study one and study two. Each study had a unique cohort of subjects, their characteristics 
listed below. For both studies. subject characteristics were similar to those obtained 
previously in our laboratory in young healthy subjects and consistent with recreationally 
active individuals. 
 
Table 4.1 Exercise and Temperature (Study 1) - Subject Characteristics 
n 5 (1F, 4M) 
 
Age (yrs) 23 ± 3 
 
Height (cm) 160.2 ± 8.2 
 
Height (kg) 73.2 ± 5.1 
 
BMI 23.3 ± 2.4 
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Table 4.2 Temperature and Histamine (Study 2) - Subject Characteristics 
n 7 (2F, 5M) 
 
Age (yrs) 26 ± 4 
 
Height (cm) 168.2 ± 11.2 
 
Height (kg) 75.4 ± 13.4 
 
BMI 23.9 ± 2.7 
 
 
 
 
Intramuscular Temperature (Study 1). Intramuscular temperature during 60 minutes 
of unilateral dynamic knee extension exercise is shown in Figure 4.1. Prior to exercise, 
skeletal muscle was 35.5 ± 0.4°C and was increased to 39.2 ± 0.7°C by the end of heating 
(p<0.01). By 20 minutes of exercise, temperature had significantly increased to 38.1 ± 
0.1°C (p<0.01). Skeletal muscle temperature was significantly higher at 30 minutes and 
all time points beyond, compared to resting skeletal muscle temperature (p<0.01). There 
was a plateau observed in skeletal muscle temperature from 30 minutes to 60 minutes, in 
which no significant differences in skeletal muscle temperature from the previous 
timepoint were observed. 
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Figure 4.1. Individual data of skeletal muscle temperature during 60 minutes of one- 
legged dynamic knee extension exercise. Data expressed as means ± SEM. * indicates 
significantly different from pre (p<0.05) 
 
Central Hemodynamics (Study 1). Heart rate and mean arterial pressure in response to 
one-hour of unilateral dynamic knee extension exercise are shown in Table 4.3. 
 
Table 4.3. Exercise and Temperature (Study 1) - Central Hemodynamics 
 
  
Heart Rate (beats min -1) 
  
Mean Arterial Pressure (mmHg) 
Time Point    
Pre-Exercise 66.2 ± 2.5 
 
83.1 ± 1.5 
Time During Exercise    
10 min 83.4 ± 1.4*  84.3 ± 2.2 
20 min 85.6 ± 2.2*  85.2 ± 3.0 
30 min 91.8 ± 3.4*  85.3 ± 3.1 
40 min 91.2 ± 2.2*  85.1 ± 2.5 
50 min 90.8 ± 3.5*  86.1 ± 1.4 
60 min 96.3 ± 2.3*  86.2 ± 2.0 
Values are expressed as mean ± SEM. * indicates significantly different from pre 
(p<0.05) 
 
 
 
Intramuscular Temperature (Study 2). Intramuscular temperature during 60 minutes 
of passive heating using PSWD is shown in Figure 4.2. Prior to heating, skeletal muscle 
was 32.4 ± 0.4°C and was increased to 38.1 ± 0.7°C by the end of heating (p<0.05). 
Skeletal muscle temperature was significantly higher at 30 minutes and all time points 
beyond, compared to resting skeletal muscle temperature (p<0.05). Similar to the 
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response observed with exercise there was a plateau observed in skeletal muscle 
temperature from 40 minutes to 60 minutes, in which no significant differences in 
skeletal muscle temperature were observed. 
 
Intramuscular Histamine Concentrations (Study 2). Intramuscular histamine 
concentrations during 60 minutes of passive heating using PSWD is shown in Figure 2. 
Intramuscular histamine increased from 2.12 ± 0.17 ng/ml at rest to 2.90 ± 0.20 ng/ml at 
60 minutes of passive heating. Histamine concentrations were not different from rest at 
20 minutes (p=0.9) nor at 40 minutes (p=0.6) of passive heating. 
 
Table 4.4. Temperature and Histamine (Study 2) – Central Hemodynamics 
  
Heart Rate (beats min -1) 
 
Mean Arterial Pressure (mmHg) 
Time Point   
Pre-Heating 59.2 ± 2.5 82.7 ± 2.5 
Time During Heating   
10 min 59.9 ± 3.6 81.2 ± 3.1 
20 min 57.7 ± 2.8 81.8 ± 3.0 
30 min 59.3 ± 4.4 80.7 ± 2.6 
40 min 60.9 ± 3.8 82.2 ± 3.7 
50 min 56.9 ± 4.6 81.5 ± 2.0 
60 min 58.3 ± 4.7 80.4 ± 3.4 
 
Values are expressed as mean ± SEM. 
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Figure 4.2. Individual data of skeletal muscle temperature during 60 minutes of pulsed 
short-wave diathermy. Data expressed as means ± SEM. * indicates significantly 
different from pre (p<0.05) 
 
 
 
 
 
 
Figure 4.3. Individual data of histamine concentrations in skeletal muscle dialysate 
during 60 minutes of pulsed short-wave diathermy. Data expressed as means ± SEM. * 
indicates significantly different from pre (p<0.05) 
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Increased temperature effect on human mast cell degranulation. For the third study 
of this chapter, we exposed isolated human mast cells to different physiological 
temperatures observed at rest and during exercise. There was no significant difference in 
mast cell % degranulation (measured as b-hexosaminidase release) at different 
temperatures as shown in Figure 4.3. Compound 48/80 was used as a positive control as 
it directly causes mast cell degranulation. 
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Figure 4.4. Mast cell degranulation (expressed as %) at different physiological 
temperatures. 48/80 was used as a positive control. Data expressed as means ± SD. 
 
 
Discussion 
 
The purpose of this study was to determine if an increase in skeletal muscle 
temperature mimicking what is observed during exercise is a stimulus to provoke 
intramuscular histamine release in skeletal muscle. In agreement with our hypothesis in 
study 2, passively increasing skeletal muscle temperature to exercising values resulted in 
increased intramuscular histamine concentrations in skeletal muscle measured via 
dialysate. To follow up, we designed an in-vitro experiment to investigate if 
physiological increases in temperature would result in increases in mast cell 
degranulation. In disagreement with our hypothesis in study 3, step-wise physiological 
increases in temperature did not result in increased mast cell degranulation. Taken 
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together, these data suggest that heat plays a significant role in the release of histamine in 
skeletal muscle during exercise. However, the in-vitro experiment suggests that the 
source of this histamine may be de novo formation via increases in the enzyme histidine 
decarboxylase, rather than mast cell degranulation. 
It has been well established that there is a rise in skeletal muscle temperature 
during exercise due to heat production from muscular contractions (77). This increase in 
muscle temperature can vary depending on the type of exercise, the exercise 
environment, training status etc. This increase in skeletal muscle temperature can serve as 
beneficial in that it can lead to increases in enzyme activity and can also alter substrate 
utilization to match exercise intensity/duration (152). Temperature can also affect 
contractile properties of skeletal muscle including cross-bridge turnover, maximum 
power output, neuromuscular function, calcium sequestration, and overall recovery 
metabolism (74, 119, 120). Typically, during exercise in addition to temperature 
increasing in skeletal muscle, there are changes in other factors such as pH and build-up 
of metabolites. However, the difficulty lies within being able to dissect each of these 
factors from each other in order to isolate its effects.  Our lab demonstrated that there is 
an increase in skeletal muscle temperature up to and a plateau effect at 39°C with 
dynamic unilateral knee extension exercise (Figure 4.1). Therefore, the goal of this study 
was to increase skeletal muscle temperature to “exercise levels” without contraction and 
to do this we utilized pulsed short-wave diathermy as our heating method. 
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Passive Heating Utilizing Pulsed Short-Wave Diathermy 
 
For study 2 in this set of experiments, the goal was to increase skeletal muscle 
temperature up to 39°C which we had previously observed as the intramuscular 
temperature reached during dynamic unilateral knee extension exercise (Figure 4.1). 
There are different modalities that have been used to raise skeletal muscle temperature, 
some of these modalities can raise skin temperature and can also have central 
hemodynamic effects. Whole-body and limb water immersion has been demonstrated to 
effectively decrease and increase skeletal muscle temperature (162, 114). For this study 
we wanted to ensure we maintained a sterile field for both the intramuscular temperature 
and intramuscular dialysate measurement probes, as well as eliminate any hydrostatic 
effects that water immersion might involve. For initial pilot experiments, we used a UV 
heat lamp which has not been commonly used in the literature, while polarized linear 
light has been utilized (34). With this UV heat lamp modality, we noted significant 
increases in skin temperature, and it appeared it was not able to penetrate to the depth of 
the skeletal muscle. In addition, subjects expressed discomfort in the rise in skin 
temperature. Therefore, after a thorough literature search on heating modalities we chose 
pulsed short-wave diathermy. 
Short wave diathermy provides electromagnetic radiation that can either be 
delivered in a continuous or pulsed manner, both having benefits in the athletic training 
community (50). We elected to use pulsed short-wave diathermy in this experiment as it 
has been shown to effectively raise skeletal muscle temperature without any significant 
changes in central hemodynamics (155). As seen in Figure 4.2, there was a quite rapid 
increase in skeletal muscle temperature utilizing pulsed short-wave diathermy. There was 
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a significant increase in skeletal muscle temperature by 30 minutes and then we observed 
a “plateau” effect similar to what we observed during unilateral dynamic knee-extension 
exercise. In addition, the resting temperature and slope of rise in skeletal muscle 
temperature was comparable to exercise. Therefore, we are confident that we were able to 
mimic the rise in skeletal muscle temperature that is observed in single leg exercise 
without significant changes in skin temperature or in central hemodynamics (Table 4.4). 
Our research adds to the body of literature demonstrating the safety and efficacy of 
pulsed short-wave diathermy’s ability to increase skeletal muscle temperature. 
Heating and Skeletal Muscle Histamine 
 
Our lab has previously shown that histamine concentrations within skeletal 
muscle increase in response to exercise (127). These data indicate that certain factors 
released or altered within skeletal muscle are causing its release from mast cells and/or de 
novo formation via histidine decarboxylase. Using infusions of the antioxidant N- 
acetylcysteine prior and during exercise with no effect on the histaminergic signaling 
pathway suggested that the oxidative stress associated with exercise is not necessary for 
histamine release (125). While we have been able to “rule out” this factor, there are still 
other signals that are present during exercise that may lead to this increase in histamine 
release. This experiment investigated if heat might be one of the factors that leads to the 
increase in histamine that is observed with exercise. 
Pulsed short-wave diathermy increased skeletal muscle temperature to values 
observed during dynamic unilateral knee extension exercise, shown in Figure 4.1 and 
Figure 4.2. Histamine concentrations measured in skeletal muscle dialysate during our 
heating protocol demonstrated that there appears to be a “threshold” for this increase in 
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histamine levels. At 20 and 40 minutes, there was not a significant increase in histamine 
levels in skeletal muscle dialysate compared to pre-heating (Figure 4.3). However, at 60 
minutes there was a 38% increase (p<0.05) in skeletal muscle dialysate levels which is 
where skeletal muscle temperature had reached 39°C. This was our “goal temperature” 
as this is where skeletal muscle temperature plateaus during kicking exercise. This 
increase in skeletal muscle dialysate levels in response to heating is comparable to the 
percentage increased observed in skeletal muscle dialysate levels observed during 
exercise, which is around ~41% (127). Given that we were able to isolate temperature 
without measurably affecting other exercise factor variables, these data suggest that the 
increase in temperature in skeletal muscle during exercise plays a significant role in 
histamine release as we observed similar increases. 
The Effect of Temperature on Human Mast Cells and Histidine Decarboxylase 
 
As previously mentioned, there are two sources of histamine that are observed in 
human tissue. Mast cells can degranulate in response to multiple factors which in turn 
releases histamine from its vesicles into circulation and the surrounding tissue (43). 
Another source is de novo formation via histidine decarboxylase which converts histidine 
to histamine. Histidine decarboxylase is induced by and can be increased in response to a 
variety of stimuli (83). As discussed, it has been demonstrated that increases in 
temperature can cause a linear increase in histidine decarboxylase levels. Therefore, it is 
logical to hypothesize that the increase in skeletal muscle temperature might be 
increasing the degranulation of mast cells, increasing histidine decarboxylase activity, or 
both. In study 3, we set out to examine if isolated human mast cells degranulate in 
response to temperature increases. 
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As seen in Figure 4.4, we exposed isolated human mast cells to differing 
physiological temperatures (34, 37, and 40°C). Given that we observed skeletal muscle 
temperature increases from 34 to 39°C with pulsed short-wave diathermy and exercise, 
we were confident these temperatures would be appropriate to utilize. Interestingly, in 
contradiction to our hypothesis, changes in temperature did not result in significant 
changes in mast cell degranulation in isolated human mast cells (Figure 4.4). We had an 
expected and robust response in mast cell degranulation in the presence of compound 
48/80, which served as a positive control to ensure that the mast cells being utilized are 
viable. The fact that we did not see differences in degranulation in response to varying 
temperatures suggests that it might be an increase in histidine decarboxylase activity with 
increases in skeletal muscle temperature, rather than direct effects on mast cell 
degranulation. However, we recognize that our isolated human mast cell preparation is 
different than intact mast cells which are found in human skeletal muscle and surrounded 
by other cell types. There is a possibility that there is other cell cross-talk in human 
skeletal muscle during heating that could result in mast cell degranulation, which we 
would not observe in an isolated mast cell preparation. Certain cell types present in 
nearby tissue may be contributing to the degranulation of mast cells or increases in 
histidine decarboxylase in response to the rise in temperature. Follow-up experiments 
should examine histidine decarboxylase activity during heating to further elucidate the 
role of temperature on histidine decarboxylase activity. 
Summary and Bridge 
 
Both whole body and single-leg aerobic exercise initiates a sustained post- 
exercise vasodilatory response that is dependent upon histaminergic signaling. We have 
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shown that histamine is released in skeletal muscle during exercise. The findings from 
this study demonstrate that the increase in temperature in skeletal muscle might be one of 
the primary causes for this histamine release. In vitro experiments with isolated mast cells 
suggest that this may be due to an increase in histidine decarboxylase activity, rather than 
heat directly causing mast cell degranulation. Chapter V will build upon the observations 
of these experiments to further understand the exercise “signal” that causes the release of 
histamine. We will attempt to identify if there is a circulating factor that is released 
locally in exercising skeletal muscle that is not present in resting tissue. 
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CHAPTER V 
 
THE EFFECT OF DIALYSATE FROM EXERCISING SKELETAL MUSCLE ON 
MAST CELL DEGRANULATION 
 
 
Introduction 
 
Following a bout of aerobic exercise, blood flow to previously exercised muscle 
remains elevated for several hours. This sustained post-exercise vasodilation is mediated 
by both central neural mechanisms and local vascular mechanisms (60). Our lab has 
demonstrated that histamine plays a significant role in this post-exercise vasodilatory 
response. Blockade of histamine H1 and H2 receptors with over-the-counter medications 
blunts this response with whole-body exercise (94) and abolishes it with isolated small 
muscle-mass exercise (7). This culmination of work suggests that this phenomenon is 
histaminergic in origin and may be independent of the neural mechanisms. 
This impact of H1/H2 histamine receptor blockade demonstrates that histamine 
receptor activation is essential for the sustained post-exercise vasodilatory response. 
Histamine acting as a ligand on these receptors appears to be critical since blocking its 
actions can blunt or abolish the phenomenon. Investigations of histamine levels in arterial 
and venous plasma have been conflicted, as some have shown no changes during exercise 
and others have shown increases (62, 101). Our lab has demonstrated that interstitial 
histamine concentrations are increased during and following exercise in skeletal muscle, 
measured by intramuscular dialysis fibers (127). The source of this histamine can be 
released from mast cells via degranulation and/or increased activity of the enzyme 
histidine decarboxylase which converts the amino acid L-histidine to histamine. While 
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we have shown that histamine levels increase in skeletal muscle in response to exercise, it 
is still not known what it is about exercise that causes the release of histamine. Our lab 
has ruled out exercise-induced oxidative stress as a potential trigger (125), however there 
still remain other exercise “factors” that have not yet been investigated. 
There are multiple exercise factors or conditions systemically and locally that are 
altered during exercise. Some of these localized responses include a decrease in pH, the 
physical contraction of skeletal muscle fibers, an increase in skeletal muscle temperature, 
and others (65, 45, 121). Considering local factors within skeletal muscle, cytokines and 
other cell types have been shown to be released directly from exercising/exercise muscle 
termed “myokines”. These can then bind to different types of cells to have further 
downstream effects. Mast cells are sensitive to a multitude of factors, including cytokines 
IL-4 and IFN-y which have been shown to be released from exercising/previously 
exercised skeletal muscle (137, 17). It is possible that the release of a single or multiple 
cytokines might be inducing mast cell degranulation, leading to the observed increase 
histamine concentrations in skeletal muscle in response to exercise. Furthermore, it is 
quite probable that is response is tightly regulated locally and these released cytokines 
may not have an effect in resting tissue. To date, no one has investigated if there is or are 
local factors released in exercising/exercised skeletal muscle that cause mast cell to 
degranulate more so than baseline levels that is not present in resting tissue. 
As stated, given that exercise increases histamine levels locally in active skeletal 
muscle, it is possible that there are local factors released in exercising/exercised skeletal 
muscle that cause mast cell degranulation leading to the rise in skeletal muscle histamine 
levels we have observed. This study was proposed to investigate there is a local 
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factor/factors that is/are present in exercising skeletal muscle that induce mast cell 
degranulation that is not present in resting tissue. It is possible that there is a factor 
released in skeletal muscle that serves as the “exercise signal” for the increases in 
intramuscular histamine observed with exercise. Our goal was to obtain interstitial fluid 
from skeletal muscle from both the resting and exercising leg during and following 
unilateral dynamic knee extension exercise and examine its effects on mast cell 
degranulation. In this study, we tested the hypothesis that skeletal muscle dialysate 
collected from exercising and previously exercised skeletal muscle in vivo would 
increase mast cell degranulation, measured in vitro by β-hexosaminidase release from 
isolated human mast cells. 
Methods 
 
 
Subjects 
 
 
For this study nine (2 females, 7 males) young healthy non-smoking subjects volunteered. 
This study was approved by the Institutional Review Board at the University of Oregon 
and was performed in accordance with the principles outlined by the Declaration of 
Helsinki. Written, informed consent was obtained from all subjects subsequent to a verbal 
and written briefing of all experimental procedures. Subjects were deemed healthy 
following a standard health history questionnaire. All subjects were required to abstain 
from caffeine, alcohol, and exercise for 24h before the study visit. Additionally, subjects 
reported to the laboratory in the morning after an overnight fast. No subjects were using 
over-the-counter or prescription medications at the time of study, with the exception of 
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oral contraceptives. Female participants were studied during the early follicular phase of 
their menstrual cycle or during the placebo phase of their oral contraceptive. 
 
Screening Visit 
 
 
During this visit, subject’s physical characteristics were obtained (height, weight, body 
mass index) and they were familiarized with the exercise model and hemodynamic 
measurements. Arterial pressure was assessed using an automated auscultatory 
sphygmomanometer (Tango+; SunTech Medical, Raleigh, NC, United States). 
 
Study Visit 
 
 
Experimental approach 
 
 
The goal of this experiment was to obtain skeletal muscle microdialysate from the 
resting and exercise leg during dynamic unilateral knee extension exercise to then expose 
to cultured human mast cells. An intramuscular microdialysis fiber was placed into both 
the right and left leg in the vastus lateralis under sterile technique. The subjects then 
performed dynamic unilateral knee extension exercise with their right leg at 60% of their 
pre-determined peak power for 60 minutes. Skeletal muscle dialysate was collected 
before, during, and after exercise at different time points. Then, cultured human mast 
cells were exposed to dialysate in order to determine if there is a circulating factor that is 
localized to exercising muscle and time dependent that impacts mast cell degranulation. 
 
Measurements 
 
 
Peak Power Assessment 
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The peak power assessment visit was used to determine peak power output during 
a unilateral dynamic knee extension peak exercise test performed to volitional fatigue. 
Dynamic knee extension exercise during both the peak and exercise visits was performed 
using a custom-built knee extension ergometer based on a computer-controlled step- 
motor that provided resistance against the subject’s lower leg. Based on real-time 
measured of angular velocity and torque, power was calculated, and a feedback loop 
maintained measured power at the assigned level. Subjects were seated with their back at 
60° upright and knee-extension exercise was performed with the right leg over a 45° 
range of motion, starting with the leg hanging at ~90° of flexion. Subjects were asked to 
maintain a cadence of 45 kicks min-1 while being provided with visual feedback of both 
kicking cadence and range of motion. Workload was ramped incrementally at a rate of 3 
watts min. During the dynamic knee extension exercise test subjects reached peak power 
in 9.5 ± 0.4 min (range 7 - 13 min). 
 
 
Dynamic Knee Extension Exercise 
 
Subjects returned to the lab after their peak power test to perform 60 minutes of 
unilateral dynamic knee extension exercise at 60% of their peak power. The exercise was 
performed at 60% of peak power and a cadence of 45 kicks per minute. Power was 
ramped at the onset of exercise to 60% peak power over the first 10 minutes. Power 
output was recorded continuously throughout the 60 minutes of unilateral dynamic knee 
extension exercise. For all subjects in this study, the right leg served as the “exercise” leg 
and the left leg served as the “resting” leg. 
 
Skeletal muscle microdialysis 
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All probes were inserted using sterile technique. The skin was anesthetized using 
a lidocaine (2%) and epinephrine (1:100,000) solution (Septodont, France) and 
underlying fascia was anesthetized using prilocaine hydrochloride (4%) (Septodont, 
France). Care was taken to ensure that the lidocaine and prilocaine was not injected into 
the skeletal muscle. Probes were inserted in the vastus lateralis in a direction parallel with 
muscle fiber orientation (~19°, relative to long-axis of muscle) using a splittable 
introducer. After insertion, probes were held in place by covering the entry site with a 
sterile transparent medical dressing. Probes used to measure interstitial histamine had a 
100-kDa molecular mass cutoff with a 30-mm polyarylethersulphone membrane (63 MD 
Catheter, MDialysis, Stockholm, Sweden). Subsequent to insertion, microdialysis probes 
were perfused continuously at a rate of 5 µl/min (CMA 400 Microdialysis pump, CMA, 
North Chelmsford, MA). Probes used to obtain skeletal muscle microdialysate were 
perfused with a 0.9% saline solution. Following insertion of the fiber, dialysate was 
collected immediately before exercise, at 20 minute intervals during 60 minutes of 
dynamic unilateral kicking exercise, and at 20 minute intervals during 60 minutes of 
supine recovery. 
 
In-Vitro Mast Cell Degranulation Assay 
 
Degranulation of mast cells was determined as the release of the granule marker 
β-hexosaminidase utilizing an in-vitro plate assay. Human mast cells (Kerafast) were 
cultured and cells were plated at 1 x 106 cells/ml in wells of a 96 well plate in imaging 
medium (50 ul total volume). 2 mg of compound 48/80 was dissolved in 1 ml imaging 
buffer. To serve as positive control, 50 ul of 2mg/ml compound 48/80 was added to 
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plated mast cells in those respective wells. In the negative control wells, 50 ul of imaging 
buffer was added. In the experimental wells, 50ul of skeletal muscle dialysate from each 
time point was added. In the histamine wells, plated cells were exposed to a physiological 
dose of histamine 10-3 mM, in order to determine the direct effect of histamine on mast 
cell degranulation. Cells were then incubated at 37°C for 20 minutes before being 
centrifuged and the supernatants removed. Supernatants were reacted with 2 mM 4- 
Nitrophenyl N-acetly-B-D-glucosamide (Sigma) at 37°C for 2 hours. Then, 0.5 M 
Tris(hydroxymethyl)aminomethane was used to stop the reaction, and the absorbance 
was read at 405 nm. Total content was determined by addition of Triton X-100 to lyse the 
cells. All test conditions were done in duplicate in a single experiment and each 
experiment consisted of analysis of dialysate from 1-2 subjects at all time points, imaging 
buffer (negative control), 48/80 (positive control), and histamine. Degranulation is 
expressed as a percentage of β-hexosaminidase activity in the supernatant divided by the 
total (supernatant plus pellet) activity. Total content was determined by addition of Triton 
X-100 to lyse the cells 
 
Heart Rate and Blood Pressure 
 
 
For this study, heart rate was monitored using a three-lead electrocardiograph and 
arterial pressure was assessed in the right arm employing an automated 
sphygmomanometer (Tango+; SunTech Medical, Raleigh, NC, United States). Mean 
arterial pressure was calculated as (systolic – diastolic)/3 + diastolic pressure. Heart rate 
and arterial pressure was obtained before exercise, at 10 minute intervals during exercise, 
and 20 minute intervals during recovery from exercise. 
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Statistical Analysis 
 
 
Our primary outcome variable for this study was mast cell degranulation 
expressed as a percentage and was analyzed using a Two-Way ANOVA (Prism, 
GraphPad, San Diego, CA) to test for differences in mast cell degranulation (expressed as 
percentage) over time and between legs (resting vs. exercise). A One-Way ANOVA was 
used to determine significant differences in central hemodynamic measurements (heart 
rate and blood pressure) before and during exercise. Fishers LSD test was used for post- 
hoc analysis. Significance was set at P < 0.05. Data are reported as mean SEM unless 
stated otherwise (e.g. SD is used in Table 5.1 to indicate variability in the subject pool). 
 
Results 
 
 
Subject Characteristics 
 
 
Subject physical characteristics and data obtained during the screening visit for 
study 1 are shown in Table 5.1. For this study, subject characteristics were similar to 
those obtained previously in our laboratory in young healthy subjects and consistent with 
recreationally active individuals. 
 
Table 5.1 Subject Characteristics 
n 9 (2F, 7M) 
 
Age (yrs) 25 ± 3 
 
Height (cm) 154.2 ± 7.2 
 
Height (kg) 71.1 ± 4.3 
 
BMI 23.5 ± 2.1 
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Central Hemodynamics. Heart rate and mean arterial pressure in response to one-hour 
of dynamic unilateral knee extension exercise are shown in Table 5.2. There was a 
significant increase in heart rate at 10 minutes into exercise (p<0.05) compared to pre- 
exercise that was sustained throughout the 60 minutes of exercise. Mean arterial pressure 
was no significantly different at any timepoint during exercise, compared to pre-exercise. 
 
Table 5.2. Central Hemodynamics 
 
  
Heart Rate (beats min) 
 
Mean Arterial Pressure (mmHg) 
Time Point   
Pre-Exercise 63.1 ± 2.3 85.1±1.5 
Time During Exercise   
10 min 88.2± 3.1* 84.3±2.2 
20 min 88.8± 2.3* 84.3±2.5 
30 min 92.0± 3.3* 86.5±3.5 
40 min 93.6± 2.9* 86.3±3.4 
50 min 91.9± 3.4* 87.2±2.4 
60 min 93.6± 2.9* 86.9±1.0 
 
 
 
Values are expressed as mean ± SEM. * indicates significantly different from pre- 
exercise (p<0.05) 
 
 
 
Mast Cell Degranulation Response. Degranulation of mast cells (expressed as %) in 
response to skeletal muscle dialysate collected before, during, and after exercise is shown 
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in Figure 5.1. There was no significant difference in mast cell degranulation percentage 
in response to dialysate collected pre-exercise between the resting and exercise leg. There 
was a significant increase (p<0.05) in the percentage of mast cells that degranulated in 
response to the dialysate at 40 and 60 minute time points of exercise and the post- 
exercise 20 minute timepoint from the exercise leg, compared to pre-exercise values. 
Compared to pre-exercise values, there was no difference in mast cell degranulation in 
response to the dialysate from the resting leg at any timepoint. There was a significant 
difference in mast cell degranulation between the exercise and resting leg dialysate at 40 
and 60 minute timepoint of exercise and post-exercise 20 (p<0.05). 
 
 
 
60 * # 
 
50 
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Figure 5.1. Mast cell degranulation in response to skeletal muscle dialysate collected 
during and after exercise. Image buffer served to subtract out background activity and 
48/80 served as a positive control. All experiments used histamine in designated control 
wells to examine the effects of histamine directly on mast cell degranulation. Open 
circles (o) denote dialysate collected from the resting leg, black boxes ( ) denote 
dialysate collected from the exercise leg. Data expressed as means ± SEM. * indicates 
significantly different from PreEx. # indicates significantly different from resting leg. 
(p<0.05) 
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Discussion 
 
The purpose of this study was to determine if there is a/are local soluble factor(s) 
released in skeletal muscle during exercise that can cause mast cell degranulation. To do 
this, we had subjects perform 60 minutes of unilateral dynamic knee extension exercise at 
60% of their peak power and collected intramuscular dialysate from both the resting leg 
and exercise leg before, during, and after exercise. We then exposed cultured mast cells 
to this collected dialysate to examine degranulation of mast cells (expressed as a 
percentage). We hypothesized that we would observe a greater percentage of mast cells 
degranulating in response to dialysate collected from exercising skeletal muscle 
compared to dialysate collected from resting skeletal muscle. In agreement with our 
hypothesis, there was a significant increase in mast cell degranulation in response to 
dialysate obtained from the exercise leg while no change compared to pre-exercise was 
observed in response to dialysate obtained from the resting leg. In addition, we observed 
differences in mast cell degranulation in response to dialysate collected from the exercise 
leg near the end of exercise and near the beginning of recovery, compared to the similar 
timepoints in the resting leg. Taken together, these data suggest that there is a/are local 
factor(s) that are released in locally in skeletal muscle in response to exercise that can 
cause mast cell degranulation, ultimately leading to histamine release. 
Our lab has previously shown that histamine concentrations within skeletal 
muscle increase in response to exercise (127). These data indicate that certain factors 
released or altered within skeletal muscle are causing its release from mast cells and/or de 
novo formation via histidine decarboxylase. Using infusions of the antioxidant N- 
acetlycysteine prior and during exercise with no effect on the histaminergic signaling 
85  
pathway suggested that the oxidative stress associated with exercise is not necessary for 
histamine release (155). While we were able to deem this factor as not a exercise 
probable trigger for mast cell degranulation, there are still other factors that are present 
due to exercise that may lead to this increase in histamine release. This experiment 
investigated if there might be a/are local factor(s) released in skeletal muscle that serve as 
a “trigger” for histamine release. 
Local Factors in Skeletal Muscle and Histamine 
 
This study provides unique insight into the exercise-related trigger that causes the 
release of histamine in skeletal muscle in response to exercise. Our lab has previously 
shown that there in an increase in skeletal muscle histamine concentrations in response to 
exercise that continues post-exercise. Using skeletal muscle microdialysis, we attempted 
to examine if there might be factors released from skeletal muscle that can cause mast 
cell degranulation, leading to increased histamine concentrations. As seen in Figure 5.1, 
we observed that there was an increased percentage of mast cells that degranulated in 
response to dialysate that was obtained from the exercising skeletal muscle as opposed to 
dialysate from resting muscle. It can be noted that we did not see this at the 20 minute 
mark of exercise, but did at the 40 and 60 minute mark. This suggests that there is a time 
or intensity component and that the release of these factors may not be immediately 
released in response to exercise. This persisted to 20 minutes following exercise, however 
no significant differences in mast cell degranulation were observed with dialysate from 
40- and 60-minutes post-exercise. This indicates that in response to exercise, skeletal 
muscle is releasing a cytokine or other soluble factor that is causing mast cells to 
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degranulate at a higher rate than that at rest. Our observations point to this being a 
localized response that appears to be quickly resolved following the cessation of exercise. 
While it has been known for quite some time that exercise causes a release of 
cytokines and other factors from skeletal muscle in response to exercise, the 
nomenclature of these being classified as “myokines” has been quite recent (26). It has 
been shown that skeletal muscle is an immunogenic producer of cytokines which then 
can exert endocrine functions as well as autocrine on local cells. These myokines released 
in response to exercise can have local effects on metabolism, angiogenesis, and muscle 
growth. In addition, these myokines can also have systemic effects acting on other target 
organs such as adipose tissue, liver, brain, and others (10). Therefore, factors released by 
skeletal muscle in response to exercise can have significant effects both locally and 
systemically, indicating a powerful role for skeletal muscle in intra- and intercellular 
signaling. In our study, it appears that myokines or other local factors released in 
response to exercise are causing mast cell degranulation. A multitude of different 
cytokines and other stimulating factors can bind to mast cell receptors, resulting in 
degranulation and the release of histamine. 
The Effect of Histamine on Human Mast Cells 
 
As previously mentioned, there are a few different cytokines and factors that can 
directly bind to mast cells to cause degranulation, releasing histamine. Mast cells express 
a multitude of receptors that are both excitatory and inhibitory. For example, most mast 
cells express toll-like TLR receptors which LPS (a major surface molecule of gram- 
negative bacteria) can bind to and cause degranulation (130). In addition, it has been 
shown that mast cells can express histamine receptors and that histamine can bind to 
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these receptors, potentially leading to degranulation. This is serving in an autocrine 
signaling manner, in which histamine is mediating histamine release from mast cells. 
While there is an array of histamine receptors found throughout the human body (H1-H4), 
mast cells from different tissues express different receptors (70). For example, it has been 
shown that human skin mast cells express H2 and H4 receptors, but not H3 receptors (85). 
Mast cells that are present in skeletal muscle tissue have not been extensively studied in 
regards to their receptor types and properties that are similar/unique to other mast cells. 
Our goal of this experiment was to examine if there is a/are local factor(s) 
released in exercising skeletal muscle that can cause increased mast cell degranulation. 
Part of our experiment involved exposing our mast cells to physiologically relevant 
concentrations of histamine. The purpose of this was to “rule out” that histamine was 
acting on the mast cells to cause degranulation. As seen in Figure 5.1, the percentage of 
mast cells that degranulated in response to histamine was similar to the imaging buffer, 
which serves as a negative control or to subtract out background activity. With this data 
regarding histamine, it suggests that the mast cell line that we were using does not 
express histamine receptors or that they are not responsive to histamine. In our pilot 
work, we tested multiple different concentrations of histamine. These concentrations 
included 10-3, 10-5, 10-7, and 10-9mM. In none of these concentrations did we observe 
notable increases in mast cell degranulation compared to imaging buffer exposure, 
serving as a negative control. It is possible that in vivo, skeletal muscle mast cells in fact 
do express histamine receptors and can degranulate in response to histamine. The 
expression of these histamine receptors on mast cells is most likely highly dependent on 
the tissue that the mast cells are found in. Further work should investigate mast cells that 
88  
are present in skeletal muscle tissue, classifying their receptors and specific 
characteristics to elucidate their role in exercise responses. In our experiment, we did not 
observe any significant degranulation of mast cells in response to physiological doses of 
histamine. Therefore, in our experiment we can confidently rule out that histamine in 
skeletal muscle dialysate was causing mast cell degranulation in our isolated mast cell 
line, and it appears that there are other cytokines or circulating factors in the skeletal 
muscle that are causing the degranulation response we observed. 
Could It Be Complement? 
 
Nearly 100 years ago, complement was discovered as a component of plasma that 
enhances the opsonization (coating of a particle to enhance phagocytosis) of bacteria by 
antibodies and facilitates antibody-dependent killing of bacteria. It gets its nomenclature 
of “complement” in that is complementary to that of humoral immunity. It is comprised 
of membrane-bound regulators and receptors as well as different plasma proteins that can 
interact with different cell types of the immune system. The C1 complex is formed when 
an antigen is bound to an antibody and then it can break in to C2a and C4b fragments, 
this is part of the classical pathway (95, 96). Then, C3 convertase can hydrolyze leaving 
C3b and C3a fragments which then cleave to C5a and C5b which can form a cylindrical 
membrane and attack cells in a direct inflammatory manner. 
Both C3a and C5a have a range of functions on their own, one of these being mast 
cell degranulation (42). C3a and C5a can bind to mast cells and drive intracellular 
signaling processes, ultimately leading to mast cell degranulation and histamine release. 
C3a has a molecular weight of ~10kDa while C5a has a molecular weight of ~113kDa (2, 
115). The skeletal muscle microdialysis fibers utilized for this study were 100kDa so we 
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can presume that if C5a was present in the tissue, it was not able to be collected in the 
skeletal muscle effluent. However, at ~10kDa, C3a is small enough to pass through and 
could have been present in the dialysate we collected. 
Aerobic based exercise has been shown to increase components of the 
complement system. Sanz et. al had subjects complete exhaustive, aerobic exercise and 
obtained blood draws before and following observed (141). They observed that there 
were increases in all components of the complement system, including a 45% increase in 
circulating C3a levels. Consistent with this finding, Smith et al had individuals perform 
aerobic exercise and obtained venous samples before and after exercise (158). In 
addition, they examined the long-term effects of aerobic exercise on complement 
component expression. They observed that following short-term aerobic exercise, there 
was an increase in the classical pathway of the complement system, with increases in C3 
and C4, with specific increase in C3a. They did note that highly trained individuals had 
lower C3 levels and showed that untrained individuals had a more exaggerated C3a 
response compared to trained individuals following exhaustive aerobic exercise. For our 
study, all subjects were considered untrained and were only moderately active, therefore 
we would expect robust complement activation in response to exercise. 
It appears that C3a and other components of the complement system have direct 
effects on mast cells and can cause degranulation and the subsequent release of 
histamine. In addition to this, others have demonstrated that aerobic exercise (which is 
the model that we used) mounts an immune response with an upregulation of the 
complement system. Therefore, it is plausible that the complement system is playing 
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some role in the increased mast cell degranulation we observed, in the skeletal muscle 
dialysate from exercising muscle when exposed to mast cells compared to resting values. 
Future experiments could help to elucidate the role of the complement system 
response to aerobic exercise and how it may affect mast cell degranulation. The protocol 
could be repeated again under similar circumstances, however both venous blood samples 
and dialysate could be collected before, during, and following exercise. There are assays 
to identify components of the complement system (C3a and C5a which are of interest) 
along with others, from collected venous blood samples. In addition, transcriptomic 
analysis of collected skeletal muscle dialysate could examine how complement might be 
changing directly in skeletal muscle, and if we observe similar or different changes 
locally as compared to systemic changes. It appears from the data thus far that this is a 
highly localized response, but it would be of interest to examine if our model results in a 
systemic wide response of some factors (such as complement, which have been observed) 
in addition to their local responses. Given the nature of activation of complement from 
aerobic exercise and their role in mast cell degranulation, further work is warranted to 
examine the role of the complement system and its possible interaction with histamine 
and exercise. 
Future Experiments 
 
This study has furthered our knowledge regarding the interaction of exercise and 
histamine release in skeletal muscle, our data indicating that there is a factor or factors 
released by exercising skeletal muscle that appears to be highly localized that causes mast 
cells to degranulate. We observed that dialysate fluid collected from exercising skeletal 
muscle was unique from dialysate fluid from resting muscle in that it caused a higher 
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percentage of mast cells to degranulate in response. In addition, there appears to be a time 
component to this release. We noted a significant difference in responsiveness of mast 
cells to collected dialysate from the latter portion of exercise and immediately after, 
however by 40 minutes of recovery this factor or factors did not appear to be present. 
This transient, robust rise in skeletal muscle in response to exercise is interesting and 
deserves further investigation. 
An “omics” approach would be a logical next step to further understand what it is 
that is being released in skeletal muscle in response to exercise. This approach would 
involve repeating this experiment, however analysis of the collected dialysate would 
involve investigating the transcriptome of this dialysate, a technique that our lab has done 
before in collaboration with our Genomics Core Facility on our campus. Utilizing this 
approach could elucidate what factor or factors might be upregulated in response to 
exercise that is unique to exercising skeletal muscle, and not present or responsive in 
resting tissue. In addition, it would be of interest to examine if there are measurable 
increases in histidine decarboxylase in skeletal muscle dialysate, to further investigate the 
impact of exercise on this enzyme. The timepoints of every 20 minutes during 60 minutes 
of exercise are appropriate time points to collect, and recovery of 60 minutes seems to be 
sufficient to capture the transient responses that are occurring in skeletal muscle. 
Perspectives and Considerations 
 
From this experiment, we can gather that exercise is causing skeletal muscle to 
release a/multiple soluble factor that results in mast cell degranulation, this response 
being highly localized. We utilized an isolated human mast cell line for the mast cell 
degranulation assay. While we are confident in the data that we obtained, we have to be 
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cautious in the overall conclusions and scope that we take from this. Mast cells in 
different tissues of the body express different receptors, such as the mast cells in skin 
have slightly different structures and receptors than mast cells in the gut. The isolated 
mast cells we utilized were not tissue-specific and were blood CD34+ derived (80). 
We did observe significant differences in the degranulation of mast cells in 
response to skeletal muscle dialysate collected from the exercising leg as opposed to the 
resting leg. However, these mast cells used in this study could differ than the mast cells 
that are expressed in human skeletal muscle tissue. We are not able to ascertain how 
different or how similar they may be in comparison to the mast cells that are present in 
human skeletal muscle tissue. Therefore, we need to be cautious in our interpretation of 
what we observed in vitro might be slightly different than what is happening in vivo. 
Regardless, we are confident in our findings that there is something unique that is 
released locally in exercising skeletal muscle that is not observed in resting tissue, which 
has profound effects on mast cell degranulation and the release of histamine. 
Summary and Bridge 
 
Both whole body and single-leg aerobic exercise initiates a sustained post- 
exercise vasodilatory response that is dependent upon histaminergic signaling. We have 
shown that the dialysate in exercising/exercised skeletal muscle is unique from resting, as 
we observed different responses of mast cell degranulation. This suggests that the 
“signal” for histamine release appears to be quite localized and confined to the skeletal 
muscle that is working. While this “signal” might be localized, we have demonstrated 
profound systemic effects that histaminergic signaling contributes to. Another line of 
research we have begun to examine is the role of histaminergic signaling on the post- 
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exercise inflammatory response. We have published data that demonstrates that histamine 
H1 and H2 antagonism augments the mRNA expression of some proteins in skeletal 
muscle following exercise. Among these are some that are involved in the post-exercise 
inflammatory response. In Chapter VI, we will further examine the role that 
histaminergic signaling has on the acute post-exercise inflammatory response in 
untrained individuals following a novel bout of aerobic exercise. 
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CHAPTER VI 
 
EFFECT OF HISTAMINE-RECEPTOR ANTAGONISM ON THE ACUTE 
INFLAMMATORY RESPONSE TO AEROBIC CYCLING EXERCISE 
 
 
Introduction 
 
Following a bout of novel exercise, there is an acute inflammatory response 
consisting of an increase of circulating white blood cells (leukocytes) (123, 131). This 
initial response immediately following exercise is typically considered “pro- 
inflammatory” and the following resolving component is typically considered “anti- 
inflammatory” (47). During both of these phases, cytokines are released from damaged 
muscle tissue (termed myokines) and from other non-active tissues. A balance of pro- 
inflammatory and anti-inflammatory cytokines is necessary for the proper repair of 
damaged tissue and for appropriate adaptation responses to occur (145). Dysregulated 
pro-inflammatory responses can lead to chronic diseases, and often exercise can be used 
as a therapeutic option as it has anti-inflammatory effects (116, 61). Both resistance 
exercise and aerobic exercise has been demonstrated to elicit leukocytosis, much 
depending on intensity and duration (56). While much has been discovered regarding this 
acute post-exercise inflammatory response, newer literature is investigating interventions 
which may serve to enhance or dampen this inflammatory response. 
One important mediator in inflammatory responses is histamine (11). Histamine 
can be released from many tissues; our lab has shown that it can be released by skeletal 
muscle in response to exercise. The source of this histamine can be either from de novo 
production via the enzyme histidine decarboxylase and/or mast cell degranulation in 
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which histamine is synthesized and released from mast cells. Histamine has the ability to 
produce many different physiological responses, including the contraction and dilation of 
certain smooth muscle (68). It initiates the margination of capillary endothelial cells to 
increase vascular permeability and allows larger molecules to pass through, that typically 
cannot (72). Histamine also aids in chemotaxis, a physiological mechanism to recruit 
various cell types to the site of injury or damaged tissue (66, 28). 
Our lab has shown an important role in histamine and histaminergic signaling in 
regulating post-exercise vascular responses, including post-exercise vasodilation and 
post-exercise hypotension. Antagonism of histamine H1 and H2 receptors with over-the- 
counter medications blunts these responses with whole-body exercise (94) and abolishes 
it with isolated small muscle-mass exercise (7). Due to its critical importance in these 
vascular responses and given its nature in inflammatory responses, histamine and 
histaminergic signaling could be necessary for appropriate acute post-exercise 
inflammatory responses. 
In addition to vascular responses, our lab has also shown that antagonism of 
histamine H1 and H2 receptors significantly alters the exercise transcriptome in skeletal 
muscle of humans following a bout of exercise (126). Exercise using dynamic unilateral 
knee extension exercise causes the differential expression of over 3000 protein coding 
genes in exercised skeletal muscle. We have shown that histamine receptor antagonism 
alters the expression of 795 of these genes that are typically affected by exercise. Among 
these genes are some that are involved in both the pro- and anti-inflammatory response to 
exercise. Therefore, it appears that histamine receptor antagonism affects RNA level 
expression changes in skeletal muscle that are related to inflammatory responses. 
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However, it is unknown if histamine receptor antagonism affects the circulating cytokine 
expression profile typically observed following a novel bout of exercise. 
Therefore, the purpose of this study was to gain insight into histamine’s role in 
the acute post-exercise inflammatory response in untrained individuals performing a 
novel bout of exercise. Specifically, human subjects performed 60 minutes of stationary 
cycling at 60% of their VO2peak. Circulating leukocytes and cytokines were measured 
periodically for 48 hours after exercise. Subjects performed the exercise two times, once 
under placebo condition and once under a condition where H1 and H2 receptor 
antagonism with over-the-counter histamine receptor antagonist medications. It was 
hypothesized that histamine receptor antagonism would decrease the inflammatory 
response to novel aerobic exercise. 
Methods 
 
 
Subjects 
 
 
For this study seven (2 females, 5 males) young healthy non-smoking subjects 
volunteered. This study was approved by the Institutional Review Board at the 
University of Oregon and was performed in accordance with the principles outlined by 
the Declaration of Helsinki. Written, informed consent was obtained from all subjects 
subsequent to a verbal and written briefing of all experimental procedures. Subjects were 
deemed healthy following a standard health history questionnaire. All subjects were 
required to abstain from caffeine, alcohol, and exercise for 24 h before the study visit. 
Additionally, subjects reported to the laboratory in the morning after an overnight fast. 
No subjects were using over-the-counter or prescription medications at the time of study, 
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with the exception of oral contraceptives. Female participants were studied during the 
early follicular phase of their menstrual cycle or during the placebo phase of their oral 
contraceptive. 
 
Screening Visit 
 
 
During this visit, subject’s physical characteristics were obtained (height, weight, body 
mass index) and they were familiarized with the exercise model and hemodynamic 
measurements. Arterial pressure was assessed using an automated auscultatory 
sphygmomanometer (Tango+; SunTech Medical, Raleigh, NC, United States). 
 
Experimental approach 
 
 
The goal of this experiment was to obtain venous blood samples from untrained 
subjects after performing 60 minutes of stationary cycling, one exercise test under 
placebo conditions and one exercise test under histamine H1 and H2 receptor antagonism 
conditions. Exercise test visits were separated by at least 30 days. A food diary was 
provided to the subjects prior to the first testing visit. The food diary encompassed the 
24-h prior to the exercise visit as well as the 48-hr observation period following exercise. 
Participants reported to the laboratory in the morning after an overnight fast. After a 
confirmed negative pregnancy test for female subjects, subjects were block randomized 
in to one of two testing orders. One order was placebo being the first visit, histamine 
receptor blockade for the second visit. The other order was histamine receptor blockade 
for the first visit, placebo for the second visit. Venous blood draws were obtained prior to 
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exercise and at selected time points over the course of 48 hours of recovery from 
exercise. Figure 6.1 below is a timeline of the study. 
 
 
 
Figure 6.1. Inflammation Study timeline. The 48-hr study and observational 
period was conducted twice after the subject consumed either Placebo or 
Blockade (Rx). Each blood drop ( ) indicates a time point at which a venous 
blood sample was obtained. 
 
 
 
Following an initial blood draw, subjects consumed the placebo or blockade pills orally 
with 6 oz of water and laid supine for 60 minutes. Subjects then performed 60 minutes of 
stationary cycling at 60% of peak oxygen uptake, which was previously determined with 
a peak oxygen uptake test. Exercise of this intensity produces a robust sustained post 
exercise vasodilatory response (59). Venous blood samples were obtained immediately 
after exercise, then at 6, 12, 24, and 48 hours after the completion of exercise. 
 
Histamine H1 and H2 Receptor Antagonism. 
 
 
Subjects consumed either placebo or histamine receptor antagonist medications, 
these consisted of fexofenadine and ranitidine for 5 subjects, fexofenadine and famotidine 
for 2 subjects. Oral administration of 540 mg of fexofenadine, a selective H1-receptor 
antagonist, reaches peak plasma concentrations within 1 hour and has a 12-hour half-life. 
Oral administration of 300 mg ranitidine, a selective H2-receptor antagonist, reaches  
peak plasma concentration within 2 hours and has a 3-hour half-life. This dosage of 
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histamine receptor antagonists results in ~90% inhibition of H1 and H2 receptors lasting 
for 6-hours after administration. Due to an FDA voluntary recall on ranitidine, 2 subjects 
received famotidine which is a selective H2 receptor antagonist. Oral administration of 
40 mg famotidine, a selective H2 receptor antagonist, reaches peak plasma concentration 
within 2 hours and has a 3-hour half-life, with pharmacokinetics similar to ranitidine. 
These H1 and H2 receptor antagonism medications do not alter blood flow, heart rate, or 
blood pressure at rest. 
 
Placebo 
 
 
The placebos were manufactured by Zeebo, free of any active ingredients and 
mainly containing microcrystalline cellulose. 
 
Measurements 
 
 
Blood Sampling. Venous blood (9ml) was collected from a superficial vein in the 
antecubital space into three 3-ml Vacutainers (BD Vacutainer, Becton, Dickinson and 
Company, Franklin Lakes NJ, USA) for collection plasma (K2 EDTA anticoagulant). 
Blood was then aliquoted for separation and quantification of white blood cell 
populations via flow cytometry (Gallios, Beckman Coulter Life Sciences, Indianapolis 
IN, USA) using the manufacturers data acquisition software (Kaluza, Beckman Coulter 
Life Sciences, Indianapolis IN, USA). Separate aliquots were centrifuged at 1,275 RCF 
and stored in cryovials at -80C until analysis. 
 
Cell Staining Protocol for Flow Cytometry. Cell suspensions were re-suspended and 
 
1.5 x 106 cells were transferred to individual 2.0ml microcentrifuge tubes for each 
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staining sample plus the unstained cells. Cells were pelleted at 500G for 5 minutes. 
Cells were re-suspended in 100ul of staining buffer (PBS + 1% BSA + 10% FBS = 
Biolegend 420201 + 50 mL FBS – Gibco 26140-129, heat deactivated at 560 for 45 
minutes) plus 10ul mouse IgG (Jackson Immuno – ChromPure 015-000-003). 
Suspensions were incubated for 30 minutes at room temperature. Cells were washed with 
1mL of staining buffer, centrifuged and supernatant was discarded. 100ul of antibody 
staining cocktail was added to each tube and incubated for 30 minutes in the dark at room 
temperature. 1 mL of staining buffer was added to each tube, cells were centrifuged and 
supernatant was discarded. Cell pellet was re-suspended in 500uL staining buffer and 
read in a flow cytometer. The following antibodies were used for the leukocyte staining 
protocol: CD62E, CD86, CD309, CD34, CD192, CD66B, CD14, CD16, CD3, CD19, 
CD56, CD45. 
Circulating Cytokine Analysis. Plasma was also analyzed for inflammatory cytokines 
via a bead based flow cytometry kit (Biolegend, LEGENDplex Human Inflammation 
Panel 1, multianalyte flow assay kit). This method of cytokine identification uses beads 
of varying size coated with antigens specific to cytokines of interest (MCP-1, IL-10, IL- 
17A, IL-18,). The size and fluorescence of the beads allows for separation and 
quantification of the cytokine by flow cytometry (Gallios, Beckman Coulter Life 
Sciences, Indianapolis IN, USA.) 
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Hemodynamic Measurements 
 
 
All resting measurements were made pre- and post-exercise with the subjects in 
the supine position. Subjects were asked to remain quiet and relaxed during the pre and 
post-exercise hemodynamic measurements. Heart rate and blood pressure during 
exercise were made with the subjects in the upright position on the stationary cycle 
ergometer. 
 
Heart Rate and Blood Pressure. Arterial blood pressure was measured in the right arm 
using an automated sphygmomanometer (Tango+, SunTech Medical, Raleigh NC, USA). 
Hear rate was monitored using a three-lead electrocardiograph (Tango+, SunTech 
Medical, Raleigh NC, USA). Heart rate and blood pressure were obtained before, during 
60 minutes of cycling exercise, and post-exercise. 
 
Femoral Blood Flow. Femoral artery blood flow velocity was measured via duplex 
ultrasonography. A linear-array vascular ultrasound probe (9 MHz, Phillips iE33, 
Andover, MA., USA) and an insonation angle of 60 was used to measure blood flow in 
the common femoral artery, approximately 2-3 cm proximal to the bifurcation. The 
Doppler ultrasound machine was interfaced with a computer running custom audio 
recording software. Velocity measurements were determined using an intensity-weighted 
algorithm (custom software), subsequent to demodulation of forward and reverse Doppler 
frequencies. Leg blood flow was calculated as cross-sectional area multiplied by femoral 
mean blood velocity and reported in ml per min. Femoral vascular conductance was 
calculated by dividing femoral blood flow by mean arterial pressures and expressed as ml 
per min per mmHg. 
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Statistical Analysis 
 
 
Our primary outcome variables for this study (leukocytes, neutrophils, 
granulocytes, monocytes, and cytokines) were analyzed using a Two-Way ANOVA 
(GraphPad Prism) to test for differences in cell populations over time and between 
conditions (placebo vs. blockage). A Two-Way ANOVA was used to determine 
significant differences in central and peripheral hemodynamic measurements during and 
following exercise. Fisher’s LSD test was used for post-hoc analysis. Significance was 
set at P < 0.05. Data are reported as mean SEM unless stated otherwise (e.g. SD is used 
in Table 6.1 to indicate variability in the subject pool). 
 
Results 
 
 
Subject Characteristics 
 
 
Subject physical characteristics and data obtained during the screening visit are 
shown in Table 6.1. For this study, subject characteristics were similar to those obtained 
previously in our laboratory. 
 
Table 6.1 Subject Characteristics 
n 7 (2F, 5M) 
 
Age (yrs) 24 ± 3 
 
Height (cm) 161.9 ± 10.2 
 
Height (kg) 75.1 ± 9.7 
 
BMI (kg*m-2) 23.2 ± 2.8 
 
Values are means ± SD. 
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Pre-exercise Hemodynamics. Pre-exercise heart rate and mean arterial blood pressure 
are shown in Table 6.2. Both heart rate and mean arterial pressure did not differ between 
control and H1/H2 blockade conditions. Pre-exercise femoral blood flow and femoral 
vascular conductance are shown in Table 6.3. Femoral blood flow did not differ between 
control and H1/H2 blockade conditions. Likewise, femoral vascular conductance did not 
differ between control and H1/H2 blockade conditions. 
 
Post-exercise Hemodynamics. Table 6.2 shows heart rate and mean arterial blood 
pressure during recovery from exercise. Heart rate was not different between control and 
H1/H2 antagonist conditions. In addition, mean arterial pressure did not differ between 
control and H1/H2 blockade conditions. Absolute values for femoral blood flow and 
femoral vascular conductance are shown in Table 6.3. 
 
Table 6.2. Central Hemodynamics 
 
 
Heart Rate (beats min -1) 
 
Mean Arterial Pressure (mmHg) 
Time Point Placebo H1/H2 Blockade Placebo H1/H2 Blockade 
Pre-Exercise 63.1 ± 2.3 65.4 ± 2.1 85.1±2.5 87.9±1.3 
Time Post Exercise     
20 min 68.8± 2.3 71.3± 2.3 79.3±2.7* 84.3±2.5 
40 min 67.2± 2.9 68.2± 2.9 80.9±2.3* 86.1±1.8 
60 min 66.6± 2.9 67.6± 2.9 82.1±2.5* 84.9±1.2 
104  
Table 6.3. Absolute Femoral Blood Flow and Femoral Vascular Conductance 
 
 
Femoral Blood Flow 
(ml min -1) 
 
Femoral Conductance 
(ml min -1 mmHg) 
 
Time Point 
 
Placebo 
 
H1/H2 Blockade 
 
Placebo 
 
H1/H2 Blockade 
Pre-Exercise 202 ± 18 220 ± 15 2.2 ± 0.4 2.1 ± 0.9 
Time Post Exercise     
20 min 360 ± 26* 244 ± 10 4.1 ± 1.1* 2.9 ± 1.3 
40 min 352 ± 18* 231 ± 15 4.0 ± 0.8* 2.7 ± 0.6 
60 min 320 ± 15* 235 ± 12 3.8 ± 1.2* 2.4 ± 0.9 
 
Values are expressed as mean ± SEM. * indicates significantly different from pre-exercise 
(p<0.05) 
 
Circulating Leukocytes. There was no difference in leukocyte count pre-exercise 
between placebo and blockade conditions. Exercise caused an increase in circulating 
leukocytes immediately after exercise (time effect p<0.05). Compared to pre-exercise, 
immediately after exercise there was a 27 ± 3.2% rise in leukocytes in the control 
condition, and a 38 ± 1.5% rise in leukocytes in the blockade condition. There were no 
differences between placebo and blockade (drug effect P = 0.69) nor was there a pattern 
of change over time between Placebo and Blockade (drug X time interaction P=0.98) 
(Figure 6.2). 
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Figure 6.2. Total Leukocyte count per ml of blood during 48-hour of recovery from 
cycling exercise. Data expressed as means ± SEM. ME = main effect (p<0.05) * 
indicates significantly different from placebo (p<0.05) Open circles (o) blockade, closed 
circles ( ) placebo 
 
 
Circulating Neutrophils. There was no difference in neutrophil count pre-exercise 
between placebo and blockade. Exercise caused an increase in circulating neutrophils 
immediately after exercise (time effect p<0.05). Compared to pre-exercise, immediately 
after exercise there was a 34 ± 4.2% rise in neutrophils in the control condition, and a 30 
± 5.3% rise in neutrophils in the blockade condition. There were no differences between 
placebo and blockade (drug effect P = 0.85) nor was there a pattern of change over time 
between Placebo and Blockade (drug X time interaction P=0.90) (Figure 6.3). 
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Figure 6.3. Neutrophil count as percent of leukocytes during 48-hour of recovery from 
cycling exercise. Data expressed as means ± SEM. ME = main effect (p<0.05) Open 
circles (o) blockade, closed circles ( ) placebo 
 
 
 
 
 
 
Granulocytes and Monocytes 
 
Granulocytes and monocyte subpopulations were not different between drug 
conditions or over time (Table 6.4). There was no significant difference for drug, time, or 
interaction in any of the monocyte subpopulation in this analysis. 
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Table 6.4. Granulocyte and monocyte sub-populations during recovery from exercise 
 
Time after exercise (h)    P-Value  
 Pre 0 6 12 24 48 Drug Time Interact  
Gran 
(%) 
Placebo 41.1 
±7.2 
42.0 
±8.1 
52.3 
±6.9 
50.9 
±8.1 
44.6 
±4.0 
42.1 
±7.2 
0.32 0.34 0.94 
 Blockade 44.5 
±5.7 
52.1 
±5.3 
54.0 
±7.0 
50.4 
±6.5 
43.4 
±10.3 
45.4 
±7.1 
   
Mon I 
(%) 
Placebo 0.61 
±0.2 
0.78 
±0.5 
3.21 
±5.1 
0.52 
±0.3 
0.87 
±0.7 
0.40 
±0.2 
0.88 0.88 0.99 
 Blockade 0.50 
±0.4 
0.82 
±0.2 
0.46 
±0.3 
1.21 
±0.6 
1.15 
±0.5 
1.15 
± 0.6 
   
Mon II 
(%) 
Placebo 0.18 
±0.4 
0.22 
±0.2 
2.25 
±2.9 
0.88 
±0.1 
0.78 
±0.2 
1.13 
±1.8 
0.72 0.90 0.99 
 Blockade 0.15 
±0.2 
0.23 
±0.2 
1.33 
±0.3 
1.07 
±0.2 
0.24 
±0.2 
0.53 
± 0.2 
   
 
Mon III 
(%) 
Placebo 0.58 
±0.2 
0.24 
±0.2 
0.22 
±0.2 
0.28 
±0.1 
0.18 
±0.1 
0.64 
±0.2 
0.58 0.97 0.99 
 Blockade 0.38 
±0.2 
0.30 
±0.1 
0.10 
±0.1 
0.24 
±0.1 
0.12 
±0.2 
0.16 
±0.2 
   
* indicates significant difference 
 
Plasma Cytokine Levels 
 
 
Plasma cytokine levels were analyzed in 5 subjects, shown in Table 6.5. There 
was a significant main effect of time in circulating MCP-1 cytokine levels (p=0.04) and a 
trending effect of drug (p=0.12). There was also a significant main effect of time in 
circulating IL-10 cytokine levels (p=0.01) however no significant effect of drug (p=0.82). 
There was no significant effect of time, drug, or interaction in circulating IL-18 or IL-17a 
cytokine levels. 
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Table 6.5. Plasma cytokine changes during recovery from exercise (n=5) 
 
Time after exercise (h)    P-Value 
  Pre 0 6 12 24 48 Drug Time Interact 
MCP-1 
(pg/mL) 
Placebo 142.5 
±9.8 
171.7± 
9.2 
154.7 
±3.8 
151.2 
±15.8 
153.2 
±6.5 
148.5 
±6.1 
0.12 0.04* 0.98 
 Blockade 155.8 
±11.7 
180.1± 
9.4 
169.9 
±9.1 
159.6 
±13.2 
155.3 
±9.2 
155.6 
±8.3 
   
 
IL-18 
(pg/mL) 
 
Placebo 
 
54.9 
±21.4 
 
45.4 
±15.4 
 
33.6 
±8.0 
 
42.9 
±10.1 
 
33.6 
±9.3 
 
39.1 
±9.7 
 
0.68 
 
0.95 
 
0.67 
 Blockade 36.1 
±5.5 
50.9 
±8.3 
55.7 
±24.2 
44.1 
±10.8 
47.9 
±10.6 
32.3 
±7.7 
   
 
IL-10 
(pg/mL) 
 
Placebo 
 
27.5 
±3.3 
 
28.9 
±2.6 
 
31.6 
±4.3 
 
26.2 
±3.3 
 
26.2 
±4.9 
 
42.3 
±5.8 
 
0.82 
 
0.01* 
 
0.90 
 Blockade 28.2 
±3.1 
29.1 
±3.0 
27.4 
±4.6 
26.5 
±4.8 
32.1 
±5.0 
42.5 
±3.2 
   
 
IL-17a 
(pg/mL) 
 
Placebo 
 
121.4 
±15.6 
 
110.9 
±6.3 
 
103.2± 
1.1 
 
104.3 
±2.1 
 
105.6 
±3.6 
 
107.5 
±5.1 
 
0.68 
 
0.74 
 
0.51 
 Blockade 106.2 
±2.4 
117.9 
±11.1 
110.5 
±5.4 
110.8 
±5.3 
107.8 
±2.9 
107.3 
±3.7 
   
 
* indicates significantly difference (p<0.05) 
 
Discussion 
 
The purpose of this study was to determine the effect of histamine receptor H1/H2 
antagonism on the acute post-exercise inflammatory response. The main finding was that 
there was no significant difference in the acute post-exercise inflammatory response 
under histamine receptor H1/H2 antagonism. We did note a significant effect of time in 
many of the systemic circulating inflammatory factors, indicating that our exercise model 
induces a systemic inflammatory response. Overall, the data suggest that histamine 
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receptor antagonism does not affect the acute post-exercise inflammatory response 
following aerobic exercise in untrained individuals. 
Acute Post-Exercise Inflammatory Response and Histamine 
 
To our knowledge, this is the first known investigation to examine the link 
between histamine and the systemic inflammatory response following a bout of aerobic 
exercise. Our exercise protocol was selected for two reasons, one of them relating 
directly back to histamine. We have shown robust post-exercise vasodilatory responses in 
individuals who perform 60 minutes of stationary cycling at 60% VO2 peak. This 
response is blunted by 80% when this exercise is performed under histamine receptor 
H1/H2 blockade (94), indicating a critical role for histamine and histaminergic signaling 
in this response. Second, this intensity and duration of exercise has been shown to elicit 
an inflammatory response in untrained individuals. Previous studies have used this 
exercise modality and have demonstrated systemic leukocytosis and increase in white 
blood cells systemically within 12 hours of exercise. Therefore, we are confident in the 
research design in its ability to elucidate the role of histaminergic signaling in the post- 
exercise inflammatory response to this type of exercise. 
We observed a notable increase in circulating leukocytes and neutrophils 
immediately after exercise that persisted until 6 hours following exercise. However, there 
were no differences between placebo or blockade condition in leukocyte and neutrophil 
counts (Figures 6.2 and 6.3). We also did not note any significant differences of drug 
condition on circulating granulocytes or monocyte sub-populations. We did note a 
significant effect of time in certain circulating cytokines such as MCP-1 and IL-10 (Table 
6.6), however no effect of drug nor an interaction. The significant upregulation of these 
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cytokines, in addition to leukocyte and neutrophil counts demonstrate an acute 
inflammatory response to this exercise model. Our data shows that while we did have an 
acute inflammatory response to our exercise model, this inflammatory response is not 
affected by histamine receptor H1 and H2 antagonism. 
Ranitidine vs Famotidine and Sustained Post-Exercise Vasodilation 
 
Sustained post-exercise vasodilation can last upwards of several hours during the 
recovery period following a bout of aerobic exercise. This response is typically absent 
following short duration exercise (7). Sustained post-exercise vasodilation is usually 
studied following large muscle-mass dynamic exercise ranging from 30-60 minutes. The 
dependence of this response is on the duration and intensity of exercise, consistently 
observed and greater in magnitude following moderate intensity (50-60%) and prolonged 
(30-60 minutes)(59). 
Our lab has been using ranitidine as a histamine H2 receptor antagonist, in 
combination with fexofenadine as the histamine H1 receptor antagonist. We typically use 
300 mg of ranitidine HCl (Brand name: Zantac) as this oral dose has been shown to 
adequately block H2 receptors with a peak plasma concentration at approximately 2.2 
hours and a 2.6 hour half-life. Furthermore, the responses are >90% inhibited within 60 
minutes and remain inhibited for 6hrs after administration (20). This blockade prevents a 
decrease in smooth muscle intracellular calcium levels that usually occur with 
histaminergic signaling. We enrolled and completed 5 subjects in the study using 
fexofenadine and ranitidine for their drug visit. During our study, the FDA issued a 
voluntary recall on ranitidine on the market due to possible contamination. Even though 
none of our batch or lot number ranitidine was affected, in caution we decided to move to 
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another H2 receptor antagonist. We chose famotidine (brand name: Pepcid AC) as it is a 
selective H2 receptor antagonist with similar pharmacokinetics for 2 subjects. 
In line with other research from our lab, we demonstrated a significant blunting of 
the sustained post-exercise vasodilatory response under blockade conditions, as seen in 
Table 6.3. This blunted response was similar regardless of H2 receptor antagonist 
(ranitidine vs famotidine). Following exercise under placebo conditions, there was a 
significant increase in femoral blood flow out to 60 minutes following exercise. At 60 
minutes, there was still a 16% increase in femoral blood flow and a 30% increase in 
femoral vascular conductance, compared to pre-exercise values. Under histamine H1/H2 
receptor antagonism, there were no significant differences in femoral blood flow or 
femoral vascular conductance at any timepoint following exercise, compared to pre- 
exercise. This did not differ depending on the H2 receptor antagonist. Immediately after 
exercise, with fexofenadine/ranitidine the change from pre-exercise was about 4% and 
with fexofenadine/famotidine approximately 3%. Examining mean arterial pressure, 
blood flow, and femoral conductance data, there does not appear to be a differential effect 
on post-exercise hemodynamics due to famotidine compared to ranitidine. However, 
given the continuation of FDA recall on ranitidine, further work should be done on 
famotidine, to ensure and verify its similarity to ranitidine in the ability to blunt the 
sustained post-exercise vasodilatory response in order to continue our work on the effect 
of histamine receptor antagonism on the exercise responsome. 
Role of Histamine in Capillary Permeability/Systemic Inflammation 
 
We noted that histamine H1/H2 receptor antagonism, specifically with 
fexofenadine/ranitidine, resulted in an augmented acute post-exercise systemic 
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inflammatory response. Leukocytes and neutrophils were present in higher counts and 
percentages over the time course following exercise. Subjects performed the same 
workload for the same amount of time, in similar environmental conditions so we are 
confident that their exercise sessions were similar in intensity between placebo and 
blockade. It is possible that these antagonist medications are influencing capillary 
permeability which is then leading to the augmented systemic circulating factor response 
we observed. 
The vasculature is composed of vascular endothelial cells and vascular mural 
cells, such as vascular smooth muscle cells and pericytes (122, 142). These functionally 
interact with each other and coordinate a variety of vascular functions. Vascular 
permeability is determined by two major factors: blood flow and endothelial barrier 
function (142). Histamine-induced vascular permeability is mediated by intracellular 
signaling pathways, such as the phosphorylation of VE-cadherin and other critical 
proteins in the endothelial barrier (33, 167). An increase in vascular permeability will 
allow larger solutes and molecules to easily pass from inside the vessel to the interstitial 
space and vice versa. 
In response to challenging exercise (both aerobic and resistance exercise based) 
there is a release of white blood cells (leukocytosis) that migrate to the damaged skeletal 
muscle tissue. Leukocytes and neutrophils are typically found within 1 hour in skeletal 
muscle, following cessation of intense exercise. These leukocytes have many sources as 
they respond to the stressor of exercise. This mobilization of white blood cells can come 
from bone marrow and the spleen, where they demarginate through blood vessel walls to 
then enter the blood stream circulation, to then migrate to the damaged tissue. There are a 
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multitude of chemotactic signals in skeletal muscle that act to bring these leukocytes, 
neutrophils, granulocytes, and other cell types to the affected tissue. As with their 
mobilization, many of these cell types are not able to easily pass through blood vessel 
walls to then enter tissue. Histamine can aid in the margination and diapedesis, allowing 
these cell types to move from the blood, through the vessel wall, and then to enter tissue. 
This movement of leukocytes in to the affected tissue is essential for proper skeletal 
muscle adaptation and remodeling that occurs in response to a bout of intense exercise. 
With our model, following a bout of intense exercise under placebo conditions, 
we hypothesized that histamine may be acting to increase vascular permeability to allow 
circulating factors which are circulating in the blood stream that are typically too large to 
pass through vasculature, to then enter skeletal muscle or other tissues. Following a bout 
of intense exercise under histamine H1/H2 receptor antagonism, vascular permeability 
may be affected to where these circulating factors are not able to enter skeletal muscle 
tissue and cross barriers as easily, therefore leaving them in systemic circulating longer 
than under placebo conditions. We did not note any significant differences of circulating 
factors between placebo and blockade conditions. However, we do not know what is 
happening locally in previously exercise skeletal muscle under histamine receptor 
antagonism. Being able to obtain skeletal muscle biopsies following exercise to compare 
blockade to placebo would help to elucidate if there are few leukocyte-type cells in 
previously exercise skeletal muscle under blockade conditions versus placebo conditions. 
Future work should investigate this as well as further examine the role of histamine on 
capillary permeability following exercise to elucidate the mechanisms of what we 
observed in this study. 
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This reduction of sustained post-exercise vasodilation with histamine receptor 
antagonism is consistent and in line with previous research from our lab. While we did 
not find differences in the circulating inflammatory marker profile of subjects under 
histamine receptor antagonism compared to placebo, we recognize that the acute 
inflammatory response to aerobic exercise is a complicated process in which some 
individuals show more robust responses than others. There great deal of variability in the 
inflammatory response to exercise in humans which can be affected by many things such 
as external environmental factors, diet, and many others. Further work should be done to 
gather a larger pool of subjects to further examine the role of histaminergic signaling on 
acute post-exercise inflammatory responses. 
Perspectives and Considerations 
 
From this experiment, we have shown that our model of aerobic exercise utilizing 
60 minutes of stationary cycling at 60% VO2 peak induces an acute inflammatory 
response. However, our data suggest that histamine H1/H2 receptor antagonism does not 
appear significantly augment this acute post-exercise inflammatory response following 
aerobic exercise in untrained individuals. 
While we did note significant differences in systemic circulating inflammatory 
factors, it is unknown what is happening within skeletal muscle. We have data showing 
out to 3 hours following exercise, beyond that is unknown. It could be possible that 
antagonizing the effects of histamine on histamine H1/H2 receptors could be affecting the 
inflammatory response in skeletal muscle. Neutrophil invasion and release of cytokines 
locally in skeletal muscle play an important role in mediating the inflammatory response, 
and could be affected by histaminergic signaling. Further work should perform this type 
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of study and obtain skeletal muscle biopsies at certain intervals out to 48 hours, to 
understand what might be changing locally in muscle in regards to the acute 
inflammatory response and its interaction with histamine. This work would involve 
immunohistochemical staining to identify cell types in skeletal muscle and protein 
abundance analysis to investigate if histaminergic signaling affects translation of proteins 
that are involved in the acute inflammatory response. 
Summary 
 
This study has addressed how antihistamine medications may impact the acute 
inflammatory response to aerobic exercise in untrained individuals. This study 
demonstrated that blocking histaminergic signaling on H1 and H2 receptors did not alter 
the systemic inflammatory response of leukocytes and neutrophils following aerobic 
exercise. Blocking histaminergic signaling on H1 and H2  receptors did not appear to 
affect the expression of circulating cytokines that are typically associated with the aerobic 
acute post-exercise inflammatory response. of histamine in the post-exercise. Future 
research should seek to investigate the role of histaminergic signaling in post-exercise 
inflammation locally in skeletal muscle. 
116  
CHAPTER VII 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
The studies of this dissertation focus on and build upon our current knowledge 
regarding the interaction of histamine and exercise. Our lab has clearly established a role 
for histamine and histaminergic signaling in the post-exercise responsome. This role 
includes vascular responses such as sustained-post exercise vasodilation, post-exercise 
hypotension and others such as glucose uptake in skeletal muscle (8, 63, 123). In addition 
to these, recent evidence from our lab suggests the role of histaminergic signaling in 
mRNA expression in previously exercised skeletal muscle (136). While we have shown 
that histamine and exercise have an intimate interaction with each other, these studies 
addressed questions that still remained in order to better understand the role of histamine 
in the exercise responsome. 
Summary of Key Findings 
 
Over the past two decades, our lab has created models to examine the effects of 
histamine receptor antagonism on exercise responses. Most of these have been aerobic 
exercise based, such as cycling or unilateral dynamic knee extension exercise. During 
dynamic aerobic exercise, there are a multitude of changes occurring in skeletal muscle, 
including changes in temperature, changes in pH, release of myokines, among others 
(138, 26). Regarding this, we wanted to know what is it about exercise that causes the 
release of histamine? It has been shown that histamine is released from skeletal muscle in 
response to exercise. Since many local factors are altered with exercise, we do not which 
one or combination of these factors are causing the release of histamine in skeletal 
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muscle. Therefore, we performed studies, detailed in Chapter IV and V, in an attempt to 
identify if temperature or local factors released by muscle in response to exercise, is the 
trigger that leads to the release of histamine in skeletal muscle. 
Data from chapter VI suggests that the increase in skeletal muscle temperature 
appears to play an important role in the release of histamine from skeletal muscle. In vitro 
experiments suggest this release of histamine may be the influence of temperature on 
enzymatic kinetics of histidine decarboxylase rather than direct mast cell degranulation. 
In addition, the data in Chapter V suggests that there is a local factor released in skeletal 
muscle in response to exercise that causes mast cells to degranulate. This response 
appears to be localized as we did not see an effect on mast cell degranulation from 
skeletal muscle dialysate collected from resting tissue. Another gap we sought to 
investigate was the effect of histamine receptor antagonism on the acute inflammatory 
response to exercise. Our lab has published promising data that blocking the actions of 
histamine on H1 and H2 receptors alters gene expression in skeletal muscle, particularly 
genes that are involved in inflammation (136). However, it was only measured to 3 hours 
post-exercise in skeletal muscle. The study detailed in Chapter VI built upon this, aimed 
to investigate the role of histaminergic signaling on the acute post-exercise inflammatory 
response in untrained individuals after a bout of novel exercise. We found that following 
a novel bout of exercise, untrained individuals had a robust systemic rise in circulating 
leukocytes, neutrophils, and some inflammatory cytokines. When these same volunteers 
exercised under histamine H1/H2 receptor antagonism, the acute inflammatory response 
was not augmented. In all, we have made significant progress in our understanding of the 
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interaction of histamine, exercise, and inflammation. And these experiments have set the 
stage for future experiments to address questions that still remain from these studies. 
During exercise, the creation and release of energy in exothermic reactions results 
in metabolic heat production in skeletal muscle (58). During both aerobic and resistance 
exercise, it has been observed that skeletal muscle temperature increases due to increased 
metabolic activity. This change in temperature has been shown to have a multitude of 
effects in skeletal muscle, altering cross-bridge cycling dynamics and metabolic activity 
(169, 125). Therefore, these set of experiments investigated if an increase in skeletal 
muscle temperature, which happens during exercise, is the stimulus for histamine release 
in skeletal muscle. In order to passive raise skeletal muscle to “exercising temperatures”, 
we utilized passive short-wave diathermy, a non-invasive method of raising skeletal 
muscle temperature (36). We were successful in increasing skeletal muscle temperature 
up to values observed during dynamic unilateral knee extension exercise, as seen in 
Figure 4.2. Analysis of the dialysate collected from skeletal muscle revealed a significant 
increase in histamine concentrations near the end of the heating protocol when 
temperature was approximately 39°C. This rise in skeletal muscle histamine 
concentration was similar in magnitude to what we had previously observed in dialysate 
collected from exercising skeletal muscle (155). The final question of this study 
remained, is temperature directly causing mast cells to degranulate? Previous literature 
has suggested that changes in temperature can cause mast cells to degranulate (171). To 
answer this question, we utilized isolated human mast cells in an in-vitro experimental 
approach. We exposed isolated human mast cells to 3 different physiological 
temperatures. We did not observe any significant differences in mast cell degranulation in 
119  
when exposed to higher and lower temperature conditions, as seen in Figure 4.3. These 
data suggest that the histamine release observed in related to temperature increases in 
skeletal muscle might be of de novo origin, rather than direct effects of temperature on 
mast cell degranulation. 
While our data suggested temperature plays a significant role, we wanted to 
further understand what is changing in skeletal muscle as opposed to resting tissue that 
causes the release of histamine. The research literature has demonstrated that cytokines 
and other cell types can be release by skeletal muscle in response to exercise. These 
cytokines can have both paracrine and autocrine effects, affecting tissues such as the liver 
and brain (121, 120) and the skeletal muscle (122). The question that framed this 
experiment in context of what we already know was, “is there or are there factors 
released locally in skeletal muscle during exercise that cause mast cell degranulation?” In 
the experiment in this chapter, we were curious if there is a factor or factors that are 
released in skeletal muscle in response to exercise that cause increased mast cell 
degranulation that are not present in resting skeletal muscle. To investigate this, we had 
subjects perform 60 minutes of unilateral dynamic knee extension exercise at 60% of 
their peak power. We once again used skeletal muscle microdialysis fibers to collect 
dialysate from the vastus lateralis of the exercising leg and the vastus lateralis of the 
resting leg. Of interest, we noted a significant increased mast cell degranulation 
percentage when exposed to dialysate from exercising skeletal muscle compared to pre- 
exercise values (Figure 5.1). This significant response persisted out to 20 minutes of 
recovery from exercise. The percentage of mast cells that degranulated from dialysate 
from the resting leg was not different at any timepoint compared to pre-exercise. We 
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noted significant differences in mast cell degranulation between 
the exercising and resting dialysate collected at 40 and 60 minutes 
during exercise and 20 minutes after exercise. 
Following a bout of exercise, there is a local and systemic 
inflammatory response which is responding to the muscle damaged by 
the exercise. This response is mediated by a multitude of factors such as 
myokines that are released by skeletal muscle (56) along with the 
response of bone marrow and the spleen to release leukocytes to 
migrate to the damage tissue (133). Histamine is known to be intimately 
involved in the inflammatory process, therefore the purpose of this 
experiment was to investigate how using over-the- counter histamine 
receptor antagonist medications would affect the systemic inflammatory 
response to a novel bout of moderate intensity aerobic exercise. 
Previous work from our lab suggested that histaminergic blockade may 
impact the inflammatory response to a bout of exercise (126). For this 
study, we utilized a model of exercise that both elicits a significant 
sustained post-exercise vasodilatory response that is mediated by 
histaminergic signaling and has been shown to elicit a robust 
inflammatory response in untrained individuals. Venous blood draws 
were obtained at multiple points following out to 48 hours post-
exercise, once under placebo conditions and once under histamine 
H1/H2 receptor antagonism. 
In our model, we found that histamine H1/H2 receptor 
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antagonism did not augment the systemic response of circulating 
leukocytes and neutrophils compared to placebo conditions, as 
shown in Figures 6.2 and 6.3. Going back through 3-day food recall 
logs, subjects consumed similar foods under both conditions and 
exercised at the same intensity under both conditions. For this study, 
we had to use two different H2 
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receptor antagonists due to a voluntary FDA recall on ranitidine. Some subjects received 
famotidine instead of ranitidine for the H2 receptor antagonist. We noted that the blunting 
of post-exercise vascular responses were similar between drug conditions. We recognize 
that the human inflammatory response to exercise is quite variable, and future studies 
should further investigate the role of histaminergic signaling on the inflammatory 
response to aerobic exercise with a larger subject pool. 
The work presented in this dissertation, in concert with others from our lab, has 
demonstrated an important role for histamine in exercise responses. Histaminergic 
signaling has important roles in endurance exercise, blood flow regulation, skeletal 
muscle glucose uptake. Our models and findings complement and add to the history of 
histamine research, helping to further understand the role and importance of histamine 
and exercise responses. We have helped increase our knowledge, however there are still 
gaps that remain regarding exercise and histaminergic signaling. 
Future Directions and Experiments 
 
Our systemic blockade could be affecting other unknown pathways both during 
and following exercise, which warrant further investigation. Histamine plays an 
important role in the many physiological responses to exercise, and this dissertation has 
shown that certain aspects of exercise trigger the release and that histaminergic signaling 
may be involved in the systemic inflammatory response to exercise. 
While we have shown that temperature appears to be an important exercise trigger 
for the release of histamine, there could be other factors in skeletal muscle causing this 
release. An insightful follow up experiment that would be a logical next step would be to 
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examine how temperature affects HDC enzymatic activity. While there is some published 
literature that has examined it (143, 144), in scientific rigor this should be revisited and 
should keep to physiological temperatures that are typically observed in human skeletal 
muscle. Also, while we established a clear role for temperature and have ruled out 
oxidative stress, there are still other exercise factors that remain to be investigated. So 
where do we go from here? 
pH is a factor that is highly influenced by exercise, as there are decreases in pH in 
skeletal muscle with higher intensity exercise. It is plausible that an increased presence of 
hydrogen ions in an acidic environment may affect mast cell degranulation. Therefore, 
pH could also be playing a role as an “exercise factor” that causes the release of 
histamine during exercise. It would be quite difficult to alter pH levels in muscle without 
affecting other factors. However, a buffering agent with direct measurements of skeletal 
muscle pH levels during exercise could be useful in a similar experiment where skeletal 
muscle dialysate could be collected to then investigate skeletal muscle histamine levels. 
In addition, in-vitro experiments could be valuable in investigating if mast cells 
degranulate in response to physiological changes in pH in their culture media. These 
additional studies will help to further investigate the exercise factor or factors that result 
in exercise-induced increases in skeletal muscle histamine concentrations. 
In addition, the contraction of skeletal muscle contraction in itself may cause mast 
cells to degranulate independent of other factors. During skeletal muscle contraction, 
actin-myosin crossbridge cycling is a dynamic process that involves the hydrolysis of 
ATP and other enzymes. This dynamic process affects other cell types in skeletal muscle 
that are critical for force production. Mast cells have been shown to be present in long- 
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term cultures of skeletal muscle of rats (30). Histamine concentrations can be 
biochemically measured in the dish in which the single or multi-fiber muscle preparations 
are prepared. Given this, it is possible to extend this to an examination of human model 
fiber preparation. This would involve multi-fiber isolation from resting skeletal muscle 
biopsy obtained from humans. Then using a setup in which one end of the fiber bundle is 
attached to a force-transducer and the other end is secured, it is possible to contract the 
muscle at different velocities and covering force ranges from 0.5-1000mN (24). This 
preparation is in solution that is pH, enzyme, and temperature controlled. Histamine 
concentrations could be measured in the culture media, to examine if histamine is 
released from skeletal muscle fiber contraction and if this is velocity/force dependent. 
The microdialysis fibers we used for the study in Chapter V had a molecular cut- 
off weight of 100kDa, so the factor or factors causing the increased mast cell 
degranulation must be smaller than this. In all, this study has demonstrated that there is a 
factor or multiple factors that are released in exercising skeletal muscle that cause 
increased mast cell degranulation. These are localized to the exercising tissue and appear 
to be resolved within 40 minutes of the cessation of exercise. A logical future direction 
would be an “omics” approach to investigate what this factor or factors may be. The 
transcriptomics approach allows for biological samples to be investigated for the 
characterization and quantification of biological molecules within that sample (126). The 
experiment could be repeated, with skeletal muscle microdialysis fibers placed in both 
the exercising and resting leg. The exercise transcriptome could be investigated from the 
collected dialysate samples, allowing us to evaluate factors that might be upregulated 
during exercise and that are unique to exercising skeletal muscle, opposed to resting 
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skeletal muscle. Furthermore, the size of the microdialysis fibers allows for a more 
“focused” approach as we know that the factors we observed in this study are smaller 
than 100kDa. Larger molecular weight cut-off probes could be used to further investigate 
factors that may be released in skeletal muscle in response to exercise that are larger than 
100kDa, as it is highly likely that there are factors larger than this that can directly cause 
mast cell degranulation, such as C5a which was discussed in Chapter V 
Even though we did not find statistical significance of our blockade condition in 
the inflammatory study, it still has promising future directions. An important follow up 
study should involve obtaining skeletal muscle biopsies at time points out to 48 hours 
following this type of exercise under these conditions. We were able to quantify many of 
the systemic, circulating factors that are typically associated with the acute post-exercise 
inflammatory response. However, another portion of the inflammatory response is 
localized to the skeletal muscle that was exercised with invading neutrophils, myokines 
released from the muscle, and other proteins that are either upregulated or downregulated 
in response to exercise. Having the localized skeletal muscle data in conjunction with the 
systemic, circulating factors data would be complementary and tell a more complete story 
of the role of histaminergic signaling on the acute inflammatory response to exercise. 
Overall, these studies have answered many questions and provide us direction and 
guidance for further experiments regarding the interaction between histamine, exercise, 
and inflammation. 
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Chapter IV 
APPENDIX A: INFORMED CONSENT DOCUMENTS 
 
 
INFORMED CONSENT FORM 
TITLE: Exercise, histamine receptors, and vascular function (Experiment: Muscle 
temperature) 
INVESTIGATOR: Dr. J. R. Halliwill and Colleagues 
This is an important form. Please read it carefully. It tells you what you need to know 
about this study. If you agree to take part in this research study, you need to sign the 
form. Your signature means that you have been told about the study and what the risks 
are. Your signature on this form also means that you want to take part in this study. 
Why is this research study being done? 
When humans exercise, there is an increase in blood flow to the skeletal muscle. This 
increase in blood flow lasts for several hours after exercise as a result of vasodilation of 
the blood vessels. Previous studies have shown that this vasodilation is largely the result 
of a release of histamine. Histamine is released from cells called mast cells, but the 
stimulus that activates this release of histamine from mast cells is still debated. The 
purpose of this study is to determine if heat is a possible stimulus for the release of 
histamine from mast cells during exercise. This protocol will explore the changes in 
temperature of both muscle and skin with dynamic knee extension exercise. This topic is 
both clinically and scientifically important. As such, this study is currently funded by the 
National Institutes of Health. You have been asked to participate in this study because 
you are a young healthy individual, who is either sedentary or recreationally active and 
free from any known cardiovascular disease. 
What will happen in the study? 
Prescreen 
1. You will arrive at Dr. Halliwill’s laboratory in Esslinger Hall at the University of 
Oregon for an initial visit. This visit will take approximately one hour. You will meet 
with one of the investigators of the study to discuss the project, to see the laboratory, 
and to read this form. You will be asked questions about your health history that will 
help the investigators to determine if you fit the inclusion criteria for the study. 
Exercise Test Visit 
1. You will return to Dr. Halliwill’s lab for an exercise test visit. You will need to wear 
a t-shirt, shorts, and refrain from eating at least two hours prior to arrival. This visit 
will take approximately one hour. When you arrive in the lab your height, weight and 
resting blood pressure will be measured. You will be given a physical activity 
questionnaire, which will allow investigators to determine your activity level. The 
questionnaire will take approximately 15 minutes to complete. You will also be asked 
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to fill out a Medical History Form to be used in case of an emergency. This document 
will be shredded after you complete the study. 
2. If you are a woman who can still become pregnant, you will be asked to undergo a 
pregnancy test during the exercise test visit (and again during the study visit). For this 
test, you will be asked to collect a sample of urine in the women’s restroom near the 
physiology lab. If the test is “positive,” indicating that you are pregnant, you will not 
be allowed to participate and will be advised to see your physician or the University 
of Oregon Health Center. 
3. A small needle will be used to obtain a blood sample from a vein near your elbow, as 
they would for a routine blood test at the doctor’s office. The blood samples will be 
used for DNA analysis to determine which versions of specific genes you have 
related to the processing of histamine. The samples will either be analyzed by 
ourselves or by a commercial lab that will only receive coded samples with no other 
identifying information. 
4. During the exercise test visit, your heart rate will be monitored by electrocardiogram 
electrodes placed on your skin. If you are a woman, the adhesive patches used for this 
test will be placed on you by one of the women in the lab. The electrical activity of 
the muscle in your legs will also be monitored by electromyogram electrodes on the 
skin of the back of your leg. Your blood pressure will be measured at periodic 
intervals by the inflation of a blood pressure cuff around your arm. The pH and tissue 
oxygenation of your working leg will be measured by a noninvasive near-infrared 
spectroscopy (NIRS) probe placed on the surface of your skin. 
5. You will perform one-legged knee extension exercise while seated on an exercise 
machine that measures how hard you are working. This exercise is like kicking a 
soccer ball over and over again. After a 5-minute warm-up, you will be asked to 
maintain a selected kicking rate as the machine increases how hard you work every 
minute until you reach your peak exercise capacity. It normally takes 10 to 15 
minutes for people to reach their peak effort. There is no win/lose threshold or 
specific value that participants need to achieve; participants simply need to do their 
best. While you exercise you will be wearing a mouth piece and nose clip. The total 
time for either test (including placement of electrodes on your skin, warm-up, 
exercise, and cool-down) is approximately thirty minutes. 
6. You should notify the investigator immediately if you feel any significant discomfort 
or concern about your well-being at any time during the initial visit. Some examples 
of discomfort include fatigue and muscle soreness. 
7. This session will serve to familiarize you with the procedures to be used on the study 
day. It will also establish your peak exercise capacity on the exercise machine and 
therefore will be used to establish the appropriate workload for the exercise session 
on the study day. 
Study Visit 
1. You will then return to Dr. Halliwill’s laboratory to participate in the study visit, 
which will be between 7 and 10 days after the exercise test visit. This testing session 
will take approximately 3 hours. 
2. You will need to wear a t-shirt, shorts, and refrain from eating at least two hours prior 
to arrival. In addition, you will need to refrain from consuming caffeine (for example, 
coffee, tea, red bull, coke, etc.) or medications (except oral contraceptives) for 24 
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hours prior to the study and abstain from alcohol or exercise for 24 hours prior to the 
study. If you use oral contraceptives, you should take this when you normally do so. 
3. If you are a woman who can still become pregnant, you will be asked to undergo a 
pregnancy test during the study visits. 
4. During the study visit, your heart rate will be monitored by electrocardiogram 
electrodes placed on your skin. If you are a woman, the adhesive patches used for this 
test will be placed on you by one of the women in the lab. Your blood pressure will 
be measured at periodic intervals by the inflation of a blood pressure cuff around your 
arm. The electrical activity of the muscle in your legs will also be monitored by 
electromyogram electrodes on the skin of the back and front of your leg. 
5. During the study visit, you will perform one-legged knee extension exercise while 
seated on an exercise machine that measures how hard you are working. During this 
exercise session you will be asked to maintain a selected kicking rate for 60 minutes. 
The pH and tissue oxygenation of your working leg will be measured by a 
noninvasive near-infrared spectroscopy (NIRS) probe placed on the surface of your 
skin. 
6. Before and after the exercise session, a small probe (ultrasound Doppler probe) will 
be held over an area of skin on your groin-hip intersection to image your femoral 
artery. The ultrasound Doppler probe uses ultrasound waves to measure blood flow in 
these arteries. The femoral artery will be studied for 10 minutes before you exercise 
and for two hours after you exercise. 
7. You will undergo the following procedure. You will have a small probe (this is called 
a “thermocouple”) placed into the vastus lateralis (outer thigh). First, the area of skin 
where the probe will enter will be numbed with a local anesthetic (prilocaine and 
lidocaine/epinephrine). Then a small needle will be placed through the skin and into 
the muscle. The small probe will be passed through the needle, and then the needle 
will be withdrawn, leaving the small probe in your muscle (about 1-2 inches). The 
probe will remain in place throughout the rest of the study. There may be some 
discomfort during the insertion of the small probes into your muscle. We will use a 
local anesthetic to numb skin where the probes will be inserted to minimize this 
discomfort, but you may feel pressure or a dull ache in the muscle as the needle 
moves through the muscle. The purpose of the thermocouple is to measure the 
temperature within the muscle. The probe will be placed in your muscle for the 
duration of the study (3 hours). 
8. You should notify the investigator immediately if you feel any significant discomfort 
or concern about your well-being at any time during the study visit. 
How long will I be in the study? 
You will be in the study for 3 days (initial visit, exercise test day, and one study visit). 
The first visit will last one hour. The exercise test visit will last one hour. The study day 
will last three hours. You will need to refrain from eating for 2 hours prior to the exercise 
test day and the study day. 
What are the risks of the study? 
There is some minor discomfort associated with the initial exercise test and exercise 
sessions, including temporary fatigue and muscle soreness. These sensations resolve 
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within minutes after the test is completed. There is the possibility of some residual 
muscle soreness in the few days following the initial exercise test and each exercise 
session. 
Thermocouples: There may be some discomfort during the insertion of the small probe 
into your muscle. We will use a local anesthetic to numb skin where the probes will be 
inserted to minimize this discomfort, but you may feel pressure or a dull ache in the 
muscle as the needle moves through the muscle. At the end of the study, the probe will be 
withdrawn and a sterile dressing will be applied. Any swelling or redness after the study 
should be gone a few hours after completion of the study, but you may feel some muscle 
soreness for several days. You will be given some ibuprofen (e.g. Advil or Motrin) to 
relieve some of the initial soreness. Although the small probes are sterile, there is a slight 
risk of infection at the sites where the probes were placed. You will be instructed on how 
to keep the area clean for a day or two following the study and will need to inform the 
researchers immediately if you have any redness or swelling in the area. The researchers 
will also ask you to return to the lab the day after the study visit so they can see how the 
site is healing. 
Blood sampling for genotyping: In total, 10 ml of blood will be withdrawn, which is less 
than a tablespoon. The blood sample will be used for genetic analysis to determine which 
versions of specific genes you have related to the processing of histamine. The blood 
sample will be labeled with a “subject identification number” or ID number, without any 
personally identifying information. The names associated with each ID number will be 
kept in a locked file cabinet in Dr. Halliwill’s office area. The list of names will be 
destroyed when study results are published or 24 months after your participation, 
whichever comes first. You have the right to withdraw your blood sample from research 
in the future should you decide to do so, but once the list of names has been destroyed, it 
will be impossible for the researchers to know which blood sample is yours. Blood 
samples will be kept for up to five years. After five years, the samples will be destroyed 
by discarding them into a biohazard waste container to be collected and destroyed by the 
Environmental Hazard and Safety department at the University of Oregon. Any excess 
samples will be discarded and destroyed in the same manner. Blood samples without any 
personally identifying information may be sent to a third-party lab for genetic analysis. 
Once the third-party lab has performed the analysis, they will destroy any remaining 
blood sample. The genetic data from this analysis, without any personally identifying 
information, may be stored by the researchers indefinitely. There may exist potential risks 
of insurability, employability, and social discrimination if the results of individual genetic 
data were to be made known to others. To safeguard against this risk, your genetic data 
will be stored by an ID number only and your name or other personally identifiable 
information. The genetic data, without any personally identifiable information, may be 
used in other research and by other parties studying the human genetics of histamine in 
collaboration with this study. Any data that may be published in scientific journals will 
not reveal the identity of the participants. Since the implications of our research are 
unknown, you will not be told the results, even if there might be some potential benefit to 
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you. We will not reveal any genetic data to your physicians, or any other health care 
provider. A new Federal law, called the Genetic Information Nondiscrimination Act 
(GINA), generally makes it illegal for health insurance companies, group health plans, 
and most employers to discriminate against you based on your genetic information. Be 
aware that this new Federal law does not protect you against genetic discrimination by 
companies that sell life insurance, disability insurance, or long-term care insurance. 
GINA also does not protect you against discrimination if you have already been 
diagnosed with the genetic disease being tested. Although we have made every effort to 
protect your identity, there is a small risk of loss of confidentiality. If the results of these 
studies of your genetic makeup were to be accidentally released, it might be possible that 
the information we will gather about you as part of this study could become available to 
an insurer or an employer, or a relative, or someone else outside the study. Even though 
there are discrimination protections in both Oregon law and Federal law, there is still a 
small chance that you could be harmed if a release occurred. If you decided not to 
participate in the DNA sampling aspects of this research protocol, it will not compromise 
your ability to participate in the other aspects of the research. 
Prilocaine and Lidocaine/Epinephrine (brand name Citanest and Lignospan): The risks 
associated with prilocaine and lidocaine/epinephrine are similar in character to those 
observed with other local anesthetics. Some of the more common adverse reactions 
include nervousness, dizziness, blurred vision, tremor, drowsiness, tinnitus, numbness, 
disorientation, hypotension, nausea and vomiting. 
Tracking of Taxable Income: Please note, compensation from participation in Human 
Subjects Research studies is taxable income. If your compensation totals $600 or more in 
a calendar year, the University is required to report the income to the IRS. The University 
requires its departments to track participant compensation and may contact you to 
complete a Form W-9 for tax reporting purposes. Because of the federal and University 
tracking requirements, your name will be associated with participation in research. 
Department and University administrators will have access to this information, but will 
not have access to research data. 
The study may include risks that are unknown at this time. 
Are there benefits to taking part in this study? 
This study will not make your health better. Electrocardiogram and other measurements 
are not being conducted for diagnostic purposes. You will be provided with the results 
from your blood test for glucose and cholesterol, as well as your body composition 
information. The results will not be reviewed by a physician. However, if results fall 
outside of the normal range, you will be informed that you should consult your primary 
care physician for additional medical evaluation. The purpose of this study is to provide 
more information on what causes blood flow increases to occur after exercise. This 
protocol will explore whether older adults exhibit the same blood flow responses after 
exercise that young adults do. Our hope is that by better understanding the physiology of 
how the human body responds to exercise, we will be better able to use exercise in the 
prevention and treatment of diseases such as hypertension (high blood pressure) and other 
130  
forms of cardiovascular disease. 
What other choices do I have if I don’t take part in this study? 
This study is only being done to gather information. You may choose not to take part in 
this study. 
What are the costs of tests and procedures? 
You will not pay for any tests or procedures that are done just for this research study. 
You will get $75 for participating in this study. This money is for the inconvenience and 
time you spent in this study. If you start the study but stop before the study has ended, the 
amount of money you receive will be pro-rated at a rate of $15 per hour that you 
complete. 
Who can answer my questions? 
You may talk to Dr. John Halliwill at any time about any question you have on this study. 
You may contact Dr. Halliwill by calling the Department of Human Physiology at (541) 
600-4337. 
What are my rights if I take part in this study? 
Taking part in this research study is your decision. You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to participate 
will not affect your relationship with the University of Oregon. 
You do not waive any liability rights for personal injury by signing this form. Biomedical 
research involves some risk of injury. In spite of all precautions, you might develop 
medical complications from participating in this study. 
The investigators may stop you from taking part in this study at any time if it is in your 
best interest, if you do not follow the study rules, or if the study is stopped. For example, 
if the investigators determine the study is overly stressful for you (as indicated by body 
language and an elevated heart rate and/or blood pressure) they may stop you from 
participating in the study. Or if you express pain or discomfort beyond what is normally 
expected, the investigators stop you from participating in the study. 
If you are physically injured because of the project, you and your insurance company will 
have to pay your doctor bills. If you are a UO student or employee and are covered by a 
UO medical plan, that plan might have terms that apply to your injury. 
If you experience harm because of the project, you can ask the State of Oregon to pay 
you. If you have been harmed, there are two University representatives you need to 
contact. Here are their addresses and phone numbers: 
General Counsel Research Compliance Services 
Office of the President 5237 University of Oregon 
1226 University of Oregon Eugene, OR 97403-5237 
Eugene, OR 97403-1226 (541) 346-2510 
(541) 346-3082 
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(Date) (Initial of Participant) 
Your initial indicates that you have read and understand the information provided above 
about the genetic testing, that you willingly agree to participate, that you may withdraw 
your consent at any time and discontinue participation without penalty. 
If you would choose to abstain from the genetic testing portion of this study, please initial 
below. There will be no penalty if you choose to abstain, and you will still be able to 
participate in all other aspects of the study. 
A law called the Oregon Tort Claims Act may limit the amount of money you can receive 
from the State of Oregon if you are harmed. 
What about confidentiality? 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. 
Subject identities will be kept confidential by assigning you a “subject identification 
number”. The names associated with each subject identification number will be kept in a 
locked file cabinet in Dr. Halliwill’s office area. 
Research Compliance Services and/or authorized representatives of the Food and Drug 
Administration (FDA) or National Institute of Health (NIH) may need to review records 
of individual subjects. As a result, they may see your name, but they are bound by rules 
of confidentiality not to reveal your identity to others. 
The list of names will be destroyed when study results are published or 24 months after 
your participation, whichever comes first. All blood and muscle dialysate fluid samples 
will be destroyed when study results are published or 5 years after your participation, 
whichever comes first. Other information may be stored by the researchers indefinitely. 
You will be asked to complete a Medical History Form on the study day which will list 
personal identifying information so that in the unlikely event of a medical emergency in 
which we would activate the emergency medical system, we would be able to provide 
this information to emergency healthcare providers. This document would be retained in 
a locked file cabinet in Dr. Halliwill’s lab for up to a week after the study day, after 
which it is placed in a locked confidential documents disposal bin which is emptied by a 
secure shredding service. 
I have had an opportunity to have my questions answered. I have been given a copy 
of this form. I agree to take part in this study. 
If you have questions regarding your rights as a research subject, contact Research 
Compliance Services, 5219 University of Oregon, Eugene, OR 97403, 541/346-2510. 
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(Datee (Signature of Individual Obtaining Consent) 
(Date) (Signature of Participant) 
Your signature indicates that you have read and understand the information provided 
above, that you willingly agree to participate, that you may withdraw your consent at any 
time and discontinue participation without penalty, that you will receive a copy of this 
form, and that you are not waiving any legal claims, rights or remedies. 
 
 
 
Informed Consent Form 
TITLE: Exercise, histamine receptors, and vascular function (Experiment: Heating 
Muscle) 
INVESTIGATOR: Dr. J. R. Halliwill and Colleagues 
This is an important form. Please read it carefully. It tells you what you need to know 
about this study. If you agree to take part in this research study, you need to sign the 
form. Your signature means that you have been told about the study and what the risks 
are. Your signature on this form also means that you want to take part in this study. 
Why is this research study being done? 
When humans exercise, there is an increase in blood flow to the skeletal muscle. This 
increase in blood flow lasts for several hours after exercise as a result of vasodilation in 
the blood vessels. Previous studies have shown that this vasodilation is largely the result 
of a release of histamine. Histamine is released from mast cells, but the stimulus that 
activates this release of histamine from mast cells is still debated. The purpose of this 
study is to determine if heat is a possible stimulus for the release of histamine from mast 
cells during exercise. This protocol will explore the changes in temperature of both 
muscle and skin with external heating of the leg to simulate what happens during 
exercise. This topic is both clinically and scientifically important. As such, this study is 
currently funded by the National Institutes of Health. You have been asked to participate 
in this study because you are a young healthy individual, who is either sedentary or 
recreationally active and free from any known cardiovascular disease. 
What will happen in the study? 
Prescreen 
1. You will arrive at Dr. Halliwill’s laboratory in Esslinger Hall at the University of 
Oregon for an initial visit. This initial visit will take approximately one hour. You 
will meet with one of the investigators of the study to discuss the project, to see the 
(Initial of Participant) (Date) 
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laboratory, and to read this form. You will be asked questions about your health 
history that will help the investigators to determine if you fit the inclusion criteria for 
the study. 
Study Visit 
1. You will return to Dr. Halliwill’s lab for a study visit. This visit will take 
approximately four hours. You will need to wear a t-shirt, shorts, and refrain from 
eating at least two hours prior to arrival. In addition, you will need to refrain from 
consuming caffeine (for example, coffee, tea, red bull, coke, etc.) or medications 
(except oral contraceptives) for 24 hours prior to the study and abstain from alcohol 
or exercise for 24 hours prior to the study. If you use oral contraceptives, you should 
take this when you normally do so. 
2. When you arrive in the lab your height, weight and resting blood pressure will be 
measured. You will be given a physical activity questionnaire, which will allow 
investigators to determine your activity level. The questionnaire will take 
approximately 15 minutes to complete. You will also be asked to fill out a Medical 
History Form to be used in case of an emergency. This document will be shredded 
after you complete the study. 
3. If you are a woman who can still become pregnant, you will be asked to undergo a 
pregnancy test during the study visit. For this test, you will be asked to collect a 
sample of urine in the women’s restroom near the physiology lab. If the test is 
“positive,” indicating that you are pregnant, you will not be allowed to participate and 
will be advised to see your physician or the University of Oregon Health Center. 
4. A small needle will be used to obtain a blood sample from a vein near your elbow, as 
they would for a routine blood test at the doctor’s office. The blood samples will be 
used for DNA analysis to determine which versions of specific genes you have 
related to the processing of histamine. The samples will either be analyzed by 
ourselves or by a commercial lab that will only receive coded samples with no other 
identifying information. 
5. Your heart rate will be monitored by electrocardiogram electrodes placed on your 
skin. If you are a woman, the adhesive patches used for this test will be placed on you 
by one of the women in the lab. The electrical activity of the muscle in your legs will 
also be monitored by electromyogram electrodes on the skin of the back of your leg. 
Your blood pressure will be measured at periodic intervals by the inflation of a blood 
pressure cuff around your arm. 
6. A small probe (ultrasound Doppler probe) will be held over an area of skin on your 
groin-hip intersection to image your femoral artery. The ultrasound Doppler probe 
uses ultrasound waves to measure blood flow in these arteries. This will occur 
periodically throughout the study. 
7. You will undergo the following procedure. You will have a small probe (this is called 
a “thermocouple”) placed into the vastus lateralis (outer thigh). First, the area of skin 
where the probe will enter will be numbed with a local anesthetic (prilocaine and 
lidocaine/epinephrine). Then a small needle will be placed through the skin and into 
the muscle. The small probe will be passed through the needle, and then the needle 
will be withdrawn, leaving the small probe in your muscle (about 1-2 inches). The 
probe will remain in place throughout the rest of the study. There may be some 
discomfort during the insertion of the small probes into your muscle. We will use a 
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local anesthetic to numb skin where the probes will be inserted to minimize this 
discomfort, but you may feel pressure or a dull ache in the muscle as the needle 
moves through the muscle. The purpose of the thermocouple is to measure the 
temperature within the muscle. The probe will be placed in your muscle for the 
duration of the study (four hours). 
8. For this particular study, we are looking at three different types of heating modalities: 
infrared heating, ultrasound and pulsed short-wave diathermy. For the infrared 
heating, you will have a heating lamp placed close to the skin of your thigh (there will 
be no direct contact between the lamp and the surface of the skin). The purpose of 
this is to increase the temperature of your muscle to around 100ºF. As skin 
temperatures above 111ºF can feel painful to some, we will keep your skin 
temperature below 108ºF. For comparison, the temperature of water in hot tubs is 
routinely 102-104ºF. We will heat your thigh for one hour. For the ultrasound heating 
procedure, an ultrasound probe will be placed directly on the skin of your thigh. For 
the short-wave pulse diathermy, the heating coil will be placed close to the skin of 
your thigh, however it will not make contact with the surface of your skin. During 
this time of heating, you may feel an itching sensation as time progresses, but this is a 
normal response. If you experience any pain or burning, please inform the 
investigator immediately. 
9. You should notify the investigator immediately if you feel any significant discomfort 
or concern about your well-being at any time during the study visit. 
How long will I be in the study? 
You will be in the study for 2 days (initial visit and one study visit). The first visit will 
last one hour. The study day will last 4 hours. You will need to refrain from eating for 2 
hours prior to the study visit. 
What are the risks of the study? 
Heating: Heating of the skin of your thigh can become painful and there is a risk of burns 
or lesions to the skin. Discomfort does not generally occur below 111ºF, and damage 
does not generally occur below 113ºF. We will keep your temperature below these levels, 
but if you experience any pain or burning, please inform the investigator immediately. 
For this study, the goal is to get your muscle to around 100ºF. We will be using different 
modalities, all of which have been safely used for decades by physical therapists and 
physicians. We will be using ultrasound heat therapy, which involves using sound waves 
to heat up your muscle. We also plan to use pulsed short-wave diathermy, which uses 
electromagnetic waves, delivered in a pulsatile manner in order to raise the temperature 
in your muscle. These methodologies have been extensively researched and have data in 
peer-reviewed articles supporting both their safety and efficacy. 
Thermocouple: There may be some discomfort during the insertion of the small 
thermocouple probe into your muscle. We will use a local anesthetic to numb skin where 
the probes will be inserted to minimize this discomfort, but you may feel pressure or a 
dull ache in the muscle as the needle moves through the muscle. At the end of the study, 
the probe will be withdrawn and a sterile dressing will be applied. Any swelling or 
redness after the study should be gone a few hours after completion of the study, but you 
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may feel some muscle soreness for several days. You will be given some ibuprofen (e.g. 
Advil or Motrin) to relieve some of the initial soreness. Although the small probes are 
sterile, there is a slight risk of infection at the sites where the probes were placed. You 
will be instructed on how to keep the area clean for a day or two following the study and 
will need to inform the researchers immediately if you have any redness or swelling in 
the area. The researchers will also ask you to return to the lab the day after the study visit 
so they can see how the sites are healing. 
Blood sampling for genotyping: In total, 10 ml of blood will be withdrawn, which is less 
than a tablespoon. The blood sample will be used for genetic analysis to determine which 
versions of specific genes you have related to the processing of histamine. The blood 
sample will be labeled with a “subject identification number” or ID number, without any 
personally identifying information. The names associated with each ID number will be 
kept in a locked file cabinet in Dr. Halliwill’s office area. The list of names will be 
destroyed when study results are published or 24 months after your participation, 
whichever comes first. You have the right to withdraw your blood sample from research 
in the future should you decide to do so, but once the list of names has been destroyed, it 
will be impossible for the researchers to know which blood sample is yours. Blood 
samples will be kept for up to five years. After five years, the samples will be destroyed 
by discarding them into a biohazard waste container to be collected and destroyed by the 
Environmental Hazard and Safety department at the University of Oregon. Any excess 
samples will be discarded and destroyed in the same manner. Blood samples without any 
personally identifying information may be sent to a third-party lab for genetic analysis. 
Once the third-party lab has performed the analysis, they will destroy any remaining 
blood sample. The genetic data from this analysis, without any personally identifying 
information, may be stored by the researchers indefinitely. There may exist potential risks 
of insurability, employability, and social discrimination if the results of individual genetic 
data were to be made known to others. To safeguard against this risk, your genetic data 
will be stored by an ID number only and your name or other personally identifiable 
information. The genetic data, without any personally identifiable information, may be 
used in other research and by other parties studying the human genetics of histamine in 
collaboration with this study. Any data that may be published in scientific journals will 
not reveal the identity of the participants. Since the implications of our research are 
unknown, you will not be told the results, even if there might be some potential benefit to 
you. We will not reveal any genetic data to your physicians, or any other health care 
provider. A new Federal law, called the Genetic Information Nondiscrimination Act 
(GINA), generally makes it illegal for health insurance companies, group health plans, 
and most employers to discriminate against you based on your genetic information. Be 
aware that this new Federal law does not protect you against genetic discrimination by 
companies that sell life insurance, disability insurance, or long-term care insurance. 
GINA also does not protect you against discrimination if you have already been 
diagnosed with the genetic disease being tested. Although we have made every effort to 
protect your identity, there is a small risk of loss of confidentiality. If the results of these 
studies of your genetic makeup were to be accidentally released, it might be possible that 
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the information we will gather about you as part of this study could become available to 
an insurer or an employer, or a relative, or someone else outside the study. Even though 
there are discrimination protections in both Oregon law and Federal law, there is still a 
small chance that you could be harmed if a release occurred. If you decided not to 
participate in the DNA sampling aspects of this research protocol, it will not compromise 
your ability to participate in the other aspects of the research. 
Prilocaine and Lidocaine/Epinephrine (brand name Citanest and Lignospan): The risks 
associated with prilocaine and lidocaine/epinephrine are similar in character to those 
observed with other local anesthetics. Some of the more common adverse reactions 
include nervousness, dizziness, blurred vision, tremor, drowsiness, tinnitus, numbness, 
disorientation, hypotension, nausea and vomiting. 
Tracking of Taxable Income: Please note, compensation from participation in Human 
Subjects Research studies is taxable income. If your compensation totals $600 or more in 
a calendar year, the University is required to report the income to the IRS. The University 
requires its departments to track participant compensation and may contact you to 
complete a Form W-9 for tax reporting purposes. Because of the federal and University 
tracking requirements, your name will be associated with participation in research. 
Department and University administrators will have access to this information, but will 
not have access to research data. 
The study may include risks that are unknown at this time. 
Are there benefits to taking part in this study? 
This study will not make your health better. Electrocardiogram and other measurements 
are not being conducted for diagnostic purposes. You will be provided with the results 
from your blood test for glucose and cholesterol, as well as your body composition 
information. The results will not be reviewed by a physician. However, if results fall 
outside of the normal range, you will be informed that you should consult your primary 
care physician for additional medical evaluation. The purpose of this study is to provide 
more information on what causes blood flow increases to occur after exercise. This 
protocol will explore whether older adults exhibit the same blood flow responses after 
exercise that young adults do. Our hope is that by better understanding the physiology of 
how the human body responds to exercise, we will be better able to use exercise in the 
prevention and treatment of diseases such as hypertension (high blood pressure) and other 
forms of cardiovascular disease. 
What other choices do I have if I don’t take part in this study? 
This study is only being done to gather information. You may choose not to take part in 
this study. 
What are the costs of tests and procedures? 
You will not pay for any tests or procedures that are done just for this research study. 
You will get $75 for participating in this study. This money is for the inconvenience and 
time you spent in this study. If you start the study but stop before the study has ended, the 
amount of money you receive will be pro-rated at a rate of $15 per hour that you 
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complete. 
Who can answer my questions? 
You may talk to Dr. John Halliwill at any time about any question you have on this study. 
You may contact Dr. Halliwill by calling the Department of Human Physiology at (541) 
600-4337. 
What are my rights if I take part in this study? 
Taking part in this research study is your decision. You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to participate 
will not affect your relationship with the University of Oregon. 
You do not waive any liability rights for personal injury by signing this form. Biomedical 
research involves some risk of injury. In spite of all precautions, you might develop 
medical complications from participating in this study. 
The investigators may stop you from taking part in this study at any time if it is in your 
best interest, if you do not follow the study rules, or if the study is stopped. For example, 
if the investigators determine the study is overly stressful for you (as indicated by body 
language and an elevated heart rate and/or blood pressure) they may stop you from 
participating in the study. Or if you express pain or discomfort beyond what is normally 
expected, the investigators stop you from participating in the study. 
If you are physically injured because of the project, you and your insurance company will 
have to pay your doctor bills. If you are a UO student or employee and are covered by a 
UO medical plan, that plan might have terms that apply to your injury. 
If you experience harm because of the project, you can ask the State of Oregon to pay 
you. If you have been harmed, there are two University representatives you need to 
contact. Here are their addresses and phone numbers: 
General Counsel Research Compliance Services 
Office of the President 5237 University of Oregon 
1226 University of Oregon Eugene, OR 97403-5237 
Eugene, OR 97403-1226 (541) 346-2510 
(541) 346-3082 
A law called the Oregon Tort Claims Act may limit the amount of money you can receive 
from the State of Oregon if you are harmed. 
What about confidentiality? 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. 
Subject identities will be kept confidential by assigning you a “subject identification 
number”. The names associated with each subject identification number will be kept in a 
locked file cabinet in Dr. Halliwill’s office area. 
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(Date) (Initial of Participant) 
Your initial indicates that you have read and understand the information provided above 
about the genetic testing, that you willingly agree to participate, that you may withdraw 
your consent at any time and discontinue participation without penalty. 
(Date) (Initial of Participant) 
If you would choose to abstain from the genetic testing portion of this study, please initial 
below. There will be no penalty if you choose to abstain, and you will still be able to 
participate in all other aspects of the study. 
(Date (Signature of Individual Obtaining Consent) 
(Date) (Signature of Participant) 
Your signature indicates that you have read and understand the information provided 
above, that you willingly agree to participate, that you may withdraw your consent at any 
time and discontinue participation without penalty, that you will receive a copy of this 
form, and that you are not waiving any legal claims, rights or remedies. 
Research Compliance Services and/or authorized representatives of the Food and Drug 
Administration (FDA) or National Institute of Health (NIH) may need to review records 
of individual subjects. As a result, they may see your name, but they are bound by rules 
of confidentiality not to reveal your identity to others. 
The list of names will be destroyed when study results are published or 24 months after 
your participation, whichever comes first. All blood and muscle dialysate fluid samples 
will be destroyed when study results are published or 5 years after your participation, 
whichever comes first. Other information may be stored by the researchers indefinitely. 
You will be asked to complete a Medical History Form on the study day which will list 
personal identifying information so that in the unlikely event of a medical emergency in 
which we would activate the emergency medical system, we would be able to provide 
this information to emergency healthcare providers. This document would be retained in 
a locked file cabinet in Dr. Halliwill’s lab for up to a week after the study day, after 
which it is placed in a locked confidential documents disposal bin which is emptied by a 
secure shredding service. 
I have had an opportunity to have my questions answered. I have been given a copy 
of this form. I agree to take part in this study. 
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INFORMED CONSENT FORM 
TITLE: Exercise, histamine receptors, and vascular function (Experiment: Exercise and 
Microdialysis) 
INVESTIGATOR: Dr. J. R. Halliwill and Colleagues 
This is an important form. Please read it carefully. It tells you what you need to know 
about this study. If you agree to take part in this research study, you need to sign the 
form. Your signature means that you have been told about the study and what the risks 
are. Your signature on this form also means that you want to take part in this study. 
Why is this research study being done? 
When humans exercise, there is an increase in blood flow to the skeletal muscle. This 
increase in blood flow lasts for several hours after exercise as a result of vasodilation in 
the blood vessels. Previous studies have shown that this vasodilation is largely the result 
of a release of histamine. Histamine may also be an important signal for stimulating 
blood vessel growth (angiogenesis) in skeletal muscle as a consequence of exercise 
training. The purpose of this study is to determine if exercise-related histamine release 
stimulates the growth of new blood vessels. This protocol will use fluid collected from 
your skeletal muscle before, during, and after exercise to determine the effect of 
histamine on angiogenic properties. This topic is both clinically and scientifically 
important. As such, this study is currently funded by the National Institutes of Health. 
You have been asked to participate in this study because you are a young healthy 
individual, who is either sedentary or recreationally active and free from any known 
cardiovascular disease. 
What will happen in the study? 
Prescreen 
1. You will arrive at Dr. Halliwill’s laboratory in Esslinger Hall at the University of 
Oregon for an initial visit. This initial visit will take approximately one hour. You 
will meet with one of the investigators of the study to discuss the project, to see the 
laboratory, and to read this form. You will be asked questions about your health 
history that will help the investigators to determine if you fit the inclusion criteria for 
the study. 
Exercise Test Visit 
2. You will return to Dr. Halliwill’s lab for an exercise test visit. You will need to wear 
a t-shirt, shorts, and refrain from eating at least two hours prior to arrival. This visit 
will take approximately one hour. When you arrive in the lab your height, weight and 
resting blood pressure will be measured. You will be given a physical activity 
questionnaire, which will allow investigators to determine your activity level. The 
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questionnaire will take approximately 15 minutes to complete. You will also be asked 
to fill out a Medical History Form to be used in case of an emergency. This document 
will be shredded after you complete the study. 
3. If you are a woman who can still become pregnant, you will be asked to undergo a 
pregnancy test during the exercise test visit (and again during the study visit). For this 
test, you will be asked to collect a sample of urine in the women’s restroom near the 
physiology lab. If the test is “positive,” indicating that you are pregnant, you will not 
be allowed to participate and will be advised to see your physician or the University 
of Oregon Health Center. 
4. A small needle will be used to obtain a blood sample from a vein near your elbow, as 
they would for a routine blood test at the doctor’s office. The blood samples will be 
used for DNA analysis to determine which versions of specific genes you have 
related to the processing of histamine. The samples will either be analyzed by 
ourselves or by a commercial lab that will only receive coded samples with no other 
identifying information. 
5. During the exercise test visit, your heart rate will be monitored by electrocardiogram 
electrodes placed on your skin. If you are a woman, the adhesive patches used for this 
test will be placed on you by one of the women in the lab. The electrical activity of 
the muscle in your legs will also be monitored by electromyogram electrodes on the 
skin of the back of your leg. Your blood pressure will be measured at periodic 
intervals by the inflation of a blood pressure cuff around your arm. 
6. You will perform one-legged knee extension exercise while seated on an exercise 
machine that measures how hard you are working. This exercise is like kicking a 
soccer ball over and over again. After a 5-minute warm-up, you will be asked to 
maintain a selected kicking rate as the machine increases how hard you work every 
minute until you reach your peak exercise capacity. It normally takes 10 to 15 
minutes for people to reach their peak effort. There is no win/lose threshold or 
specific value that participants need to achieve; participants simply need to do their 
best. While you exercise you will be wearing a mouth piece and nose clip. The total 
time for either test (including placement of electrodes on your skin, warm-up, 
exercise, and cool-down) is approximately thirty minutes. 
7. You should notify the investigator immediately if you feel any significant discomfort 
or concern about your well-being at any time during the initial visit. Some examples 
of discomfort include fatigue and muscle soreness. 
This session will serve to familiarize you with the procedures to be used on the study 
day. It will also establish your peak exercise capacity on the exercise machine and 
therefore will be used to establish the appropriate workload for the exercise session 
on the study day. 
Study Visit 
1. You will return to Dr. Halliwill’s lab for a study visit. This visit will take 
approximately six hours. You will need to wear a t-shirt, shorts, and refrain from 
eating at least two hours prior to arrival. In addition, you will need to refrain from 
consuming caffeine (for example, coffee, tea, Red Bull, coke, etc.) or medications 
(except oral contraceptives) for 24 hours prior to the study and abstain from alcohol 
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or exercise for 24 hours prior to the study. If you use oral contraceptives, you should 
take this when you normally do so. 
2. If you are a woman who can still become pregnant, you will be asked to undergo a 
pregnancy test during the study visit. For this test, you will be asked to collect a 
sample of urine in the women’s restroom near the physiology lab. If the test is 
“positive,” indicating that you are pregnant, you will not be allowed to participate and 
will be advised to see your physician or the University of Oregon Health Center. 
3. A small needle will be used to obtain a blood sample from a vein near your elbow, as 
they would for a routine blood test at the doctor’s office. The blood samples will be 
used to determine circulating levels of angiogenic factors. The samples will either be 
analyzed by ourselves or by a commercial lab that will only receive coded samples 
with no other identifying information. 
 
4. Your heart rate will be monitored by electrocardiogram electrodes placed on your 
skin. If you are a woman, the adhesive patches used for this test will be placed on you 
by one of the women in the lab. The electrical activity of the muscle in your legs will 
also be monitored by electromyogram electrodes on the skin of the back of your leg. 
Your blood pressure will be measured at periodic intervals by the inflation of a blood 
pressure cuff around your arm. 
5. During the study visit, you will perform one-legged knee extension exercise while 
seated on an exercise machine that measures how hard you are working. During this 
exercise session you will be asked to maintain a selected kicking rate for 60 minutes. 
The pH and tissue oxygenation of your working leg will be measured by a 
noninvasive near-infrared spectroscopy (NIRS) probe placed on the surface of your 
skin. 
6. You will undergo the following procedure. You will have two small probes (called 
“microdialysis fibers”) placed into the vastus lateralis (outer thigh). First, the area of 
skin where each probe will enter will be numbed with a local anesthetic (prilocaine 
and lidocaine/epinephrine). Then a small needle will be placed through the skin and 
into the muscle. The small probe will be passed through the needle, and then the 
needle will be withdrawn, leaving the small probe in your muscle (about 1-2 inches). 
This will be done for each of the two probes. The probes will remain in place 
throughout the rest of the study. There may be some discomfort during the insertion 
of the small probes into your muscle. We will use a local anesthetic to numb skin 
where the probes will be inserted to minimize this discomfort, but you may feel 
pressure or a dull ache in the muscle as the needle moves through the muscle. The 
thermocouple is used to measure the temperature within the muscle. All the probes 
will be in placed in your muscle for four hours. 
7. The microdialysis probes will be used to infuse saline into your muscle. This will 
allow us to collect a sample of the fluid surrounding the muscle before, during, and 
after you exercise. 
8. At the end of the study visit, the probes will be withdrawn from your leg and a sterile 
dressing will be applied. Any swelling or redness after the study should be gone a few 
hours after completion of the study, but you may feel some muscle soreness for 
several days. You will be given some ibuprofen (e.g. Advil or Motrin) to relieve some 
of the initial soreness. Although the small probes are sterile, there is a slight risk of 
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infection at the sites where the probes were placed. You will be instructed on how to 
keep the area clean for a day or two following the study and will need to inform the 
researchers immediately if you have any redness or swelling in the area. 
9. You should notify the investigator immediately if you feel any significant discomfort 
or concern about your well-being at any time during the study visit. 
How long will I be in the study? 
You will be in the study for 3 days (initial visit, one exercise test visit, and one study 
visit) for a total of 8 hours. The first visit will last one hour. The exercise test visit will 
also last one hour. The study day will last six hours. You will need to refrain from eating 
for 2 hours prior to the study visit. 
What are the risks of the study? 
Microdialysis probes: There may be some discomfort during the insertion of the small 
probes into your muscle. We will use a local anesthetic to numb skin where the probes 
will be inserted to minimize this discomfort, but you may feel pressure or a dull ache in 
the muscle as the needle moves through the muscle. At the end of the study, the probe 
will be withdrawn and a sterile dressing will be applied. Any swelling or redness after the 
study should be gone a few hours after completion of the study, but you may feel some 
muscle soreness for several days. You will be given some ibuprofen (e.g. Advil or 
Motrin) to relieve some of the initial soreness. Although the small probes are sterile, there 
is a slight risk of infection at the sites where the probes were placed. You will be 
instructed on how to keep the area clean for a day or two following the study and will 
need to inform the researchers immediately if you have any redness or swelling in the 
area. The researchers will also ask you to return to the lab the day after the study visit so 
they can see how the sites are healing. In addition, there is the risk that the microdialysis 
fibers will break while they are in the muscle and no longer function. It is possible for 
subjects to have an allergic reaction to the microdialysis fibers and/or the fluid being 
infused through the fibers. 
Blood sampling for genotyping: In total, 10 ml of blood will be withdrawn, which is less 
than a tablespoon. The blood sample will be used for genetic analysis to determine which 
versions of specific genes you have related to the processing of histamine. The blood 
sample will be labeled with a “subject identification number” or ID number, without any 
personally identifying information. The names associated with each ID number will be 
kept in a locked file cabinet in Dr. Halliwill’s office area. The list of names will be 
destroyed when study results are published or 24 months after your participation, 
whichever comes first. You have the right to withdraw your blood sample from research 
in the future should you decide to do so, but once the list of names has been destroyed, it 
will be impossible for the researchers to know which blood sample is yours. Blood 
samples will be kept for up to five years. After five years, the samples will be destroyed 
by discarding them into a biohazard waste container to be collected and destroyed by the 
Environmental Hazard and Safety department at the University of Oregon. Any excess 
samples will be discarded and destroyed in the same manner. Blood samples without any 
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personally identifying information may be sent to a third-party lab for genetic analysis. 
Once the third-party lab has performed the analysis, they will destroy any remaining 
blood sample. The genetic data from this analysis, without any personally identifying 
information, may be stored by the researchers indefinitely. There may exist potential risks 
of insurability, employability, and social discrimination if the results of individual genetic 
data were to be made known to others. To safeguard against this risk, your genetic data 
will be stored by an ID number only and your name or other personally identifiable 
information. The genetic data, without any personally identifiable information, may be 
used in other research and by other parties studying the human genetics of histamine in 
collaboration with this study. Any data that may be published in scientific journals will 
not reveal the identity of the participants. Since the implications of our research are 
unknown, you will not be told the results, even if there might be some potential benefit to 
you. We will not reveal any genetic data to your physicians, or any other health care 
provider. A new Federal law, called the Genetic Information Nondiscrimination Act 
(GINA), generally makes it illegal for health insurance companies, group health plans, 
and most employers to discriminate against you based on your genetic information. Be 
aware that this new Federal law does not protect you against genetic discrimination by 
companies that sell life insurance, disability insurance, or long-term care insurance. 
GINA also does not protect you against discrimination if you have already been 
diagnosed with the genetic disease being tested. Although we have made every effort to 
protect your identity, there is a small risk of loss of confidentiality. If the results of these 
studies of your genetic makeup were to be accidentally released, it might be possible that 
the information we will gather about you as part of this study could become available to 
an insurer or an employer, or a relative, or someone else outside the study. Even though 
there are discrimination protections in both Oregon law and Federal law, there is still a 
small chance that you could be harmed if a release occurred. If you decided not to 
participate in the DNA sampling aspects of this research protocol, it will not compromise 
your ability to participate in the other aspects of the research. 
Prilocaine and Lidocaine/Epinephrine (brand name Citanest and Lignospan): The risks 
associated with prilocaine and lidocaine/epinephrine are similar in character to those 
observed with other local anesthetics. Some of the more common adverse reactions 
include nervousness, dizziness, blurred vision, tremor, drowsiness, tinnitus, numbness, 
disorientation, hypotension, nausea and vomiting. 
Tracking of Taxable Income: Please note, compensation from participation in Human 
Subjects Research studies is taxable income. If your compensation totals $600 or more in 
a calendar year, the University is required to report the income to the IRS. The University 
requires its departments to track participant compensation and may contact you to 
complete a Form W-9 for tax reporting purposes. Because of the federal and University 
tracking requirements, your name will be associated with participation in research. 
Department and University administrators will have access to this information, but will 
not have access to research data. 
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The study may include risks that are unknown at this time. 
Are there benefits to taking part in this study? 
This study will not make your health better. Electrocardiogram and other measurements 
are not being conducted for diagnostic purposes. You will be provided with the results 
from your blood test for glucose and cholesterol, as well as your body composition 
information. The results will not be reviewed by a physician. However, if results fall 
outside of the normal range, you will be informed that you should consult your primary 
care physician for additional medical evaluation. The purpose of this study is to provide 
more information on what causes blood flow increases to occur after exercise. This 
protocol will explore whether older adults exhibit the same blood flow responses after 
exercise that young adults do. Our hope is that by better understanding the physiology of 
how the human body responds to exercise, we will be better able to use exercise in the 
prevention and treatment of diseases such as hypertension (high blood pressure) and other 
forms of cardiovascular disease. 
What other choices do I have if I don’t take part in this study? 
This study is only being done to gather information. You may choose not to take part in 
this study. 
What are the costs of tests and procedures? 
You will not pay for any tests or procedures that are done just for this research study. 
You will get $120 for participating in this study. This money is for the inconvenience and 
time you spent in this study. If you start the study but stop before the study has ended, the 
amount of money you receive will be pro-rated at a rate of $15 per hour that you 
complete. 
Who can answer my questions? 
You may talk to Dr. John Halliwill at any time about any question you have on this study. 
You may contact Dr. Halliwill by calling the Department of Human Physiology at (541) 
600-4337. 
What are my rights if I take part in this study? 
Taking part in this research study is your decision. You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to participate 
will not affect your relationship with the University of Oregon. 
You do not waive any liability rights for personal injury by signing this form. Biomedical 
research involves some risk of injury. In spite of all precautions, you might develop 
medical complications from participating in this study. 
The investigators may stop you from taking part in this study at any time if it is in your 
best interest, if you do not follow the study rules, or if the study is stopped. For example, 
if the investigators determine the study is overly stressful for you (as indicated by body 
language and an elevated heart rate and/or blood pressure) they may stop you from 
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participating in the study. Or if you express pain or discomfort beyond what is normally 
expected, the investigators stop you from participating in the study. 
If you are physically injured because of the project, you and your insurance company will 
have to pay your doctor bills. If you are a UO student or employee and are covered by a 
UO medical plan, that plan might have terms that apply to your injury. 
If you experience harm because of the project, you can ask the State of Oregon to pay 
you. If you have been harmed, there are two University representatives you need to 
contact. Here are their addresses and phone numbers: 
General Counsel Research Compliance Services 
Office of the President 5237 University of Oregon 
1226 University of Oregon Eugene, OR 97403-5237 
Eugene, OR 97403-1226 (541) 346-2510 
(541) 346-3082 
A law called the Oregon Tort Claims Act may limit the amount of money you can receive 
from the State of Oregon if you are harmed. 
What about confidentiality? 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. 
Subject identities will be kept confidential by assigning you a “subject identification 
number”. The names associated with each subject identification number will be kept in a 
locked file cabinet in Dr. Halliwill’s office area. 
Research Compliance Services and/or authorized representatives of the Food and Drug 
Administration (FDA) or National Institute of Health (NIH) may need to review records 
of individual subjects. As a result, they may see your name, but they are bound by rules 
of confidentiality not to reveal your identity to others. 
The list of names will be destroyed when study results are published or 24 months after 
your participation, whichever comes first. All blood and muscle dialysate fluid samples 
will be destroyed when study results are published or 5 years after your participation, 
whichever comes first. Other information may be stored by the researchers indefinitely. 
You will be asked to complete a Medical History Form on the study day which will list 
personal identifying information so that in the unlikely event of a medical emergency in 
which we would activate the emergency medical system, we would be able to provide 
this information to emergency healthcare providers. This document would be retained in 
a locked file cabinet in Dr. Halliwill’s lab for up to a week after the study day, after 
which it is placed in a locked confidential documents disposal bin which is emptied by a 
secure shredding service. 
I have had an opportunity to have my questions answered. I have been given a copy 
of this form. I agree to take part in this study. 
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(Date) (Initial of Participant) 
Your initial indicates that you have read and understand the information provided above 
about the genetic testing, that you willingly agree to participate, that you may withdraw 
your consent at any time and discontinue participation without penalty. 
(Date) (Initial of Participant) 
If you would choose to abstain from the genetic testing portion of this study, please initial 
below. There will be no penalty if you choose to abstain, and you will still be able to 
participate in all other aspects of the study. 
(Date) (Signature of Individual Obtaining Consent) 
(Date) (Signature of Participant) 
Your signature indicates that you have read and understand the information provided 
above, that you willingly agree to participate, that you may withdraw your consent at any 
time and discontinue participation without penalty, that you will receive a copy of this 
form, and that you are not waiving any legal claims, rights or remedies. 
If you have questions regarding your rights as a research subject, contact Research 
Compliance Services, 5219 University of Oregon, Eugene, OR 97403, 541/346-2510. 
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Chapter VI 
 
 
INFORMED CONSENT FORM 
 
 
TITLE: EXERCISE, INFLAMMATION, AND HISTAMINE (AEROBIC EXERCISE) 
INVESTIGATOR: Dr. J. R. Halliwill and Colleagues 
This is an important form. Please read it carefully. It tells you what you need to know 
about this study. If you agree to take part in this research study, you need to sign the 
form. Your signature means that you have been told about the study and what the risks 
are. Your signature on this form also means that you want to take part in this study. 
Why is this research study being done? When humans exercise, it generates pro- and 
anti-inflammatory signals. Histamine is released by exercising muscles and has the 
potential to either trigger or modulate the inflammatory response. The long-term goal of 
this research protocol is to better understand the link between exercise, histamine, and 
inflammatory signaling so that we can determine how and when to intervene in the 
inflammatory process, preserving the beneficial and avoiding the deleterious effects of 
inflammation in the context of exercise training and physical rehabilitation from injury. 
This topic is both clinically and scientific important. You have been asked to participate 
in this study because you are a healthy individual who does not participate in routine 
aerobic or endurance exercise. 
What will happen in the study? 
Initial Visit 
You will arrive at Dr. Halliwill’s laboratory in Esslinger Hall at the University of 
Oregon for an initial visit. This initial visit will take approximately half an hour. You 
will meet with one of the investigators of the study to discuss the project, to see the 
laboratory, and to read this form. Your height and weight and resting blood pressure 
will be measured, and you will be asked questions about your health history. You will 
be given a physical activity questionnaire, which will allow investigators to determine 
your activity level. 
Fitness Test Visit 
1. You will return to Dr. Halliwill’s laboratory for an exercise test to determine your 
fitness level. The total time for this visit is approximately one hour. You will need to 
wear a t-shirt, shorts, and refrain from eating at least two hours prior to arrival. In 
addition, you will need to refrain from consuming caffeine (for example, coffee, tea, 
red bull, coke, etc.) or medications (except oral contraceptives) for 12 hours prior to 
the study and abstain from alcohol or exercise for 24 hours prior to the study. If you 
use oral contraceptives, you should take this when you normally do so. 
2. If you are a woman who can still become pregnant, you will be asked to undergo a 
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pregnancy test during the exercise test visit (and again during the study visits). For 
this test, you will be asked to collect a sample of urine in the women’s restroom near 
the physiology lab. If the test is “positive,” indicating that you are pregnant, you will 
not be allowed to participate and will be advised to see your physician or the 
University of Oregon Health Center. 
3. Aerobic Fitness Test: You will pedal on an exercise bicycle while wearing a mouth 
piece, nose clip, and electrocardiogram electrodes (heart rhythm monitor). If you are 
a woman, the adhesive patches used for this test will be placed on you by one of the 
women in the lab. After a 5-minute warm-up, you will be asked to maintain a selected 
pedaling rate as pedaling resistance (work) is increased every minute until you reach 
your maximum exercise capacity. Your blood pressure will be measured at periodic 
intervals by the inflation of a blood pressure cuff around your arm. This is to measure 
your overall aerobic fitness level. It normally takes 10 to 15 minutes for people to 
reach their maximum effort. This session will establish your maximal exercise 
tolerance on a bike and will be used to establish the appropriate workload for the 
exercise session on the study visits. 
4. You should notify the investigator immediately if you feel any significant discomfort 
or concern about your well-being at any time during the initial visit. Some examples 
of discomfort include fatigue and muscle soreness. 
Study Visits 
1. You will then return to Dr. Halliwill’s laboratory to participate in the two study visits, 
one of which will be about a week after the Exercise Test visit, and the other will be 
about a month after that. The study visits will last about 5 hours each. You will be 
given a food log to track what foods you consume prior to these visits, and you will 
be asked to eat similar foods before each visit. 
2. You will need to wear a t-shirt, shorts, and refrain from eating at least two hours prior 
to arrival. In addition, you will need to refrain from consuming caffeine (for example, 
coffee, tea, red bull, coke, etc.) or medications (except oral contraceptives) for 12 
hours prior to the study and abstain from alcohol or exercise for 24 hours prior to the 
study. If you use oral contraceptives, you should take this when you normally do so. 
3. If you are a woman who can still become pregnant, you will be asked to undergo a 
pregnancy test during the study visits. 
4. During the study visits, your heart rate will be monitored by electrocardiogram 
electrodes placed on your skin. If you are a woman, the adhesive patches used for this 
test will be placed on you by one of the women in the lab. Your blood pressure will 
be measured at periodic intervals by the inflation of a blood pressure cuff around your 
arm. 
5. On one of the study visits you will be given a 540 mg dose of fexofenadine 
hydrochloride (brand name Allegra) and a 300 mg dose of ranitidine hydrochloride 
(brand name Zantac). On the other study visit you will be given placebo tablets that 
look like the Allegra and Zantac. You will not know which pills you are taking on 
either study day. The 540 mg dose of fexofenadine hydrochloride is greater than the 
180 mg over-the-counter recommended. This amount of fexofenadine is still safe for 
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humans as single doses up to 1980 mg and 690 mg two times per day for a month 
showed no ill outcomes. The 300 mg dose of ranitidine hydrochloride s in-line with 
the manufacturers recommended dose. 
6. During the study visits, you will pedal on a bicycle at a moderate rate for 1 hour. 
7. Before and after the exercise session, a small probe (ultrasound Doppler probe) will 
be held over an area of skin on your groin-hip intersection to image your femoral 
artery. The ultrasound Doppler probe uses ultrasound waves to measure blood flow in 
these arteries. The femoral artery will be studied for 10 minutes before you exercise 
and for one hour after you exercise. 
8. Before and after the exercise session, an elastic band placed around your calf will be 
used to measure changes in leg volume in response to inflation of a pressure cuff 
above your knee. The pressure cuff above your knee will be inflated for several 
minutes at a time to a pressure which will feel snug but not uncomfortable. It is used 
to limit blood return out of your lower leg, but will not limit blood from flowing into 
your lower leg. 
9. Blood sampling. A small needle will be used to obtain a blood sample from a vein 
near your elbow, as they would for a routine blood test at the doctor’s office. This 
will be done at the beginning and end of the study visit. There will also be a blood 
draw at the follow up visits: 6 hours, 12 hours, 24 hours and 48 hours after exercise. 
The blood samples will be used to measure markers of inflammation. You should not 
donate blood or volunteer for another research study where blood will be drawn for 8 
weeks following completion of the study. The 8-week period is recommended to 
allow your body to reproduce the blood that was taken during the study days. 
Follow-up Visits 
You will be asked to return for four follow-up visits at 6, 12, 24, and 48 hours after each 
of the two Experiment Visits. During each Follow-Up Visit, the researchers will obtain 
another blood sample,The total time for each follow-up visit is 15 minutes when blood is 
being obtained. 
How long will I be in the study? 
You will be in the study for a total of 12 sessions. These sessions include the Initial Visit, 
the Fitness Test Visit, the two Study Visits, and a total of 8 Follow-up Visits (4 after each 
Study Visit). Your total involvement would be about 14.5 hours. 
What are the risks of the study? 
1. Exercise Test. There is some minor discomfort associated with exercise testing, 
including temporary fatigue, shortness of breath, and muscle soreness. These 
sensations resolve within minutes after the test is completed. There is the possibility 
of some residual muscle soreness in the few days following the exercise test. There is 
also the risk of a heart attack or death during an exercise test. The risk of a 
complication requiring hospitalization is about 1 incident in 1000. The risk of a heart 
attack during or immediately after an exercise test is less than 1 incident in 2500. The 
risk of death during or immediately after an exercise test is less than 1 incident in 
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10,000. In the unlikely case of a life-threatening heart rhythm, the laboratory is 
equipped with an Automatic Electronic Defibrillator that is in the same room where 
the study is taking place. In the event of an emergency, 911 will be called and we will 
direct an ambulance to the correct location. 
2. Blood sampling. In total, about 360 ml of blood will be withdrawn over the course of 
the experiments, which is a less than those associated with standard blood donation 
programs, where 450-500ml of blood (half a quart) is routinely withdrawn. You 
should not donate blood or volunteer for another research study where blood will be 
drawn for 8 weeks following completion of the study. The 8-week period is 
recommended to allow your body to reproduce the blood that was taken during the 
study days. 
3. Tracking of Taxable Income. Please note, compensation from participation in Human 
Subjects Research studies is taxable income. If your compensation totals $600 or 
more in a calendar year, the University is required to report the income to the IRS. 
The University requires its departments to track participant compensation and may 
contact you to complete a Form W-9 for tax reporting purposes. Because of the 
federal and University tracking requirements, your name will be associated with 
participation in research. Department and University administrators will have access 
to this information, but will not have access to research data. 
The study may include risks that are unknown at this time. 
Are there benefits to taking part in this study? 
This study will not make your health better. Measurements are not being conducted for 
diagnostic purposes. The results will not be reviewed by a physician. The purpose of this 
study is to provide more information on how humans respond to exercise. Our hope is 
that by better understanding the physiology of how the human body responds to exercise, 
we will be better able to use exercise in the prevention and treatment of diseases such as 
hypertension (high blood pressure) and other forms of cardiovascular disease. 
What other choices do I have if I don’t take part in this study? 
This study is only being done to gather information. You may choose not to take part in 
this study. 
What are the costs of tests and procedures? 
You will not pay for any tests or procedures that are done just for this research study. 
You will get $220 for participating in this study. This money is for the inconvenience and 
time you spent in this study. If you start the study but stop before the study has ended, the 
amount of money you receive will be pro-rated at a rate of $15 per hour that you 
complete. 
Who is funding this research study? 
This study is being funded by the American Heart Association (AHA). 
Who can answer my questions? 
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You may talk to Dr. John Halliwill at any time about any question you have on this study. 
You may contact Dr. Halliwill by calling the Department of Human Physiology at (541) 
600-4337. 
What are my rights if I take part in this study? 
Taking part in this research study is your decision. You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to participate 
will not affect your relationship with the University of Oregon. 
You do not waive any liability rights for personal injury by signing this form. Biomedical 
research involves some risk of injury. In spite of all precautions, you might develop 
medical complications from participating in this study. 
The investigators may stop you from taking part in this study at any time if it is in your 
best interest, if you do not follow the study rules, or if the study is stopped. For example, 
if the investigators determine the study is overly stressful for you (as indicated by body 
language and an elevated heart rate and/or blood pressure) they may stop you from 
participating in the study. Or if you express pain or discomfort beyond what is normally 
expected, the investigators stop you from participating in the study. 
If you are physically injured because of the project, you and your insurance company will 
have to pay your doctor bills. If you are a UO student or employee and are covered by a 
UO medical plan, that plan might have terms that apply to your injury. 
If you experience harm because of the project, you can ask the State of Oregon to pay 
you. If you have been harmed, there are two University representatives you need to 
contact. Here are their addresses and phone numbers: 
General Counsel Research Compliance Services 
Office of the President 5237 University of Oregon 
1226 University of Oregon Eugene, OR 97403-5237 
Eugene, OR 97403-1226 (541) 346-2510 
(541) 346-3082 
A law called the Oregon Tort Claims Act may limit the amount of money you can receive 
from the State of Oregon if you are harmed. 
What about confidentiality? 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. 
Subject identities will be kept confidential by assigning you a “subject identification 
number”. The names associated with each subject identification number will be kept in a 
locked file cabinet in Dr. Halliwill’s office area. 
Research Compliance Services and/or authorized representatives of the Food and Drug 
Administration (FDA) or National Institute of Health (NIH) may need to review records 
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of individual subjects. As a result, they may see your name, but they are bound by rules 
of confidentiality not to reveal your identity to others. 
The list of names will be destroyed when study results are published or 24 months after 
your participation, whichever comes first. All blood and muscle samples will be 
destroyed when study results are published or 5 years after your participation, whichever 
comes first. Other information may be stored by the researchers indefinitely. 
You will be asked to complete a Medical History Form on the study day which will list 
personal identifying information so that in the unlikely event of a medical emergency in 
which we would activate the emergency medical system, we would be able to provide 
this information to emergency healthcare providers. This document would be retained in 
a locked file cabinet in Dr. Halliwill’s lab for up to a week after the study day, after 
which it is placed in a locked confidential documents disposal bin which is emptied by a 
secure shredding service. 
I have had an opportunity to have my questions answered. I have been given a copy 
of this form. I agree to take part in this study. 
If you have questions regarding your rights as a research subject, contact Research 
Compliance Services, 5219 University of Oregon, Eugene, OR 97403, 541/346-2510. 
Your signature indicates that you have read and understand the information provided 
above, that you willingly agree to participate, that you may withdraw your consent at any 
time and discontinue participation without penalty, that you will receive a copy of this 
form, and that you are not waiving any legal claims, rights or remedies. 
 
(Signature of Participant) (Date) 
 
 
(Signature of Individual Obtaining Consent) (Date) 
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APPENDIX B STANDARD OPERATING PROCEDURES ASSAYS 
Leukocyte isolation and preparation for flow cytometry 
  Take a vial of PFA from the freezer to thaw (may need to put in a beaker of water to 
accelerate) 
  Make dilution of 10x RBC lysis buffer (brown bottle in fridge) - 3 ml + 27 ml H2O in 
a green lid tube 
  Add 2.0 ml fresh whole blood to RBC lysis buffer.  Incubate 10 min at RT 
  Wipe down shaft of pipet with disinfectant towel to remove blood splatter 
  Spin tube at 500 x G for 10 min (program 1) 
  Pour off supernatant into beaker with a splash of bleach in hood. 
  Resuspend in 30 mL 1x PBS from fridge. Pipet to break up cell pellet. 
  Pass through 40 micron filter into fresh tube. 
  Spin 10 min @ 500G, discard super into bleach beaker 
  Resuspend in 3-5 ml PBS :  ml (R) 
  In a tiny tube, mix 10 ul trypan blue with 10 ul cell suspension.  Load 10ul 
to each slide well 
  Insert slide into countess and zoom to adjust focus (cells with blue edge with white 
center) 
  Count both sides of slide, record cells/ml alive and %alive. Average two sides. 
Alive:  ,  Average  cells/ml (A) 
Initials:   
% alive:  ,  Average  % 
  Divide 1,000,000 by A cells/ml =  ml for 1,000,000 cells (B) 
  (One or two unstained samples total per subject-week is enough)Remove B amount 
of suspension to microcentrifuge tube to save as unstained. Store in fridge until fixing 
step 
  Remaining cells R – B =  ml x A cells/ml= 
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  cells (C) 
Only subtract B if you have removed a sample for “unstained” 
  Dilute cells to 1 x 106 cells/ml with cold PBS (if C is 4.2x106 cells, bring volume up 
to 4.2 ml) (D) 
  If there’s no reconstituted violet dye less than 2 weeks old in the freezer, make a fresh 
tube by adding 50 ul DMSO to lyophilized stain (both DMSO and stain are in 
Invitrogen pouch in freezer. Label stain with date after reconstituting). 
  Add 1 ul violet stain per ml of cell suspension (same as 1 ul per million cells – 
volume D but in ul. Swirl and incubate in the dark at RT for 30 min. 
  Retrieve unstained cells from fridge (if unstained cells were collected at this time 
point). 
  Fill violet stained cells up to 30 ml with PBS to dilute stain before spinning 
  Spin tubes 10 min @ 500G, discard super 
  To each tube, add 1 ml 4% PFA per million cells (volume D). Pipet to break up cell 
clumps. 
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  Incubate at RT in dark for 10 min 
  Top off cell suspension to 30 ml w/ PBS to dilute PFA. 
  Spin and discard super into Formaldehyde Waste Bottle. 
  Resuspend cells in 2.0 mL PBS. Transfer to 2mL tube with label. 
  Store in the dark in the fridge until ready for staining & cytometering (up to one 
week) 
  Make sure remaining PFA and violet dye solutions are returned to freezer 
  Blood beaker with 10% bleach can be washed down the sink 20 minutes after the last 
addition 
Subject ID  Time point    
Date   Initials:   
Alive:  ,  Average 
(A):   cells/mL 
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% alive:   ,  Average:  % 
R:  mL 
B:  mL C:  cells D:  mL (added 
  mL) 
1,000,000/avg live cells avg live cells x remaining vol C/106 mL 
Leukocyte Staining for Flow Cytometry 
Channel/Antibody/Stock solution(ug/ul)/Antibody volume(ul)/Stain 
Buffer(ul)/Master Cocktail 
1 FL1-10 Unstained 0 100 
2-9 FL1 CD62E 0.75ug .100 7.5 60 
FL2 CD86 1.56ug .200 7.8 62.4 
FL3 CD309 0.125ug .025 5 40 
FL4 CD34 5ug .200 25 200 
FL5 CD192 0.156ug .200 .78 6.24 
FL6 CD66B 0.5ug .200 2.5 20 
FL7 CD14 0.625ug .200 3.13 25 
FL8 CD16 0.156ug .200 .78 6.24 
FL9 CD3 0.156ug .200 .78 6.24 
CD19 0.0625ug .050 1.25 10 
CD56 0.156ug .200 .78 6.24 
FL10 CD45 0.75ug .100 7.5 60 
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Histamine ELISA 
Sample preparation and acylation 
1. Pipette 25 μL of standards, 25 μL of controls, 25 μL of plasma samples, 10 μL of 
urine samples, or 50 μL of supernatant from the release test* into the respective wells 
of the Reaction Plate. 
2. Add 25 μL of Acylation Buffer to all wells. 
3. Add 25 μL of Acylation Reagent to all wells. 
4. Incubate for 45 min at RT (20-25°C) on a shaker (approx. 600 rpm). 
5. Add 200 μL of distilled water to all wells. 
6. Incubate for 15 min. at RT (20-25°C) on a shaker (approx. 600 rpm). 
2. Take 25 μL of the prepared standards, controls and samples for the Histamine ELISA 
Histamine ELISA 
1. Pipette 25 μL of the acylated standards, controls and samples into the appropriate 
wells of the Histamine Microtiter Strips. 
2. Pipette 100 μL of the Histamine Antiserum into all wells and cover plate with 
Adhesive Foil. 
3. Incubate for 3 hours at RT (20-25°C) on a shaker (approx. 600 rpm). 
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4. Alternatively: shake the Histamine Microtiter Strips briefly by hand and incubate for 
15 – 20 hours at 2 – 8 °C. 
5. Remove the foil. Discard or aspirate the contents of the wells and wash each well 4 
times thoroughly with 300 μL Wash Buffer. Blot dry by tapping the inverted plate on 
absorbent material. 
6. Pipette 100 μL of the Enzyme Conjugate into all wells. 
7. Incubate for 30 min at RT (20-25°C) on a shaker (approx. 600 rpm). 
8. Discard or aspirate the contents of the wells and wash each well 4 times thoroughly 
with 300 μL Wash Buffer. Blot dry by tapping the inverted plate on absorbent 
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material. 
9. Pipette 100 μL of the Substrate into all wells and incubate for 20-30 min at RT (20- 
25°C) on a shaker (approx. 600 rpm). Avoid exposure to direct sun light! 
10. Add 100 μL of the Stop Solution to each well and shake the microtiter plate to ensure 
a homogeneous distribution of the solution. 
11. Read the absorbance of the solution in the wells within 10 minutes, using a 
microplate reader set to 450 nm with a reference wavelength between 620 nm and 
650 nm. 
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Mast Cell Culturing protocols 
To make growth medium: 
• Remove 50 ml from basal medium (Gibco 10639011) bottle and store in sterile 
conical tube 
• Add entire contents of nutrient supplement (included w/ basal), 5 ml pen/strep 
(Gibco 15140), 5 ml L-glutamine (Gibco 25030-081), 1 ml Primocin (Fisher) 
• Store at 4° (Primocin only good for 3 months at 4°. Add fresh primocin as needed. 
) 
 
Waking cells 
• Warm vial of cells in 37 degree bath just until thawed 
• Wash tube with 70% ethanol 
• Transfer cell suspension to 15 ml conical tube containing 5 ml warm growth 
medium 
• Mix cells and centrifuge (450 x g at RT for 5 min) to pellet 
• Resuspend cells in 5 ml growth medium and transfer to a T25 flask 
• Leave cells alone for ~3 days then transfer to a T75 with additional 15 mL fresh 
media. 
• It takes about a week for cells to recover after thawing 
• Split cells every 3-4 days (Mondays and Fridays) 
Passage/feeding – cells must be split or fed every 2-3 days. Split 1:2 – 1:5 depending on 
needs. 
• To split, add 40 mL medium to each flask and mix. Transfer 20 ml from each 
flask to two new flasks (n=3) 
• To feed, transfer suspension to a 50 ml conical tube and centrifuge at 450 x g for 
5 min at RT. Pull off half the supernatant (10 ml), add 10 ml fresh growth 
medium, resuspend, transfer to new growth flask 
Freezing 
• Count cells to determine viability (should be greater than 80%) 
• Centrifuge cells at 600 rpm for 10 minutes. Remove supernatant 
• Resuspend in enough pZERVE (protide pharmaceuticals) to have a density of 5 x 
106 cells/ml. 
• Dispense suspension into sterile cryotubes in 1-2ml aliquots. Seal and store at RT 
for 30 min with gentle agitation 
• Place vials in an insulated container (styrofoam works) in -20 for 1 hr. 
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• Remove insulation and place vials in -80 for 1 hour (*Do not store in -80 for more 
than 2 hrs) 
• Transfer vials to vapor phase of LN2 for 24 hrs. Move vials to liquid phase 
• *as an alternative, try doing one vial the traditional way (IPA canister in -80 for 
overnight, then transfer to liquid LN2) 
 
 
Degranulation Assay 
• Plate cells at 1 x 106 cells/ml in wells of a 96 well plate in imaging medium (50 ul 
total volume) See recipe below. 
• Plate imaging medium only in blank wells 
• Dissolve 2 mg compound 48/80 (H20 soluble up to 50 mg/ml, store dry at -20) in 
1 ml imaging buffer, sterile filter 
• In the positive control wells, add 50 ul of 2 mg/ml compound 48/80 to a final 
concentration of 1 mg/ml 
• In experimental wells, add 50 ul microdialysate in triplicate wells 
• After 20 minutes*, remove suspension from all wells, pellet cells, pull off 
supernatant and transfer to new tube (need not be sterile). Keep the pellet. (*for 
initial trial, do only 48/80 and sample at 5, 20, 60 minutes) 
• React supernatant with substrate, 2 mM 4-Nitrophenyl N-acetyl-β-D- 
glucosaminide diluted in 0.2M citrate buffer (soluble to 5 mg/ml. Do 4.25 mg in 
1 ml and add 15 ul per well) for 2 hr at 37 C 
• Stop reaction with 50 ul 1 M Tris-Cl, pH 9 
• Measure absorbance at 405 nm 
• To determine total B-hexosaminidase content, lyse cells in pellet with Triton – X 
100 (0.06%). 
• React lysate with 2 mM substrate for two hrs at 37 C 
• Measure absorbance at 405 nm. 
• Subtract background signal and present data as percent of total B-hexosaminidase 
activity. 
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Imaging buffer (250mL) 
142 mM NaCl 58.44 g/mol  2.0746 g 
5 mM NaHCO3 84.01 g/mol  0.105 g 
10 mM HEPES 238.3 g/mol  0.5958 g 
16 mM Glucose 180.16 g/mol  0.7206 g 
2 mM KCl 74.55 g/mol  0.0373 g 
2 mM CaCl2 219.08 g/mol  0.1095 g 
1 mM MgCl2 203.31 g/mol  0.0508 g 
0.1% BSA  0.25 g 
pH to 7.3 w/ NaOH 
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